ID,Cohort,ReferenceCoded,Reference,YearPublished,YearDataCollection,StudyType,Sample,Design,Country,DefinitionCannabisGroup,AgeMean,AgeRangeLower,AgeRangeUpper,OutcomeDefinitionCases,OutcomeDefinitionLabel,Severity,OutcomeScale,OutcomeMeasure,OutcomeMeasureCoded,OutcomeItem,Prevalence_PaperReport,Predictor,Predictor_clean,MeanDurationMCtreatment,DoseTHC,DoseTHC_note,StandardTHC,RouteTHC,DoseTHC_within,CandidateGene,ReverseD,PredictorCoded,PredictorBroad,CHECKED,Statistic,Test_dependency,Rcode,metaP_code,effectType,ratesControl,IncludeStudy,IncludeD
1,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,GeneralPopulation,Survey - CommunitySample,NewZealand,EverCannabisUse,27,18,35,Psychosis-like,Can.PLE,NA,Binary,Single item,,"After taking cannabis, have you had strange, unpleasant experiences such as hearing voices or becoming convinced that someone is trying to harm you, or that you are being persecuted?",15,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,yes,Gender,Demographic,yes,chi-square,independent,extract_thomas_gender,pEstimate_thomas_gender,cohen,,Yes,Yes
2,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,GeneralPopulation,Survey - CommunitySample,NewZealand,EverCannabisUse,27,18,35,Psychosis-like,Can.PLE,NA,Binary,Single item,,"After taking cannabis, have you had strange, unpleasant experiences such as hearing voices or becoming convinced that someone is trying to harm you, or that you are being persecuted?",15,Frequency (heavy vs. light),Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,chi-square,independent,extract_thomas_frequency,pEstimate_thomas_frequency,cohen,,Yes,Yes
3,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,GeneralPopulation,Survey - CommunitySample,NewZealand,EverCannabisUse,27,18,35,Psychosis-like,Can.PLE,NA,Binary,Single item,,"After taking cannabis, have you had strange, unpleasant experiences such as hearing voices or becoming convinced that someone is trying to harm you, or that you are being persecuted?",15,current vs. former user,Cannabis use (current),NA,NA,NA,NA,NA,NA,NA,yes,CannabisSeverity,CannabisHistory,yes,chi-square,independent,extract_thomas_currentCan,pEstimate_thomas_currentCan,cohen,,Yes,Yes
4,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,GeneralPopulation,Survey - CommunitySample,NewZealand,EverCannabisUse,27,18,35,Psychosis-like,Can.PLE,NA,Binary,Single item,,"After taking cannabis, have you had strange, unpleasant experiences such as hearing voices or becoming convinced that someone is trying to harm you, or that you are being persecuted?",15,Cannabis dependency (present vs. absent),Cannabis dependency,NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,chi-square,independent,extract_thomas_dependeny,pEstimate_thomas_dependeny,cohen,,Yes,Yes
5,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,GeneralPopulation,Survey - CommunitySample,NewZealand,EverCannabisUse,27,18,35,Psychosis-like,Can.PLE,psych_like,Binary,Single item,,"After taking cannabis, have you had strange, unpleasant experiences such as hearing voices or becoming convinced that someone is trying to harm you, or that you are being persecuted?",15,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,thomas1996_canPLEDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,GeneralPopulation,Survey - CommunitySample,US,Past3monthsCannabisUse,34.96,18,80,Paranoia,Can.PAR,NA,Binary,Single item,," Indicate which immediate effects they experience (list of 45 items): Paranoia, Hallucinations",14.5,Recreational use (vs. medical),Recreational use (vs. medical),NA,NA,NA,NA,NA,NA,NA,no,Reason (medicinal vs. recreational),CannabisHistory,yes,chi-square,independent,extract_SextonParanoia_reasonUse,pEstimate_SextonParanoia_reasonUse,cohen,,Yes,Yes
8,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,GeneralPopulation,Survey - CommunitySample,US,Past3monthsCannabisUse,34.96,18,80,Hallucinations,Can.HAL,NA,Binary,Single item,," Indicate which immediate effects they experience (list of 45 items): Paranoia, Hallucinations",3.8,Recreational use (vs. medical),Recreational use (vs. medical),NA,NA,NA,NA,NA,NA,NA,no,Reason (medicinal vs. recreational),CannabisHistory,yes,chi-square,independent,extract_SextonHallucinations_reasonUse,pEstimate_SextonHallucinations_reasonUse,cohen,,Yes,Yes
9,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,GeneralPopulation,Survey - CommunitySample,US,Past3monthsCannabisUse,34.96,18,80,Paranoia,Can.PAR,NA,Binary,Single item,," Indicate which immediate effects they experience (list of 45 items): Paranoia, Hallucinations",14.5,Age,Age,NA,NA,NA,NA,NA,NA,NA,yes,Age,Demographic,yes,chi-square,independent,extract_SextonParanoiaAge,pEstimate_SextonParanoiaAge,cohen,,Yes,Yes
10,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,GeneralPopulation,Survey - CommunitySample,US,Past3monthsCannabisUse,34.96,18,80,Hallucinations,Can.HAL,NA,Binary,Single item,," Indicate which immediate effects they experience (list of 45 items): Paranoia, Hallucinations",3.8,Age,Age,NA,NA,NA,NA,NA,NA,NA,yes,Age,Demographic,yes,chi-square,independent,extract_SextonHallucinationAge,pEstimate_SextonHallucinationAge,cohen,,Yes,Yes
11,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,GeneralPopulation,Survey - CommunitySample,US,Past3monthsCannabisUse,34.96,18,80,Paranoia,Can.PAR,psych_like,Binary,Single item,," Indicate which immediate effects they experience (list of 45 items): Paranoia, Hallucinations",14.5,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,sexton2019_canParDF,NA,rates,,Yes,Yes
12,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,GeneralPopulation,Survey - CommunitySample,US,Past3monthsCannabisUse,34.96,18,80,Hallucinations,Can.HAL,psych_like,Binary,Single item,," Indicate which immediate effects they experience (list of 45 items): Paranoia, Hallucinations",3.8,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,sexton2019_canHalDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Paranoia,Can.PAR,NA,Continuous,Paranoia (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",31,Depression (present vs. absent),Depression,NA,NA,NA,NA,NA,NA,NA,no,Depression,MentalHealthPersonality,yes,odd ratio,independent,arendt_depression_paranoiaEstimate,pEstimate_arendt_depression_paranoia,cohen,,Yes,Yes
15,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Delusions,Can.DEL,NA,Continuous,Delusions (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",NA,Depression (present vs. absent),Depression,NA,NA,NA,NA,NA,NA,NA,no,Depression,MentalHealthPersonality,yes,meanComparison,independent,"pes(p=pValueNS_allStudies, n.1=arendt_depressed_n, n.2=arendt_nonDepressed_n)",pEstimate_arendt_depression_delusions,cohen,,Yes,Yes
16,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Depersonalization,Can.DEP,NA,Continuous,Depersonalization (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",NA,Depression (present vs. absent),Depression,NA,NA,NA,NA,NA,NA,NA,no,Depression,MentalHealthPersonality,yes,meanComparison,independent,"pes(p=pValueNS_allStudies, n.1=arendt_depressed_n, n.2=arendt_nonDepressed_n)",pEstimate_arendt_depression_depersionalisation,cohen,,No,No
17,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Hallucinations,Can.HAL,NA,Continuous,Hallucinations (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",NA,Depression (present vs. absent),Depression,NA,NA,NA,NA,NA,NA,NA,no,Depression,MentalHealthPersonality,yes,meanComparison,independent,"pes(p=pValueNS_allStudies, n.1=arendt_depressed_n, n.2=arendt_nonDepressed_n)",pEstimate_arendt_depression_hallucinations,cohen,,Yes,Yes
18,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Paranoia,Can.PAR,NA,Continuous,Paranoia (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",NA,Violence (present vs. absent),Violence,NA,NA,NA,NA,NA,NA,NA,no,Agression,MentalHealthPersonality,yes,meanComparison,independent,"pes(p=pValueNS_allStudies, n.1=arendt_violent_n, n.2=arendt_nonViolent_n)",pEstimate_arendt_violence_paranoia,cohen,,Yes,Yes
19,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Delusions,Can.DEL,NA,Continuous,Delusions (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",NA,Violence (present vs. absent),Violence,NA,NA,NA,NA,NA,NA,NA,no,Agression,MentalHealthPersonality,yes,meanComparison,independent,"pes(p=pValueNS_allStudies, n.1=arendt_violent_n, n.2=arendt_nonViolent_n)",pEstimate_arendt_violence_delusions,cohen,,Yes,Yes
21,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Hallucinations,Can.HAL,NA,Continuous,Hallucinations (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",NA,Violence (present vs. absent),Violence,NA,NA,NA,NA,NA,NA,NA,no,Agression,MentalHealthPersonality,yes,meanComparison,independent,"pes(p=pValueNS_allStudies, n.1=arendt_violent_n, n.2=arendt_nonViolent_n)",pEstimate_arendt_violence_hallucinations,cohen,,Yes,Yes
22,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Delusions,Can.DEL,psych_like,Continuous,Delusions (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,arendt2007_canDelDF,NA,rates,,Yes,Yes
23,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Paranoia,Can.PAR,psych_like,Continuous,Paranoia (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,arendt2007_canParDF,NA,rates,,Yes,Yes
24,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,CannabisDependant,Study -CUDsample,Denmark,DiagnosisCUD,22.3,16,30,Hallucinations,Can.HAL,psych_like,Continuous,Hallucinations (total score),,"How often have you experienced the following reactions to cannabis use, while ‘‘ high ’’ or under the influence of cannabis? Delusional, Suscpicious/Paranoid, Depersonalization, Auditory or vidual hallucinations. Average scores are estimated from a Likert scale with values: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always.",NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,arendt2007_canHalDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,NA,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",27.4,Age (younger),Age (young),NA,NA,NA,NA,NA,NA,NA,no,Age,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_age,cohen,,Yes,Yes
27,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,NA,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",27.4,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_gender,cohen,,Yes,Yes
28,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,NA,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",27.4,Ethnicity,Ethnicity,NA,NA,NA,NA,NA,NA,NA,no,Ethnicity,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_ethnicity,cohen,,Yes,Yes
29,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,NA,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",27.4,GeneralHealth,General health,NA,NA,NA,NA,NA,NA,NA,no,Health,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_health,cohen,,Yes,Yes
30,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,NA,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",27.4,SocioeconomicStatus,SES,NA,NA,NA,NA,NA,NA,NA,no,SES,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_ses,cohen,,Yes,Yes
31,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,NA,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",27.4,Cannabis dependency (present vs. absent),Cannabis dependency,NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,chi-square,independent,extract_levyHallucinations_CUD,pEstimate_levyHallucinations_CUD,cohen,,Yes,Yes
32,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,NA,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",27.4,Frequency (high vs. low),Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,chi-square,independent,extract_levyHallucinations_frequency,pEstimate_levyHallucinations_frequency,cohen,,Yes,Yes
33,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,NA,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",27.4,Anxiety (present vs. absent),Anxiety,NA,NA,NA,NA,NA,NA,NA,no,Anxiety,MentalHealthPersonality,yes,chi-square,independent,extract_levyHallucinations_anxiety,pEstimate_levyHallucinations_anxiety,cohen,,Yes,Yes
34,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,NA,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",27.4,Depression (present vs. absent),Depression,NA,NA,NA,NA,NA,NA,NA,no,Depression,MentalHealthPersonality,yes,chi-square,independent,extract_levyHallucinations_depression,pEstimate_levyHallucinations_depression,cohen,,Yes,Yes
35,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,NA,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,Age,Age,NA,NA,NA,NA,NA,NA,NA,no,Age,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_age,cohen,,Yes,Yes
36,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,NA,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_gender,cohen,,Yes,Yes
37,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,NA,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,Ethnicity,Ethnicity,NA,NA,NA,NA,NA,NA,NA,no,Ethnicity,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_ethnicity,cohen,,Yes,Yes
38,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,NA,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,GeneralHealth,General health,NA,NA,NA,NA,NA,NA,NA,no,Health,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_health,cohen,,Yes,Yes
39,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,NA,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,SocioeconomicStatus,SES,NA,NA,NA,NA,NA,NA,NA,no,SES,Demographic,yes,pValue,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_ses,cohen,,Yes,Yes
40,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,NA,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,Cannabis dependency (present vs. absent),Cannabis dependency,NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,chi-square,independent,extract_levyParanoia_CUD,pEstimate_levyParanoia_CUD,cohen,,Yes,Yes
41,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,NA,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,Frequency (heavy vs. light),Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,chi-square,independent,extract_levyParanoia_frequency,pEstimate_levyParanoia_frequency,cohen,,Yes,Yes
42,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,NA,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,Anxiety (present vs. absent),Anxiety,NA,NA,NA,NA,NA,NA,NA,no,Anxiety,CannabisHistory,yes,chi-square,independent,extract_levyParanoia_anxiety,pEstimate_levyParanoia_anxiety,cohen,,Yes,Yes
43,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,NA,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,Depression (present vs. absent),Depression,NA,NA,NA,NA,NA,NA,NA,no,Depression,CannabisHistory,yes,chi-square,independent,extract_levyParanoia_depression,pEstimate_levyParanoia_depression,cohen,,Yes,Yes
44,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,Hallucinations,Can.HAL,psych_like,Binary,Hallucinations (ever vs. never),,"“In the past 12 months, how often have you seen, felt, or heard things that were not really there [ie, hallucinations] during or after using marijuana?”",33.6,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,levy2019_canHalDF,NA,rates,,Yes,Yes
45,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,GeneralPopulation,Study -AdolescentSample,US,PastYearCannabisUse,16.6,14,18,ParanoiaAnxiety,Can.PAR,psych_like,Binary,Paranoia (ever vs. never),,"“In the past 12 months, how often have you felt anxious or paranoid during or after using marijuana?” ",33.6,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,levy2019_canParDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
47,Barkus,Barkus_sample,"Barkus, Emma, and Shon Lewis. ""Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample."" Psychological Medicine 38, no. 9 (2008): 1267-1276.",2008,NA,Observational,GeneralPopulation,Study - StudentSample,UK,EverCannabisUse,22,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ-PLE subscale ,,25 items,NA,Schizotype (high vs. low),Schizotype (high),NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,meanComparison,independent,"fes(barkus_schizotype_psych_f, barkus_n/2, barkus_n/2,  dig=20)",pEstimate_barkus_schizotype_psych,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
49,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Paranoia,Can.PAR,NA,Categorical,How often have you felt suspicious while smoking cannabis?,,,46.5,Pre-existing psychosis (present vs. absent),Pre-existing psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,"chies(bianconi_patients_paranoia_chisquare, bianconi_patients_paranoia_n, dig=50)",pEstimate_bianconi_patients_paranoia,cohen,,Yes,Yes
50,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Hallucinations,Can.HAL,NA,Categorical,How often have your heard voices while smoking cannabis?,,,18.6,Pre-existing psychosis (present vs. absent),Pre-existing psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,"chies(bianconi_patients_hallucination_chisquare, bianconi_patients_hallucination_n, dig=50)",pEstimate_bianconi_patients_hallucination,cohen,,Yes,Yes
51,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Psychosis-like,Can.PLE,NA,Continous,"Psychosis-like (factor), with the following indicators: How often have you had visions while smoking cannabis?; How often have you heard voices while smoking cannabis?; How often have you felt like going mad while smoking cannabis?",,,NA,Pre-existing psychosis (present vs. absent),Pre-existing psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,linearRegression,independent,"beta_to_d_independent(beta=bianconi_caseness_beta, se=bianconi_caseness_se, N1=252, N2=217)",pEstimate_bianconi_caseness,cohen,,Yes,Yes
52,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Psychosis-like,Can.PLE,NA,Continous,"Psychosis-like (factor), with the following indicators: How often have you had visions while smoking cannabis?; How often have you heard voices while smoking cannabis?; How often have you felt like going mad while smoking cannabis?",,,NA,CannabisType (high vs. low potency),Cannabis potency (high),NA,NA,NA,NA,NA,NA,NA,no,THCcontent,CannabisStrain,yes,linearRegression,independent,"beta_to_d_independent(beta=bianconi_typeCan_beta, se=bianconi_typeCan_se, n=bianconi_regression_n)",pEstimate_bianconi_typeCan,cohen,,Yes,Yes
53,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Psychosis-like,Can.PLE,NA,Continous,"Psychosis-like (factor), with the following indicators: How often have you had visions while smoking cannabis?; How often have you heard voices while smoking cannabis?; How often have you felt like going mad while smoking cannabis?",,,NA,CannabisBeliefs,Cannabis beliefs,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,linearRegression,independent,"beta_to_d_independent(beta=bianconi_belief_beta, se=bianconi_belief_se, n=bianconi_regression_n)",pEstimate_bianconi_belief,cohen,,Yes,Yes
54,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Psychosis-like,Can.PLE,NA,Continous,"Psychosis-like (factor), with the following indicators: How often have you had visions while smoking cannabis?; How often have you heard voices while smoking cannabis?; How often have you felt like going mad while smoking cannabis?",,,NA,AlcoholUse,Alcohol use,NA,NA,NA,NA,NA,NA,NA,no,Alcohol,OtherDrugs,yes,linearRegression,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes
55,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Psychosis-like,Can.PLE,NA,Continous,"Psychosis-like (factor), with the following indicators: How often have you had visions while smoking cannabis?; How often have you heard voices while smoking cannabis?; How often have you felt like going mad while smoking cannabis?",,,NA,OtherDrugUse,Other drug use,NA,NA,NA,NA,NA,NA,NA,no,OtherDrugs,OtherDrugs,yes,linearRegression,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,No,No
56,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Psychosis-like,Can.PLE,NA,Continous,"Psychosis-like (factor), with the following indicators: How often have you had visions while smoking cannabis?; How often have you heard voices while smoking cannabis?; How often have you felt like going mad while smoking cannabis?",,,NA,CigaretteUse,Cigarette use,NA,NA,NA,NA,NA,NA,NA,no,Nicotine,OtherDrugs,yes,linearRegression,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes
57,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Psychosis-like,Can.PLE,NA,Continous,"Psychosis-like (factor), with the following indicators: How often have you had visions while smoking cannabis?; How often have you heard voices while smoking cannabis?; How often have you felt like going mad while smoking cannabis?",,,NA,Money spent on cannabis,Cannabis amount (high),NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,linearRegression,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes
58,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Psychosis-like,Can.PLE,NA,Continous,"Psychosis-like (factor), with the following indicators: How often have you had visions while smoking cannabis?; How often have you heard voices while smoking cannabis?; How often have you felt like going mad while smoking cannabis?",,,NA,DurationCannabisUse,Long-term cannabis use,NA,NA,NA,NA,NA,NA,NA,no,CannabisDuration,CannabisHistory,yes,linearRegression,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes
59,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Psychosis-like,Can.PLE,NA,Continous,"Psychosis-like (factor), with the following indicators: How often have you had visions while smoking cannabis?; How often have you heard voices while smoking cannabis?; How often have you felt like going mad while smoking cannabis?",,,NA,FrequencyCannabisUse,Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,linearRegression,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes
60,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Paranoia,Can.PAR,psych_like,Categorical,How often have you felt suspicious while smoking cannabis?,,,46.5,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,bianconi2016_canParDF,NA,rates,,Yes,Yes
61,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,MixedPsychosis,Study - CaseControlPsychosis,Uk,EverCannabisUse,28.5,NA,NA,Hallucinations,Can.HAL,psych_like,Categorical,How often have your heard voices while smoking cannabis?,,,18.6,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,bianconi2016_canHalDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
63,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like,High.PLE,NA,Continuous,PSI,PSI,NA,NA,"AKT1 (rs2494732, risk allele: C)","AKT1 (rs2494732, risk allele: C)",NA,NA,NA,NA,NA,NA,AKT1,no,AKT1,excluded,,hierarchicalRegression,independent,"compute.es::tes(2.443 , n_morgan/2, n_morgan/2, dig=20)",pEstimate_morgan_akt,cohen,,Yes,Yes
64,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like,High.PLE,NA,Continuous,PSI,PSI,NA,NA,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,yes,Gender,excluded,,hierarchicalRegression,independent,"compute.es::tes(1.042 , n_morgan/2, n_morgan/2, dig=20)",pEstimate_morgan_gender,cohen,,Yes,Yes
65,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like,High.PLE,NA,Continuous,PSI,PSI,NA,NA,Schizotype,Schizotype (high),NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,excluded,,hierarchicalRegression,independent,"compute.es::tes(8.410 , n_morgan/2, n_morgan/2, dig=20) ",pEstimate_morgan_schizotype,cohen,,Yes,Yes
66,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like,High.PLE,NA,Continuous,PSI,PSI,NA,NA,Cannabis dependency (present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,excluded,,hierarchicalRegression,independent,"compute.es::tes(0.688 , n_morgan/2, n_morgan/2, dig=20) ",pEstimate_morgan_canDep,no,,no,exluded as not placebo-controlled experiment
67,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like,High.PLE,NA,Continuous,PSI,PSI,NA,NA,Ethnicity ,Ethnicity ,NA,NA,NA,NA,NA,NA,NA,no,Ethnicity,excluded,,hierarchicalRegression,independent,"compute.es::tes(1.614 , n_morgan/2, n_morgan/2, dig=20)",pEstimate_morgan_ethnicity,cohen,,Yes,Yes
68,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like,High.PLE,NA,Continuous,PSI,PSI,NA,NA,YearsCannabisUse,Long-term cannabis use,NA,NA,NA,NA,NA,NA,NA,yes,CannabisDuration,excluded,,hierarchicalRegression,independent,"compute.es::tes(2.019 , n_morgan/2, n_morgan/2, dig=20)",pEstimate_morgan_yearsCan,cohen,,Yes,Yes
69,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like,High.PLE,NA,Continuous,PSI,PSI,NA,NA,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",NA,NA,NA,NA,NA,NA,COMT,no,CandidateGene,excluded,,hierarchicalRegression,independent,"compute.es::tes(0.691 , n_morgan/2, n_morgan/2, dig=20) ",pEstimate_morgan_comt,cohen,,Yes,Yes
70,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like,High.PLE,NA,Continuous,PSI,PSI,NA,NA,THC/CBD ratio,CBD content (low),NA,NA,NA,NA,NA,NA,NA,no,CBD,excluded,,hierarchicalRegression,independent,"compute.es::tes(0.799 , n_morgan_sub/2, n_morgan_sub/2, dig=20) ",pEstimate_morgan_strain,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
72,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Single dose smoked  (quasiexperimental),Single dose smoked ,NA,NA,NA,NA,NA,NA,NA,no,Other,excluded,yes,meanComparison,dependent,extract_curran2019_dose_PSI,pEstimate_curran2019_dose_PSI,cohen,,no,no
73,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Single dose smoked  (quasiexperimental),Single dose smoked ,NA,NA,NA,NA,NA,NA,NA,no,Other,excluded,yes,meanComparison,dependent,extract_curran2019_dose_BPRS,pEstimate_curran2019_dose_BPRS,cohen,,no,no
74,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Cannabis dependency (present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_cannabis_dependence_r, n=curran2019_cannabis_dependence_n, dig=20)",pEstimate_curran2019_PSI_cannabis_dependence,cohen,,no,no
75,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Cannabis dependency (present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_cannabis_dependence_r, n=curran2019_cannabis_dependence_n, dig=20)",pEstimate_curran2019_BPRS_cannabis_dependence,cohen,,no,no
76,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Cannabis use disorder (present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_dsm_CUD_r, n=curran2019_dsm_CUD_n, dig=20)",pEstimate_curran2019_PSI_dsm_CUD,cohen,,no,no
77,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Cannabis use disorder (present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_dsm_CUD_r, n=curran2019_dsm_CUD_n, dig=20)",pEstimate_curran2019_BPRS_dsm_CUD,cohen,,no,no
78,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Age,Age,NA,NA,NA,NA,NA,NA,NA,no,Age,Demographic,yes,correlation,independent,"res(curran2019_PSI_age_r, n=curran2019_age_n, dig=20)",pEstimate_curran2019_PSI_age,cohen,,Yes,Yes
79,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Age,Age,NA,NA,NA,NA,NA,NA,NA,no,Age,Demographic,yes,correlation,independent,"res(curran2019_BPRS_age_r, n=curran2019_age_n, dig=20)",pEstimate_curran2019_BPRS_age,cohen,,Yes,Yes
80,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,correlation,independent,"res(curran2019_PSI_gender_r, n=curran2019_gender_n, dig=20)",pEstimate_curran2019_PSI_gender,cohen,,Yes,Yes
81,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,correlation,independent,"res(curran2019_BPRS_gender_r, n=curran2019_gender_n, dig=20)",pEstimate_curran2019_BPRS_gender,cohen,,Yes,Yes
82,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,THC content (increasing %),Potency (high),NA,NA,NA,NA,NA,NA,NA,no,THCcontent,CannabisStrain,yes,correlation,independent,"res(curran2019_PSI_perTHCcontent_r, n=curran2019_perTHCcontent_n, dig=20)",pEstimate_curran2019_PSI_perTHCcontent,cohen,,Yes,Yes
83,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,THC content (increasing %),Potency (high),NA,NA,NA,NA,NA,NA,NA,no,THCcontent,CannabisStrain,yes,correlation,independent,"res(curran2019_BPRS_perTHCcontent_r, n=curran2019_perTHCcontent_n, dig=20)",pEstimate_curran2019_BPRS_perTHCcontent,cohen,,Yes,Yes
84,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,CBD content in smoked cannabis,CBD content (low),NA,NA,NA,NA,NA,NA,NA,no,CBDcontent,CannabisStrain,yes,correlation,independent,"res(curran2019_PSI_perCBDcontent_r, n=curran2019_perCBDcontent_n, dig=20)",pEstimate_curran2019_PSI_perCBDcontent,cohen,,Yes,Yes
85,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,CBD content in smoked cannabis,CBD content (low),NA,NA,NA,NA,NA,NA,NA,no,CBDcontent,CannabisStrain,yes,correlation,independent,"res(curran2019_BPRS_perCBDcontent_r, n=curran2019_perCBDcontent_n, dig=20)",pEstimate_curran2019_BPRS_perCBDcontent,cohen,,Yes,Yes
86,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,THC in urine (increasing THC-COOH/creatinine),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,THC-COOH levels,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_THCconcentration_urine_r, n=curran2019_THCconcentration_urine_n, dig=20)",pEstimate_curran2019_PSI_THCconcentration_urine,cohen,,Yes,Yes
87,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,THC in urine (increasing THC-COOH/creatinine),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,THC-COOH levels,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_THCconcentration_urine_r, n=curran2019_THCconcentration_urine_n, dig=20)",pEstimate_curran2019_BPRS_THCconcentration_urine,cohen,,Yes,Yes
88,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,THC in hair (analyte present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_THCconcentration_hair_r, n=curran2019_THCconcentration_hair_n, dig=20)",pEstimate_curran2019_PSI_THCconcentration_hair,cohen,,no,no
89,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,THC in hair (analyte present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_THCconcentration_hair_r, n=curran2019_THCconcentration_hair_n, dig=20)",pEstimate_curran2019_BPRS_THCconcentration_hair,cohen,,no,no
90,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,CBD in hair (analyte absent vs. present),CBD in hair,NA,NA,NA,NA,NA,NA,NA,no,CBDcontent,CannabisStrain,yes,correlation,independent,"res(curran2019_PSI_CBDconcentration_hair_r, n=curran2019_CBDconcentration_hair_n, dig=20)",pEstimate_curran2019_PSI_CBDconcentration_hair,cohen,,Yes,Yes
91,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,CBD in hair (analyte absent vs. present),CBD in hair,NA,NA,NA,NA,NA,NA,NA,no,CBDcontent,CannabisStrain,yes,correlation,independent,"res(curran2019_BPRS_CBDconcentration_hair_r, n=curran2019_CBDconcentration_hair_n, dig=20)",pEstimate_curran2019_BPRS_CBDconcentration_hair,cohen,,Yes,Yes
92,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,CBN in hair (analyte present vs. absent),CBN in body (high),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,"res(curran2019_PSI_CBNconcentration_hair_r, n=curran2019_CBNconcentration_hair_n, dig=20)",pEstimate_curran2019_PSI_CBNconcentration_hair,cohen,,Yes,Yes
93,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,CBN in hair (analyte present vs. absent),CBN in body (high),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,"res(curran2019_BPRS_CBNconcentration_hair_r, n=curran2019_CBNconcentration_hair_n, dig=20)",pEstimate_curran2019_BPRS_CBNconcentration_hair,cohen,,Yes,Yes
94,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,THC-COOH in hair (analyte present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,THC-COOH levels,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_THC_COOHhair_r, n=curran2019_THC_COOHhair_n, dig=20)",pEstimate_curran2019_PSI_THC_COOHhair,cohen,,Yes,Yes
95,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,THC-COOH in hair (analyte present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,THC-COOH levels,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_THC_COOHhair_r, n=curran2019_THC_COOHhair_n, dig=20)",pEstimate_curran2019_BPRS_THC_COOHhair,cohen,,Yes,Yes
96,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,THC-OH in hair (analyte present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_THC_OHhair_r, n=curran2019_THC_OHhair_n, dig=20)",pEstimate_curran2019_PSI_THC_OHhair,cohen,,no,no
97,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,THC-OH in hair (analyte present vs. absent),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_THC_OHhair_r, n=curran2019_THC_OHhair_n, dig=20)",pEstimate_curran2019_BPRS_THC_OHhair,cohen,,no,no
98,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Age when first used (younger),Age onset cannabis use (young),NA,NA,NA,NA,NA,NA,NA,no,Age onset,CannabisHistory,yes,correlation,independent,"res(curran2019_PSI_age_firstUse_r, n=curran2019_age_firstUse_n, dig=20)",pEstimate_curran2019_PSI_age_firstUse,cohen,,Yes,Yes
99,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Age when first used (younger),Age onset cannabis use (young),NA,NA,NA,NA,NA,NA,NA,no,Age onset,CannabisHistory,yes,correlation,independent,"res(curran2019_BPRS_age_firstUse_r, n=curran2019_age_firstUse_n, dig=20)",pEstimate_curran2019_BPRS_age_firstUse,cohen,,Yes,Yes
100,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Recency of use (longer abstinence),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,yes,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_recency_days_r, n=curran2019_recency_days_n, dig=20)",pEstimate_curran2019_PSI_recency_days,cohen,,no,no
101,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Recency of use (longer abstinence),Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,yes,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_recency_days_r, n=curran2019_recency_days_n, dig=20)",pEstimate_curran2019_BPRS_recency_days,cohen,,no,no
102,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Days per months used cannabis (more days),Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_frequecny_month_r, n=curran2019_frequecny_month_n, dig=20)",pEstimate_curran2019_PSI_frequecny_month,cohen,,no,no
103,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Days per months used cannabis (more days),Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_frequecny_month_r, n=curran2019_frequecny_month_n, dig=20)",pEstimate_curran2019_BPRS_frequecny_month,cohen,,no,no
104,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Time to smoke 3.5g cannabis,Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,yes,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_time_smoked3.5g_r, n=curran2019_time_smoked3.5g_n, dig=20)",pEstimate_curran2019_PSI_time_smoked3.5g,cohen,,no,no
105,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Time to smoke 3.5g cannabis,Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_time_smoked3.5g_r, n=curran2019_time_smoked3.5g_n, dig=20)",pEstimate_curran2019_BPRS_time_smoked3.5g,cohen,,no,no
106,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Prefered potency (high potency),Potency (high),NA,NA,NA,NA,NA,NA,NA,no,THCcontent,CannabisStrain,yes,correlation,independent,"res(curran2019_PSI_highPotency_preference_r, n=curran2019_highPotency_preference_n, dig=20)",pEstimate_curran2019_PSI_highPotency_preference,cohen,,Yes,Yes
107,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Prefered potency (high potency),Potency (high),NA,NA,NA,NA,NA,NA,NA,no,THCcontent,CannabisStrain,yes,correlation,independent,"res(curran2019_BPRS_highPotency_preference_r, n=curran2019_highPotency_preference_n, dig=20)",pEstimate_curran2019_BPRS_highPotency_preference,cohen,,Yes,Yes
108,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (PSI),THC.PLE,NA,Continuous,PSI,PSI,NA,NA,Money spent on cannabis,Cannabis amount (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_PSI_money_spent_week_r, n=curran2019_money_spent_week_n, dig=20)",pEstimate_curran2019_PSI_money_spent_week,cohen,,no,no
109,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,NA,QuasiExperiment,UK,PastMonthCannabisUser,20.6,16,23,Psychosis-like (BPRS),THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,Money spent on cannabis,Cannabis amount (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,correlation,independent,"res(curran2019_BPRS_money_spent_week_r, n=curran2019_money_spent_week_n, dig=20)",pEstimate_curran2019_BPRS_money_spent_week,cohen,,no,no
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
111,Henquet,HenquetExperiment,"Henquet, Cécile, Araceli Rosa, Lydia Krabbendam, Sergi Papiol, Lourdes Fa_anás, Marjan Drukker, Johannes G. Ramaekers, and Jim van Os. ""An experimental study of catechol-o-methyltransferase Val 158 Met moderation of _-9-tetrahydrocannabinol-induced effects on psychosis and cognition."" Neuropsychopharmacology 31, no. 12 (2006): 2748.",2016,NA,Experiment,PsychosisCases,"Experiment (DoubleBlind, PlaceboControlled, CrossOver) in Psychosis Cases",Netherlands,EverCannabisUse,27.4,18,56,Psychosis-like,THC.PLE,NA,Continuous,CAPE (positive dimension),CAPE,NA,NA,Single dose smoked  (0% vs 13% THC) [in cases with pre-existing psychosis],Single dose smoked (13% THC) [in cases with psychosis],NA,0.3mg THC/kg ,"EXLUDED BECAUSE CASES OF PSYCHOSIS. Active cigarettes were prepared from cannabis containing 13% THC.Subjects smoked the cigarette as completely as possible. mean weight not available, used 80kg as average. 0.3*80=24 ==> 4.8 units",NA,NA,NA,NA,no,Other,Other,yes,betaEstimate,dependent,"beta_to_d_independent(beta=beta_henquet_THC, se=se_henquet_THC, n=n_effective_henquet)",pEstimate_henquet_THCdose,cohen,,No,No
112,Henquet,HenquetExperiment,"Henquet, Cécile, Araceli Rosa, Lydia Krabbendam, Sergi Papiol, Lourdes Fa_anás, Marjan Drukker, Johannes G. Ramaekers, and Jim van Os. ""An experimental study of catechol-o-methyltransferase Val 158 Met moderation of _-9-tetrahydrocannabinol-induced effects on psychosis and cognition."" Neuropsychopharmacology 31, no. 12 (2006): 2748.",2016,NA,Experiment,PsychosisCases,"Experiment (DoubleBlind, PlaceboControlled, CrossOver) in Psychosis Cases",Netherlands,EverCannabisUse,27.4,18,56,Psychosis-like,THC.PLE,NA,Continuous,CAPE (positive dimension),CAPE,NA,NA,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",NA,NA,NA,NA,NA,NA,COMT,no,COMT,CandidateGene,yes,Two-way interaction.,independent,"chies(1.19, n_effective_henquet, dig=50)",pEstimate_henquet_gen_can_interaction,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NA,,,,,,,,,,,,
114,Cuttler,Sexton_survey,"Cuttler, Carrie, Laurie K. Mischley, and Michelle Sexton. ""Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users."" Cannabis and cannabinoid research 1, no. 1 (2016): 166-175.",2016,NA,Observational,GeneralPopulation,Survey - Community Sample,US,Past3monthsCannabisUse,33.72,18,80,Paranoia,Can.PAR,NA,Binary,Select from a list of 41 possible effects of cannabis which they experience when they are stoned (yes/no).,,NA,NA,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,yes,Gender,Demographic,yes,chi-square,independent,extract_cuttler_paranoia,pEstimate_cuttler_paranoia,cohen,,Yes,Yes
115,Cuttler,Sexton_survey,"Cuttler, Carrie, Laurie K. Mischley, and Michelle Sexton. ""Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users."" Cannabis and cannabinoid research 1, no. 1 (2016): 166-175.",2016,NA,Observational,GeneralPopulation,Survey - Community Sample,US,Past3monthsCannabisUse,33.72,18,80,Hallucinations,Can.HAL,NA,Binary,Select from a list of 41 possible effects of cannabis which they experience when they are stoned (yes/no).,,NA,NA,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,chi-square,independent,extract_cuttler_hallucinations,pEstimate_cuttler_hallucinations,cohen,,Yes,Yes
116,Cuttler,Sexton_survey,"Cuttler, Carrie, Laurie K. Mischley, and Michelle Sexton. ""Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users."" Cannabis and cannabinoid research 1, no. 1 (2016): 166-175.",2016,NA,Observational,GeneralPopulation,Survey - Community Sample,US,Past3monthsCannabisUse,33.72,18,80,Paranoia,Can.PAR,psych_like,Binary,Select from a list of 41 possible effects of cannabis which they experience when they are stoned (yes/no).,,NA,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,cuttler2016_canParDF,NA,rates,,Yes,Yes
117,Cuttler,Sexton_survey,"Cuttler, Carrie, Laurie K. Mischley, and Michelle Sexton. ""Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users."" Cannabis and cannabinoid research 1, no. 1 (2016): 166-175.",2016,NA,Observational,GeneralPopulation,Survey - Community Sample,US,Past3monthsCannabisUse,33.72,18,80,Hallucinations,Can.HAL,psych_like,Binary,Select from a list of 41 possible effects of cannabis which they experience when they are stoned (yes/no).,,NA,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,cuttler2016_canHalDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
119,Vadhan,Vadhan,"Vadhan, Nehal P., Cheryl M. Corcoran, Gill Bedi, John G. Keilp, and Margaret Haney. ""Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study."" Psychiatry research 257 (2017): 372-374.",2017,NA,Experiment,MixedPsychosis,Case control psychosis - Randomized Experiment,US,WeeklyCannabisUse,NA,NA,NA,Paranoia,THC.PAR,NA,Continuous,VAS (paranoia),VAS,NA,NA,Clinical high-risk for psychosis  vs. control,High risk psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,,meanComparison,independent,"mes(vadhan_cases_5percTHC_t1_m, vadhan_healthy_5percTHC_t1_m, vadhan_cases_5percTHC_t1_sd, vadhan_healthy_5percTHC_t1_sd, vadhan_cases_n, vadhan_healthy_n, dig=20)",pEstimate_vadhan_caseness_paranoia_smoked_0perc_5.5percTHC,cohen,,Yes,Yes
120,Vadhan,Vadhan,"Vadhan, Nehal P., Cheryl M. Corcoran, Gill Bedi, John G. Keilp, and Margaret Haney. ""Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study."" Psychiatry research 257 (2017): 372-374.",2017,NA,Experiment,GeneralPopulation,Healthy controls - Randomized Experiment,US,WeeklyCannabisUse,NA,NA,NA,Paranoia,THC.PAR,NA,Continuous,VAS (paranoia),VAS,NA,NA,Single dose smoked (50% of joint) (0% vs 5% THC) [in UHR subjects],Single dose smoked (5% THC) [in UHR subjects],NA,NA,NA,NA,NA,NA,NA,no,Other,excluded,yes,meanComparison,dependent,extract_vadhan_cases_paranoia_smoked_0perc_5.5percTHC,pEstimate_vadhan_cases_paranoia_smoked_0perc_5.5percTHC,cohen,,No,No
121,Vadhan,Vadhan,"Vadhan, Nehal P., Cheryl M. Corcoran, Gill Bedi, John G. Keilp, and Margaret Haney. ""Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study."" Psychiatry research 257 (2017): 372-374.",2017,NA,Experiment,Psychosis,UHRl psychosis - Randomized Experiment,US,WeeklyCannabisUse,NA,NA,NA,Paranoia,THC.PAR,NA,Continuous,VAS (paranoia),VAS,NA,NA,Single dose smoked (50% of joint) (0% vs 5% THC),Single dose smoked (5% THC),NA,5%,NOTE: smoked 50% of an active marijuana cigarette,4.25,inhaled,NA,NA,no,SingleDose,excluded,yes,meanComparison,dependent,extract_vadhan_healthy_paranoia_smoked_0perc_5.5percTHC,pEstimate_vadhan_healthy_paranoia_smoked_0perc_5.5percTHC,cohen,,No,No
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
123,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,GeneralPopulation,Survey,UK,EverCannabisUse,29.5,18,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ-PLE,,NA,NA,Cessation of use (current vs. former),Cannabis use (current),NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,meanComparison,independent,"mes(Sami_continued_m, Sami_ceased_m, Sami_continued_sd, Sami_ceased_sd, Sami_continued_N, Sami_ceased_N, dig=20)",pEstimate_Sami_psychlike_ceased_vs_continued,cohen,,Yes,Yes
124,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,GeneralPopulation,Survey,UK,EverCannabisUse,29.5,18,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ-PLE,,NA,NA,Gender (male vs. female) in ceased cannabis users,Gender (male),NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,meanComparison,independent,"mes(Sami_ceased_male_m, Sami_ceased_female_m, Sami_ceased_male_sd, Sami_ceased_female_sd, Sami_ceased_male_N, Sami_ceased_female_N, dig=20)",pEstimate_Sami_psychlike_gender_ceased,cohen,,Yes,Yes
125,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,GeneralPopulation,Survey,UK,EverCannabisUse,29.5,18,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ-PLE,,NA,NA,Gender (male vs. female) in continued cannabis users,Gender (male),NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,meanComparison,independent,"mes(Sami_continued_male_m, Sami_continued_female_m, Sami_continued_male_sd, Sami_continued_female_sd, Sami_continued_male_N, Sami_continued_female_N, dig=20)",pEstimate_Sami_psychlike_gender_continued,cohen,,Yes,Yes
126,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,GeneralPopulation,Survey,UK,EverCannabisUse,29.5,18,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ-PLE,,NA,NA,Intention to quit cannabis in the future (yes vs. no),Intention to quit,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,"mes(Sami_continued_quitYes_m, Sami_continued_quitNo_m, Sami_continued_quitYes_sd, Sami_continued_quitNo_se, Sami_continued_quitYes_N, Sami_continued_quitNo_N, dig=20)",pEstimate_Sami_continued_quit_yes_vs_no,cohen,,Yes,Yes
127,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,GeneralPopulation,Survey,UK,EverCannabisUse,29.5,18,NA,Psychosis-like,Can.PAR,psych_like,Binary,CEQ-Paranoia,,Feeling suspicious while under the influence of cannabis?,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,sami2019survey_canParDF,NA,rates,,Yes,Yes
128,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,GeneralPopulation,Survey,UK,EverCannabisUse,29.5,18,NA,Psychosis-like,Can.HAL,psych_like,Binary,CEQ-Hallucinations,,Hearing voices while under the influence of cannabis?,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,sami2019survey_canHalDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
130,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,GeneralPopulation,"Experiment (DoubleBlind, PlaceboControlled, CrossOver)",US,InfrequentCannabisUser,27.3,NA,NA,Paranoia,THC.PAR,NA,Continuous,DEQ,DEQ,Do you feel an unpleasant drug effect? - Paranoid,NA,Route (25mg THC: vaporizer vs. smoke),Route (vaporized),NA,NA,NA,NA,inhaled,NA,NA,no,Route (vaporized),CannabisDynamics,yes,meanComparison(change),dependent,extract_spindle_paranoia_25mgTHC_smoked_vs_vaped,pEstimate_Spindle_paranoia_vaporizer_smoke_25mgTHC,cohen,,No,No
131,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,GeneralPopulation,"Experiment (DoubleBlind, PlaceboControlled, CrossOver)",US,InfrequentCannabisUser,27.3,NA,NA,Paranoia,THC.PAR,NA,Continuous,DEQ,DEQ,Do you feel an unpleasant drug effect? - Paranoid,NA,Single dose smoked (0mg vs 10mg THC),Single dose smoked (10mg THC),NA,10mg,NA,2,inhaled,1,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_spindle_paranoia_smoked_0mg_10mgTHC,pEstimate_spindle_paranoia_smoked_0mg_10mgTHC,cohen,,Yes,Yes
132,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,GeneralPopulation,"Experiment (DoubleBlind, PlaceboControlled, CrossOver)",US,InfrequentCannabisUser,27.3,NA,NA,Paranoia,THC.PAR,NA,Continuous,DEQ,DEQ,Do you feel an unpleasant drug effect? - Paranoid,NA,Single dose smoked (0mg vs 25mg THC),Single dose smoked (25mg THC),NA,25mg,NA,5,inhaled,2,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_spindle_paranoia_smoked_0mg_25mgTHC,pEstimate_spindle_paranoia_smoked_0mg_25mgTHC,cohen,,Yes,Yes
133,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,GeneralPopulation,"Experiment (DoubleBlind, PlaceboControlled, CrossOver)",US,InfrequentCannabisUser,27.3,NA,NA,Paranoia,THC.PAR,NA,Continuous,DEQ,DEQ,Do you feel an unpleasant drug effect? - Paranoid,NA,Single dose vaped (0mg vs 10mg THC),Single dose vaped (10mg THC),NA,10mg,NA,2,inhaled,1,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_spindle_paranoia_vaped_0mg_10mgTHC,pEstimate_spindle_paranoia_vaped_0mg_10mgTHC,cohen,,Yes,Yes
134,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,GeneralPopulation,"Experiment (DoubleBlind, PlaceboControlled, CrossOver)",US,InfrequentCannabisUser,27.3,NA,NA,Paranoia,THC.PAR,NA,Continuous,DEQ,DEQ,Do you feel an unpleasant drug effect? - Paranoid,NA,Single dose vaped (0mg vs 25mg THC),Single dose vaped (25mg THC),NA,25mg,NA,5,inhaled,2,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_spindle_paranoia_vaped_0mg_25mgTHC,pEstimate_spindle_paranoia_vaped_0mg_25mgTHC,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
136,Spindle2,Spindle2019,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute pharmacokinetic profile of smoked and vaporized cannabis in human blood and oral fluid."" Journal of analytical toxicology 43, no. 4 (2019): 233-258.",2019,2016-2017,Experiment,GeneralPopulation,"Experiment (DoubleBlind, PlaceboControlled, CrossOver)",US,InfrequentCannabisUser,27.3,NA,NA,Hallucinations,THC.HAL,psych_like,Binary,Acute reaction following THC administration,,NA,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,spindle2019vapeTHC_halDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
138,Spindle3,MEGA_Vandrey_Schlienz_Spindle,"Spindle, Tory R., Edward J. Cone, Elia Goffi, Elise M. Weerts, John M. Mitchell, Ruth E. Winecker, George E. Bigelow, Ronald R. Flegel, and Ryan Vandrey. ""Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users."" Drug and Alcohol Dependence (2020): 107937.",2020,NA,Experiment,NA,"Randomized, double-blind, placebo-controlled, within-subjects crossover ",US,"Previous cannabis use, not in the last month",31,18,45,Paranoia,THC.PAR,NA,Binary,Single item,,Do you feel an unpleasant drug effect? - Paranoid,NA,Single dose vaped (0mg vs 3.7mg THC of CBD dominant cannabis),Single dose vaped (3.7mg THC),NA,NA,NA,0.74,NA,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_spindle2020_paranoia_canCBD,pEstimate_spindle2020_paranoia_canCBD,cohen,,Yes,Yes
139,Spindle3,MEGA_Vandrey_Schlienz_Spindle,"Spindle, Tory R., Edward J. Cone, Elia Goffi, Elise M. Weerts, John M. Mitchell, Ruth E. Winecker, George E. Bigelow, Ronald R. Flegel, and Ryan Vandrey. ""Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users."" Drug and Alcohol Dependence (2020): 107937.",2020,NA,Experiment,NA,"Randomized, double-blind, placebo-controlled, within-subjects crossover ",US,"Previous cannabis use, not in the last month",31,18,45,Paranoia,THC.PAR,NA,Binary,Single item,,Do you feel an unpleasant drug effect? - Paranoid,NA,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,yes,Gender,Demographic,yes,meanComparison,independent,"fes(spindle2020_paranoia_sex_f, spindle2020_male_n, spindle2020_female_n,  dig=20)",pEstimate_spindle2020_paranoia_sex,cohen,,No,No
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
141,Schlienz,Vandrey_T32DA07209,"Schlienz, Nicolas J., Tory R. Spindle, Edward J. Cone, Evan S. Herrmann, George E. Bigelow, John M. Mitchell, Ronald Flegel, Charles LoDico, and Ryan Vandrey. ""Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis."" Drug and alcohol dependence (2020): 107969.",2020,NA,Experiment,GeneralPopulation,"Experiment ( within-subjects crossover design, Placebo-Controlled, double blind)",US,InfrequentCannabisUser (not in the past 60 days),25.2,18,45,Paranoia,THC.PAR,NA,Continuous,VAS (paranoia),VAS,NA,NA,Single dose oral (0mg vs 10mg THC),Single dose oral (10mg THC),NA,10mg,NA,2,inhaled,1,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_schlienz2020_edibleTHC_0mg_10mgTHC,pEstimate_schlienz2020_edibleTHC_0mg_10mgTHC,cohen,,Yes,Yes
142,Schlienz,Vandrey_T32DA07209,"Schlienz, Nicolas J., Tory R. Spindle, Edward J. Cone, Evan S. Herrmann, George E. Bigelow, John M. Mitchell, Ronald Flegel, Charles LoDico, and Ryan Vandrey. ""Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis."" Drug and alcohol dependence (2020): 107969.",2020,NA,Experiment,GeneralPopulation,"Experiment ( within-subjects crossover design, Placebo-Controlled, double blind)",US,InfrequentCannabisUser (not in the past 60 days),25.2,18,45,Paranoia,THC.PAR,NA,Continuous,VAS (paranoia),VAS,NA,NA,Single dose vaped (0mg vs 25mg THC),Single dose vaped (25mg THC),NA,25mg,NA,5,inhaled,2,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_schlienz2020_edibleTHC_0mg_25mgTHC,pEstimate_schlienz2020_edibleTHC_0mg_25mgTHC,cohen,,Yes,Yes
143,Schlienz,Vandrey_T32DA07209,"Schlienz, Nicolas J., Tory R. Spindle, Edward J. Cone, Evan S. Herrmann, George E. Bigelow, John M. Mitchell, Ronald Flegel, Charles LoDico, and Ryan Vandrey. ""Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis."" Drug and alcohol dependence (2020): 107969.",2020,NA,Experiment,GeneralPopulation,"Experiment ( within-subjects crossover design, Placebo-Controlled, double blind)",US,InfrequentCannabisUser (not in the past 60 days),25.2,18,45,Paranoia,THC.PAR,NA,Continuous,VAS (paranoia),VAS,NA,NA,Single dose vaped (0mg vs 50mg THC),Single dose vaped (50mg THC),NA,50mg,NA,10,inhaled,3,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_schlienz2020_edibleTHC_0mg_50mgTHC,pEstimate_schlienz2020_edibleTHC_0mg_50mgTHC,cohen,,Yes,Yes
144,Schlienz,Vandrey_T32DA07209,"Schlienz, Nicolas J., Tory R. Spindle, Edward J. Cone, Evan S. Herrmann, George E. Bigelow, John M. Mitchell, Ronald Flegel, Charles LoDico, and Ryan Vandrey. ""Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis."" Drug and alcohol dependence (2020): 107969.",2020,NA,Experiment,GeneralPopulation,"Experiment ( within-subjects crossover design, Placebo-Controlled, double blind)",US,InfrequentCannabisUser (not in the past 60 days),25.2,18,45,Paranoia,THC.PAR,NA,Continuous,VAS (paranoia),VAS,NA,NA,Dose response oral (0mg/10mg/25mf/ 50mg THC),Dose response oral (0mg/10mg/25mf/ 50mg THC),NA,NA,NA,NA,NA,NA,NA,no,DoseResponseTHC,CannabisDynamics,yes,meanComparison(change),dependent,"pes(0.00009, n_effective_schlienz2020_edibleTHC/2, n_effective_schlienz2020_edibleTHC/2, dig=50)",pEstimate_schlienz2020_edibleTHC_doseTHC,cohen,,No,No
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
146,Fuente,Fuente,"de la Fuente, Alethia, Federico Zamberlan, Andrés Sánchez Ferrán, Facundo Carrillo, Enzo Tagliazucchi, and Carla Pallavicini. ""Over eight hundred cannabis strains characterized by the relationship between their psychoactive effects, perceptual profiles, and chemical compositions."" bioRxiv (2019): 759696.",2019,2010-2018,Observational,GeneralPopulation,OnlineRatings,Worldwide,CannabisUser,NA,NA,NA,Paranoia,Can.PAR,NA,Continuous,"Unpleasant effects (mean, paranoia)",,NA,NA,Type of cannabis (indica vs. sativa),Indica (vs. sativa),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison(change),independent,"mes(M_Indica, M_Sativa, SD_Indica, SD_Sativa, N_Indica, N_Sativa, dig=20)",pEstimate_fuente2019_paranoia_indica_sativa,cohen,,Yes,Yes
147,Fuente,Fuente,"de la Fuente, Alethia, Federico Zamberlan, Andrés Sánchez Ferrán, Facundo Carrillo, Enzo Tagliazucchi, and Carla Pallavicini. ""Over eight hundred cannabis strains characterized by the relationship between their psychoactive effects, perceptual profiles, and chemical compositions."" bioRxiv (2019): 759696.",2019,2010-2018,Observational,GeneralPopulation,OnlineRatings,Worldwide,CannabisUser,NA,NA,NA,Paranoia,Can.PAR,NA,Continuous,"Unpleasant effects (mean, paranoia)",,NA,NA,Type of cannabis (indica vs. hybrid),Indica (vs. hybrid),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison(change),independent,"mes(M_Indica, M_Hybrid, SD_Indica, SD_Hybrid, N_Indica, N_Hybrid, dig=20)",pEstimate_fuente2019_paranoia_indica_hybrid,cohen,,Yes,Yes
148,Fuente,Fuente,"de la Fuente, Alethia, Federico Zamberlan, Andrés Sánchez Ferrán, Facundo Carrillo, Enzo Tagliazucchi, and Carla Pallavicini. ""Over eight hundred cannabis strains characterized by the relationship between their psychoactive effects, perceptual profiles, and chemical compositions."" bioRxiv (2019): 759696.",2019,2010-2018,Observational,GeneralPopulation,OnlineRatings,Worldwide,CannabisUser,NA,NA,NA,Paranoia,Can.PAR,NA,Continuous,"Unpleasant effects (mean, paranoia)",,NA,NA,Type of cannabis (hybrid vs. sativa),Hybrid (vs. sativa),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison(change),independent,"mes(M_Hybrid, M_Sativa, SD_Hybrid, SD_Sativa, N_Hybrid, N_Sativa, dig=20)",pEstimate_fuente2019_paranoia_sativa_hybrid,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
150,Mason,Morgan_Curran_MRC,"Mason, O., C. J. A. Morgan, S. K. Dhiman, A. Patel, N. Parti, and H. V. Curran. ""Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis."" Psychological medicine 39, no. 6 (2009): 951-956.",2009,NA,QuasiExperimental,GeneralPopulation,QuasiExperimental,UK,PastMonthCannabisUser,24.2,NA,NA,Psychosis-like,High.PLE,NA,Continuous,PSI (total),PSI,NA,NA,Frequency of cannabis use,Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,yes,Tolerance,exlcuded,yes,correlation,independent,"res(mason_can_r, n=mason_can_frequency_n, dig=20)",pEstimate_mason_canFrequency_psychlike,cohen,,no,no
151,Mason,Morgan_Curran_MRC,"Mason, O., C. J. A. Morgan, S. K. Dhiman, A. Patel, N. Parti, and H. V. Curran. ""Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis."" Psychological medicine 39, no. 6 (2009): 951-956.",2009,NA,QuasiExperimental,GeneralPopulation,QuasiExperimental,UK,PastMonthCannabisUser,24.2,NA,NA,Psychosis-like,High.PLE,NA,Continuous,PSI (total),PSI,NA,NA,Cannabis group (current user vs. control with at least 6 months of use),Cessation of use (current user),NA,NA,NA,NA,NA,NA,NA,no,Cessation,exlcuded,yes,meanComparison,independent,"fes(mason_can_vs_control_PSI_f, mason_can_n, mason_control_n,  dig=20)",pEstimate_mason_can_vs_control_PSI,cohen,,no,no
152,Mason,Morgan_Curran_MRC,"Mason, O., C. J. A. Morgan, S. K. Dhiman, A. Patel, N. Parti, and H. V. Curran. ""Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis."" Psychological medicine 39, no. 6 (2009): 951-956.",2009,NA,QuasiExperimental,GeneralPopulation,QuasiExperimental,UK,PastMonthCannabisUser,24.2,NA,NA,Paranoia,High.PAR,NA,Continuous,PSI (delusion subscale),PSI,NA,NA,Cannabis group (current user vs. control with at least 6 months of use),Cessation of use (current user),NA,NA,NA,NA,NA,NA,NA,no,Cessation,exlcuded,yes,meanComparison,independent,"fes(mason_can_vs_control_paranoia_f, mason_can_n, mason_control_n,  dig=20)",pEstimate_mason_can_vs_control_paranoia,cohen,,no,no
153,Mason,Morgan_Curran_MRC,"Mason, O., C. J. A. Morgan, S. K. Dhiman, A. Patel, N. Parti, and H. V. Curran. ""Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis."" Psychological medicine 39, no. 6 (2009): 951-956.",2009,NA,QuasiExperimental,GeneralPopulation,QuasiExperimental,UK,PastMonthCannabisUser,24.2,NA,NA,Psychosis-like,High.PLE,NA,Continuous,PSI (total),PSI,NA,NA,Schizotype (high vs. low),Schizotype (high),NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,exlcuded,yes,meanComparison,independent,"fes(mason_highSchizotype_vs_lowSchizotype_PSI_f, mason_can_n, mason_control_n,  dig=20)",pEstimate_mason_highSchizotype_vs_lowSchizotype_PSI,cohen,,no,no
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
155,D'Souza,DSouza,"D'Souza, Deepak Cyril, Edward Perry, Lisa MacDougall, Yola Ammerman, Thomas Cooper, Gabriel Braley, Ralitza Gueorguieva, and John Harrison Krystal. ""The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis."" Neuropsychopharmacology 29, no. 8 (2004): 1558-1572.",2004,NA,Experiment,MixedPsychosis,Experiment,US,EverCannabisUse,29,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Caseness (psychosis patient vs health control),Psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,dependent,"chies(chiSquEstimate_souza_dose_case_interaction, n_effective_healthy_souza+n_effective_cases_souza, dig=50)",pEstimate_Dsouza_PANSS_pos_dose_case_interaction,cohen,,Yes,No
156,D'Souza,DSouza,"D’Souza, Deepak Cyril, Walid Michel Abi-Saab, Steven Madonick, Kimberlee Forselius-Bielen, Anne Doersch, Gabriel Braley, Ralitza Gueorguieva, Thomas B. Cooper, and John Harrison Krystal. ""Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction."" Biological psychiatry 57, no. 6 (2005): 594-608.",2005,NA,Experiment,GeneralPopulation,Experiment,US,EverCannabisUse,44,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose IV (0mg vs 2.5mg),Single dose IV (2.5mg),NA,2.5mg,NA,0.5,intravenous,1,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_souza_2.5mg_THC_panss,pEstimate_Dsouza_PANSS_pos_dose,cohen,,Yes,No
157,D'Souza,DSouza,"D’Souza, Deepak Cyril, Walid Michel Abi-Saab, Steven Madonick, Kimberlee Forselius-Bielen, Anne Doersch, Gabriel Braley, Ralitza Gueorguieva, Thomas B. Cooper, and John Harrison Krystal. ""Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction."" Biological psychiatry 57, no. 6 (2005): 594-608.",2005,NA,Experiment,GeneralPopulation,Experiment,US,EverCannabisUse,44,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose IV (0mg vs 5mg),Single dose IV (5mg),NA,5mg,NA,1,intravenous,2,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_souza_5mg_THC_panss,pEstimate_Dsouza_PANSS_pos_dose,cohen,,Yes,No
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
159,Solowij,Solowij,"Solowij, Nadia, Samantha Broyd, Lisa-marie Greenwood, Hendrika van Hell, Dave Martelozzo, Kuna Rueb, Juanita Todd et al. ""A randomised controlled trial of vaporised _ 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects."" European archives of psychiatry and clinical neuroscience 269, no. 1 (2019): 17-35.",2019,NA,Experiment,GeneralPopulation,Experiment,Australia,UsedPast2Years,NA,21,44,Delusional thinking,High.DEL,NA,Continuous,PSI (delusion subscale),PSI,NA,NA,Intoxication experiences (8mg THC),Intoxication experiences (8mg THC),NA,NA,NA,NA,NA,NA,NA,no,SubjectiveHigh,exlcuded,yes,correlation,independent,"res(rValueNS_allStudies, n=nSolowij, dig=20) ",pEstimate_solowij_delusions,cohen,,no,no
160,Solowij,Solowij,"Solowij, Nadia, Samantha Broyd, Lisa-marie Greenwood, Hendrika van Hell, Dave Martelozzo, Kuna Rueb, Juanita Todd et al. ""A randomised controlled trial of vaporised _ 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects."" European archives of psychiatry and clinical neuroscience 269, no. 1 (2019): 17-35.",2019,NA,Experiment,GeneralPopulation,Experiment,Australia,UsedPast2Years,NA,21,44,Paranoia,High.PAR,NA,Continuous,PSI (paranoia subscale),PSI,NA,NA,Intoxication experiences (8mg THC),Intoxication experiences (8mg THC),NA,NA,NA,NA,NA,NA,NA,no,SubjectiveHigh,exlcuded,yes,correlation,independent,"res(rValueNS_allStudies, n=nSolowij, dig=20) ",pEstimate_solowij_paranoia,cohen,,no,no
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
162,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,chi-square,independent,extract_krebs_gender,pEstimate_krebs_gender,cohen,,Yes,Yes
163,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,Family history (mood disorder),Mood disorder (fam hx),NA,NA,NA,NA,NA,NA,NA,no,Depression,MentalHealthPersonality,yes,chi-square,independent,extract_krebs_mood,pEstimate_krebs_mood,cohen,,Yes,Yes
164,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,Family history (psychosis),Psychosis (fam hx),NA,NA,NA,NA,NA,NA,NA,yes,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_krebs_psychosishx,pEstimate_krebs_psychosishx,cohen,,Yes,Yes
165,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,Age (young vs. old),Age (young),NA,NA,NA,NA,NA,NA,NA,yes,Age,Demographic,yes,chi-square,independent,extract_krebs_age,pEstimate_krebs_age,cohen,,Yes,Yes
166,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,"CNR1 (rs806379, risk allele: T)","CNR1 (rs806379, risk allele: T)",NA,NA,NA,NA,NA,NA,CNR1,yes,CNR1,CandidateGene,yes,chi-square,independent,"chies(KrebsCNR1_rs806379,59+485, dig=50)",pEstimate_krebs_rs806379,cohen,,Yes,Yes
167,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,"CNR1 (rs1535255, risk allele: C)","CNR1 (rs1535255, risk allele: C)",NA,NA,NA,NA,NA,NA,CNR1,no,CNR1,CandidateGene,yes,chi-square,independent,"chies(KrebsCNR1_rs1535255,58+485, dig=50)",pEstimate_krebs_rs1535255,cohen,,Yes,Yes
168,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,"CNR1 (rs2023239, risk allele: A)","CNR1 (rs2023239, risk allele: A)",NA,NA,NA,NA,NA,NA,CNR1,yes,CNR1,CandidateGene,yes,chi-square,independent,"chies(KrebsCNR1_rs2023239, 59+481, dig=50)",pEstimate_krebs_rs2023239,cohen,,Yes,Yes
169,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,"CNR1 (rs1049353, A)","CNR1 (rs1049353, A)",NA,NA,NA,NA,NA,NA,CNR1,no,CNR1,CandidateGene,yes,chi-square,independent,"chies(KrebsCNR1_rs1049353, 59+476, dig=50)",pEstimate_krebs_rs1049353,cohen,,Yes,Yes
170,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,"CNR1 (rs12720071, risk allele: G)","CNR1 (rs12720071, risk allele: G)",NA,NA,NA,NA,NA,NA,CNR1,yes,CNR1,CandidateGene,yes,chi-square,independent,"chies(KrebsCNR1_rs12720071, 59+485, dig=50)",pEstimate_krebs_rs12720071,cohen,,Yes,Yes
171,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",NA,NA,NA,NA,NA,NA,COMT,no,COMT,CandidateGene,yes,chi-square,independent,"chies(KrebsCOMT_rs4680, 59+479, dig=50)",pEstimate_krebs_rs4680,cohen,,Yes,Yes
172,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,"BDNF (rs6265, risk allele: G)","BDNF (rs6265, risk allele: G)",NA,NA,NA,NA,NA,NA,BDNF,no,BDNF,CandidateGene,yes,chi-square,independent,"chies(KrebsBDNF_rs6265, 59+479, dig=50)",pEstimate_krebs_rs6265,cohen,,Yes,Yes
173,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,"AKT1 (rs1130233, risk allele: A)","AKT1 (rs1130233, risk allele: A)",NA,NA,NA,NA,NA,NA,AKT1,no,AKT1,CandidateGene,yes,chi-square,independent,"chies(KrebsAKT_rs1130233, 59+479, dig=50)",pEstimate_krebs_rs1130233,cohen,,Yes,Yes
174,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,NA,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,"AKT1 (rs2494732, risk allele: C)","AKT1 (rs2494732, risk allele: C)",NA,NA,NA,NA,NA,NA,AKT1,yes,AKT1,CandidateGene,yes,chi-square,independent,"chies(KrebsAKT_rs2494732, 59+479, dig=50)",pEstimate_krebs_rs2494732,cohen,,Yes,Yes
175,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,GeneralPopulation,Survey,France,EverCannabisUse,19.8,NA,NA,Psychosis-like,Can.PLE,psych_like,Binary,Cut-off subjective experiences at first time cannabis use questionnaire,,NA,12,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,krebs2014_PLE_DF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
177,Barkus,Barkus_sample2,"Barkus, Emma J., John Stirling, Richard S. Hopkins, and Shon Lewis. ""Cannabis-induced psychosis-like experiences are associated with high schizotypy."" Psychopathology 39, no. 4 (2006): 175-178.",2006,NA,Observational,GeneralPopulation,Survey,UK,EverCannabisUse,22.1,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Schizotype (disorganised),Schizotype (disorganized),NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,correlation,independent,"res(spqb_d_cor, n=N_Barkus_2006, dig=20)",pEstimate_barkus_spqb_d_cor,cohen,,Yes,Yes
178,Barkus,Barkus_sample2,"Barkus, Emma J., John Stirling, Richard S. Hopkins, and Shon Lewis. ""Cannabis-induced psychosis-like experiences are associated with high schizotypy."" Psychopathology 39, no. 4 (2006): 175-178.",2006,NA,Observational,GeneralPopulation,Survey,UK,EverCannabisUse,22.1,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Schizotype (cognitive-perceptual),Schizotype (cognitive-perceptual),NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,correlation,independent,"res(spqb_cp_cor, n=N_Barkus_2006, dig=20)",pEstimate_barkus_spqb_cp_cor,cohen,,Yes,Yes
179,Barkus,Barkus_sample2,"Barkus, Emma J., John Stirling, Richard S. Hopkins, and Shon Lewis. ""Cannabis-induced psychosis-like experiences are associated with high schizotypy."" Psychopathology 39, no. 4 (2006): 175-178.",2006,NA,Observational,GeneralPopulation,Survey,UK,EverCannabisUse,22.1,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Schizotype,Schizotype,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,correlation,independent,"res(spqb_tot_cor, n=N_Barkus_2006, dig=20)",pEstimate_barkus_spqb_tot_cor,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
181,Winstock,Winstock,"Winstock, Adam R., and Monica J. Barratt. ""Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample."" Drug and alcohol dependence 131, no. 1-2 (2013): 106-111.",2013,2012,Observational,GeneralPopulation,Survey,Worldwide,EverCannabisUse,NA,NA,NA,Paranoia,Can.PAR,NA,Continuous,Single Item,,"Effects of using cannabis, rates on a 10 item scale (paranois)",NA,Type of cannabis (spice vs. normal),Synthetic cannabis,NA,NA,NA,NA,NA,NA,NA,no,THCcontent,CannabisStrain,yes,meanComparison,dependent,extract_winstock_delusional,pEstimate_winstock_delusional,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
183,Englund,Englund,"Englund, Amir, Zerrin Atakan, Aleksandra Kralj, Nigel Tunstall, Robin Murray, and Paul Morrison. ""The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial."" Journal of Psychopharmacology 30, no. 2 (2016): 140-151.",2016,NA,Experiment,GeneralPopulation,"Randomized, double-blind, placebo-controlled, cross- over study",UK,"EverCannabis, less than 25/lifetime",23.8,21,35,Psychosis-like (severity),THC.PLE,NA,Continuous,CAPE (positive dimension),,NA,NA,Single dose IV (0mg vs 1mg THC),Single dose IV (1mg THC),NA,1mg,NA,0.2,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_englund_cape_IV_1mg_THC,pEstimate_englund_cape_IV_1mg_THC,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
185,Stone,Stone,"Stone, J.M., Morrison, P.D., Brugger, S., Nottage, J., Bhattacharyya, S., Sumich, A., Wilson, D., Tunstall, N., Feilding, A., Brenneisen, R. and McGuire, P., 2012. Communication breakdown: delta-9 tetrahydrocannabinol effects on pre-speech neural coherence. Molecular psychiatry, 17(6), pp.568-569.",2012,NA,Experiment,GeneralPopulation,"Experiment (DoubleBlind, PlaceboControlled, CrossOverO",UK,EverCannabisUse,26,21,31,Paranoia,THC.PAR,NA,Continuous,SECQ (paranoia),,NA,NA,Single dose IV (0mg vs 1.25mg THC),Single dose IV (1.25mg THC),NA,1.25mg,NA,0.25,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_stone_paranoia_0perc_1.25mgTHC,pEstimate_stone_paranoia_0perc_1.25mgTHC,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
187,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,PastMonthCannabisUser,22,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),NA,8mg,inhale from balloon until empty,1.6,inhaled,NA,NA,no,SingleDose,CannabisDynamics,yes,p-value,dependent,"pes(p_PSI_8mgTHC, n_effective_morgan_experiment/2, n_effective_morgan_experiment/2, dig=20) ",pEstimate_morgan_PSI_8mgTHC,cohen,,No,No
188,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,PastMonthCannabisUser,22,NA,NA,Delusions,THC.DEL,NA,Continuous,PSI (delusion subscale),,NA,NA,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),NA,8mg,inhale from balloon until empty,1.6,inhaled,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_morgan_psi_delusions_8mgTHC,pEstimate_morgan_psi_delusions_8mgTHC,cohen,,Yes,Yes
189,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,PastMonthCannabisUser,22,NA,NA,Paranoia,THC.PAR,NA,Continuous,PSI (paranoia subscale),,NA,NA,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),NA,8mg,inhale from balloon until empty,1.6,inhaled,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_morgan_psi_paranoia_8mgTHC,pEstimate_morgan_psi_paranoia_8mgTHC,cohen,,Yes,Yes
190,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,PastMonthCannabisUser,22,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,BPRS (positive subscale),BPRS,NA,NA,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),NA,8mg,inhale from balloon until empty,1.6,inhaled,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_morgan_bprs_8mgTHC,pEstimate_morgan_bprs_8mgTHC,cohen,,Yes,Yes
191,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,PastMonthCannabisUser,22,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,BPRS (positive subscale),BPRS,NA,NA,CBD (16mg),CBD (16mg),NA,NA,NA,NA,NA,NA,NA,no,CBD (administration),CannabisDynamics,yes,meanComparison,dependent,extract_morgan_bprs_8mgTHC_16mgCBD,pEstimate_morgan_bprs_8mgTHC_16mgCBD,cohen,,Yes,Yes
192,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,PastMonthCannabisUser,22,NA,NA,Psychosis-like,THC.DEL,NA,Continuous,PSI (delusion subscale),,NA,NA,CBD (16mg),CBD (16mg),NA,NA,NA,NA,NA,NA,NA,no,CBD (administration),CannabisDynamics,yes,meanComparison,dependent,extract_morgan_psi_delusions_16mgCBD,pEstimate_morgan_delusions_8mgTHC_16mgCBD,cohen,,Yes,Yes
193,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,PastMonthCannabisUser,22,NA,NA,Psychosis-like,THC.PAR,NA,Continuous,PSI (paranoia subscale),,NA,NA,CBD (16mg),CBD (16mg),NA,NA,NA,NA,NA,NA,NA,no,CBD (administration),CannabisDynamics,yes,meanComparison,dependent,extract_morgan_psi_paranoia_16mgCBD,pEstimate_morgan_paranoia_8mgTHC_16mgCBD,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
195,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, Philip McGuire, David Lythgoe, Steve Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis."" Molecular psychiatry (2019): 1-10.",2019,,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover design",UK,Previous cannabis use but no use in the last 6 months,24.44,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,69,Single dose IV 1.19 mg/2 ml THC,Single dose IV 1.19 mg/2 ml THC,NA,1.19 mg,NA,0.38,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,p-value,dependent,"pes(colizzi_panss_pos_THC_p, n_effective_colizzi_experiment/2, n_effective_colizzi_experiment/2, dig=20) ",pEstimate_colizzi_panss_pos_THC,cohen,,Yes,Yes
196,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, Philip McGuire, David Lythgoe, Steve Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis."" Molecular psychiatry (2019): 1-10.",2019,,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover design",UK,Previous cannabis use but no use in the last 6 months,24.44,NA,NA,Acute psychotic reaction,THC.PLE,NA,Binary,PANSS (positive),PANSS,NA,69,Glutamate levels (baseline),Glutamate levels (baseline),NA,NA,NA,NA,NA,NA,NA,no,Glutamate,Neurotransmission,yes,meanComparison,independent,colizzi_can_sensitive_glutamate_baseline,pEstimate_colizzi_can_sensitive_glutamate_baseline,cohen,,Yes,Yes
197,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, Philip McGuire, David Lythgoe, Steve Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis."" Molecular psychiatry (2019): 1-10.",2019,,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover design",UK,Previous cannabis use but no use in the last 6 months,24.44,NA,NA,Acute psychotic reaction,THC.PLE,NA,Binary,PANSS (positive),PANSS,NA,69,Change in glutamate levels (following THC administration),Glutamate levels (change following THC),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,"mes(colizzi_can_sensitive_glutamate_change_mean, colizzi_can_non_sensitive_glutamate_change_mean, colizzi_can_sensitive_glutamate_change_sd, colizzi_can_non_sensitive_glutamate_change_sd, colizzi_sensitive_n, colizzi_non_sensitive_n, dig=20)",pEstimate_colizzi_can_sensitive_glutamate_change,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
199,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Pre−existing psychosis (present vs. absent),Psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,meanComparison,independent,eugei_sami_PLEs_casenessExtracted,pEstimate_eugei_sami_PLEs_caseness,cohen,,Yes,Yes
200,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Frequency of cannabis use,Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,meanComparison,independent,eugei_sami_PLEs_frequencyExtracted,pEstimate_eugei_sami_PLEs_frequency,cohen,,Yes,Yes
201,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,CannabisType (high vs. low potency),Cannabis type (high potency),NA,NA,NA,NA,NA,NA,NA,no,THCcontent,CannabisStrain,yes,meanComparison,independent,eugei_sami_PLEs_potencyExtracted,pEstimate_eugei_sami_PLEs_potency,cohen,,Yes,Yes
202,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Money spent on cannabis,Cannabis amount (high),NA,NA,NA,NA,NA,NA,NA,no,CannabisSeverity,CannabisHistory,yes,meanComparison,independent,eugei_sami_PLEs_moneyExtracted,pEstimate_eugei_sami_PLEs_money,cohen,,Yes,Yes
203,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Frequency of cannabis use x caseness interaction,Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,eugei_sami_PLEs_frequencyxcasenessExtracted,pEstimate_eugei_sami_PLEs_frequencyxcaseness,cohen,,Yes,Yes
204,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Potency (high vs. low potency)  x caseness interaction,Potency (high)  x caseness interaction,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,eugei_sami_PLEs_potencyxcasenessExtracted,pEstimate_eugei_sami_PLEs_potencyxcaseness,cohen,,Yes,Yes
205,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Money spent on cannabis  x caseness interaction,Cannabis amount  x caseness interaction,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,eugei_sami_PLEs_moneyxcasenessExtracted,pEstimate_eugei_sami_PLEs_moneyxcaseness,cohen,,Yes,Yes
206,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Inhalant use (lifetime),Inhalant use (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Inhalants,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_inhalantsLifetimeExtracted,pEstimate_eugei_sami_PLEs_inhalantsLifetime,cohen,,Yes,Yes
207,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Inhalant misuse (lifetime),Inhalant misuse (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Inhalants,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_inhalantsmisuseExtracted,pEstimate_eugei_sami_PLEs_inhalantsmisuse,cohen,,Yes,Yes
208,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Crack use (lifetime),Crack use (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Crack,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_crackLifetimeExtracted,pEstimate_eugei_sami_PLEs_crackLifetime,cohen,,Yes,Yes
209,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Crack misuse (lifetime),Crack misuse (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Crack,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_crackmisuseExtracted,pEstimate_eugei_sami_PLEs_crackmisuse,cohen,,Yes,Yes
210,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Cocaine use (lifetime),Cocaine use (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Cocaine,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_cocaineLifetimeExtracted,pEstimate_eugei_sami_PLEs_cocaineLifetime,cohen,,Yes,Yes
211,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Cocaine misuse (lifetime),Cocaine misuse (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Cocaine,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_cocainemisuseExtracted,pEstimate_eugei_sami_PLEs_cocainemisuse,cohen,,Yes,Yes
212,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Stimulant use (lifetime),Stimulant use (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Stimulants,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_stimulantsLifetimeExtracted,pEstimate_eugei_sami_PLEs_stimulantsLifetime,cohen,,Yes,Yes
213,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Stimulant misuse (lifetime),Stimulant misuse (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Stimulants,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_stimulantsmisuseExtracted,pEstimate_eugei_sami_PLEs_stimulantsmisuse,cohen,,Yes,Yes
214,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Sedative use (lifetime),Sedative use (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Sedatives,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_sedativesLifetimextracted,pEstimate_eugei_sami_PLEs_sedativesLifetime,cohen,,Yes,Yes
215,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Sedative misuse (lifetime),Sedative misuse (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Sedatives,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_sedativesmisuseExtracted,pEstimate_eugei_sami_PLEs_sedativesmisuse,cohen,,Yes,Yes
216,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Opioid use (lifetime),Opioid use (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Opioids,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_opioidsLifetimeExtracted,pEstimate_eugei_sami_PLEs_opioidsLifetime,cohen,,Yes,Yes
217,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Opioid misuse (lifetime),Opioid misuse (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Opioids,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_opioidsmisuseExtracted,pEstimate_eugei_sami_PLEs_opioidsmisuse,cohen,,Yes,Yes
218,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Hallucinogen use (lifetime),Hallucinogen use (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Hallucinogens,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_hallucinogensLifetimeExtracted,pEstimate_eugei_sami_PLEs_hallucinogensLifetime,cohen,,Yes,Yes
219,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Hallucinogen misuse (lifetime),Hallucinogen misuse (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Hallucinogens,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_hallucinogensmisuseExtracted,pEstimate_eugei_sami_PLEs_hallucinogensmisuse,cohen,,Yes,Yes
220,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Ketamine use (lifetime),Ketamine use (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Ketamine,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_ketamineLifetimeExtracted,pEstimate_eugei_sami_PLEs_ketamineLifetime,cohen,,Yes,Yes
221,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Ketamine misuse (lifetime),Ketamine misuse (lifetime),NA,NA,NA,NA,NA,NA,NA,no,Ketamine,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_ketaminemisuseExtracted,pEstimate_eugei_sami_PLEs_ketaminemisuse,cohen,,Yes,Yes
222,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Novel psychoactive substance use (lifetime),Novel psychoactive substance use (lifetime),NA,NA,NA,NA,NA,NA,NA,no,NPC,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_novelPsychoactLifetimeExtracted,pEstimate_eugei_sami_PLEs_novelPsychoactLifetime,cohen,,Yes,Yes
223,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,MixedPsychosis,Case control,"UK, Holland, Spain, France, Italy, Brazil",EverCannabisUse,31.4,NA,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ,,NA,NA,Novel psychoactive substance misuse (lifetime),Novel psychoactive substance misuse (lifetime),NA,NA,NA,NA,NA,NA,NA,no,NPC,OtherDrugs,yes,meanComparison,independent,eugei_sami_PLEs_novelPsychoactmisuseExtracted,pEstimate_eugei_sami_PLEs_novelPsychoactmisuse,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
225,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, S., Atakan, Z., Martin-Santos, R., Crippa, J.A., Kambeitz, J., Prata, D., Williams, S., Brammer, M., Collier, D.A. and McGuire, P.K., 2012. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Molecular psychiatry, 17(12), pp.1152-1155.",2012,2012,Experiment,NA,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (total),PANSS,NA,NA,"AKT1 (rs1130233, risk allele: A)","AKT (rs1130233, risk allele: A)",NA,NA,NA,NA,NA,NA,AKT1,yes,AKT1,CandidateGene,yes,meanComparison,independent,"fes(bhattacharyya_AKT1_psych_change_THC_f, bhattacharyya_AKT1_psych_change_THC_carrierA_n, bhattacharyya_AKT1_psych_change_THC_homozygousG_n,  dig=20)",pEstimate_bhattacharyya_AKT1_psych_change_THC,cohen,,Yes,Yes
226,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, S., Atakan, Z., Martin-Santos, R., Crippa, J.A., Kambeitz, J., Prata, D., Williams, S., Brammer, M., Collier, D.A. and McGuire, P.K., 2012. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Molecular psychiatry, 17(12), pp.1152-1155.",2012,2012,Experiment,NA,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (total),PANSS,NA,NA,"DAT1 (3’UTR VNTR, risk allele: 9-repeat variant)","DAT1 (3’UTR VNTR, risk allele: 9-repeat variant)",NA,NA,NA,NA,NA,NA,DAT1,no,DAT1,CandidateGene,yes,meanComparison,independent,"fes(bhattacharyya_DAT1_psych_change_THC_f, bhattacharyya_AKT1_psych_change_THC_carrier9repeat_n, bhattacharyya_AKT1_psych_change_THC_homozygous10repeat_n,  dig=20)",pEstimate_bhattacharyya_DAT1_psych_change_THC,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
228,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, José Alexandre Crippa, Paul Allen, Rocio Martin-Santos, Stefan Borgwardt, Paolo Fusar-Poli, Katya Rubia et al. ""Induction of psychosis byδ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing."" Archives of general psychiatry 69, no. 1 (2012): 27-36.",2012,2012,Experiment,NA,"randomised, double-blind crossover design",UK,Previous cannabis use,26.67,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose oral (0mg vs 10mg THC),Single dose oral (10mg THC),NA,10mg,NA,2,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_bhattacharyya_10mgTHC_PANSS_pos,pEstimate_bhattacharyya_10mgTHC_PANSS_pos,cohen,,No,No
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
230,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Age (mean age differences between cannabis sensitive and non-sensitive individuals),Age (younger),NA,NA,NA,NA,NA,NA,NA,no,Age,Demographic,yes,meanComparison,independent,"mes(atakan2013_TP_age_mean, atakan2013_NP_age_mean, atakan2013_TP_age_SD, atakan2013_NP_age_SD, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_age,cohen,,No,No
231,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Years of education (more years),Education (more),NA,NA,NA,NA,NA,NA,NA,no,Education,Demographic,yes,meanComparison,independent,atakan2013_TP_educationExtracted,pEstimate_atakan2013_TP_education,cohen,,No,No
232,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Frequency of cannabis use,Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,chi square,independent,"pes(atakan2013_TP_cannabisSeverity_p, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_cannabis,cohen,,No,No
233,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Cigarette smoker,Cigarette use (yes),NA,NA,NA,NA,NA,NA,NA,no,Nicotine,OtherDrugs,yes,chi square,independent,"pes(atakan2013_TP_cigarette_p, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_cigarette,cohen,,No,No
234,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,AlcoholUse,Alcohol use,NA,NA,NA,NA,NA,NA,NA,no,Alcohol,OtherDrugs,yes,chi square,independent,"pes(atakan2013_TP_alcoholSeverity_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_alcohol,cohen,,No,No
235,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Other drug use (used verus not used),Other drugs (used),NA,NA,NA,NA,NA,NA,NA,no,OtherDrugs,OtherDrugs,yes,chi square,independent,"pes(atakan2013_TP_otherDrugs_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_otherDrugs,cohen,,No,No
236,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Employment status (unemployed verus employed),Employment status (unemployed),NA,NA,NA,NA,NA,NA,NA,yes,EmploymentStatus,Demographic,yes,chi square,independent,extract_atakan2013_TP_employment,pEstimate_atakan2013_TP_employment,cohen,,Yes,Yes
237,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Anxiety (baseline STAI),Prior anxiety (high),NA,NA,NA,NA,NA,NA,NA,yes,Anxiety,MentalHealthPersonality,yes,meanComparison,independent,"pes(atakan2013_TP_baselinePLC_STAI_p, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_baselinePLC_STAI,cohen,,Yes,Yes
238,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Subjective drug effects rating,Subjective drug effects rating (ARCI),NA,NA,NA,NA,NA,NA,NA,no,SubjectiveHigh,CannabisDynamics,yes,meanComparison,independent,"pes(atakan2013_TP_baselinePLC_ARCI_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_ARCI,cohen,,Yes,Yes
239,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Intoxication level following THC administration,Intoxication level,NA,NA,NA,NA,NA,NA,NA,no,SubjectiveHigh,CannabisDynamics,yes,meanComparison,independent,"pes(atakan2013_TP_THC_AIS_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_ARCI,cohen,,Yes,Yes
240,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,VAMS tranquillization subscale,VAMS tranquillization subscale,NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,meanComparison,independent,"pes(atakan2013_TP_baselinePLC_VAMS_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_VAMS,cohen,,Yes,Yes
241,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Psychosis symptoms prior to THC administration (PANSS positive),Psychosis symptoms prior THC administration,NA,NA,NA,NA,NA,NA,NA,yes,PsychosisLiability,MentalHealthPersonality,yes,meanComparison,independent,"pes(atakan2013_TP_baselinePLC_PANSS_pos_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_PANSS_pos,cohen,,Yes,Yes
242,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,PANSS negative score prior THC administration,PANSS negative score prior THC administration,NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,meanComparison,independent,"pes(atakan2013_TP_baselinePLC_PANSS_neg_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_PANSS_neg,cohen,,Yes,Yes
243,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,PANSS general symptom score prior THC administration,PANSS general symptom score prior THC administration,NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,meanComparison,independent,"pes(atakan2013_TP_baselinePLC_PANSS_gen_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_PANSS_gen,cohen,,Yes,Yes
244,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,PANSS total score prior THC administration,PANSS total score prior THC administration,NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,meanComparison,independent,"pes(atakan2013_TP_baselinePLC_PANSS_tot_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_PANSS_tot,cohen,,Yes,Yes
245,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Reaction time to Go signals (Go/No-Go task),Reaction time to Go signals (Go/No-Go task),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,"mes(atakan2013_TP_recT_mean, atakan2013_NP_recT_mean, atakan2013_TP_recT_SD, atakan2013_NP_recT_SD, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_recT,cohen,,Yes,Yes
246,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Reaction time to Oddball signals (Go/No-Go task),Reaction time to Oddball signals (Go/No-Go task),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,"mes(atakan2013_TP_recT_Odd_mean, atakan2013_NP_recT_Odd_mean, atakan2013_TP_recT_Odd_SD, atakan2013_NP_recT_Odd_SD, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_recT_Odd,cohen,,Yes,Yes
247,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Inhibition error  (Go/No-Go task),Inhibition error  (Go/No-Go task),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,"mes(atakan2013_TP_impulse_mean, atakan2013_NP_impulse_mean, atakan2013_TP_impulse_SD, atakan2013_NP_impulse_SD, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_impulse,cohen,,Yes,Yes
248,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Heart rate prior THC administration,Heart rate prior THC administration,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,"pes(pValueNS_allStudies, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_heartRate,cohen,,Yes,Yes
249,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Attenuated activation in right middle temporal gyrus,Attenuated activation in right middle temporal gyrus,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,"pes(0.00069, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_MTG_activation,cohen,,Yes,Yes
250,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,NA," double-blind, placebo-controlled within- subject study",UK,Previous cannabis exposure (less than 25 times/lifetime),26.2,20,40,Psychosis-like,THC.PLE,NA,Binary,PANSS (positive),PANSS,PANSS score of 3 or more after THC administration (=transient psychotic individuals) vs. non-psychotic (= a score of less than 3 following THC administration),NA,Attenuated activation in the cerebellum,Attenuated activation in the cerebellum,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,"pes(0.0049, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_cerebellum_activation,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
252,Bloomfield,Morgan_Curran_MRC,"Bloomfield, Michael AP, Celia JA Morgan, Alice Egerton, Shitij Kapur, H. Valerie Curran, and Oliver D. Howes. ""Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms."" Biological psychiatry 75, no. 6 (2014): 470-478.",2014,NA,QuasiExperimental,NA,QuasiExperimental,UK,PastMonthCannabisUser,21.55,18,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Dopaminergic function (dopamine synthesis capacity),Dopaminergic function,NA,NA,NA,NA,NA,NA,NA,yes,Dopaminergic function,Neurotransmission,yesyes,correlation,independent,"res(bloomberg_dop_synthesis_psych_r, n=bloomberg_dop_synthesis_can_user, dig=20)",pEstimate_bloomberg_dop_synthesis_psych,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
254,Radhakrishnan,DSouza_2,"Radhakrishnan, Rajiv, Patrick D. Skosnik, Jose Cortes-Briones, R. Andrew Sewell, Michelle Carbuto, Ashley Schnakenberg, John Cahill et al. ""GABA deficits enhance the psychotomimetic effects of Δ 9-THC."" Neuropsychopharmacology 40, no. 8 (2015): 2047-2056.",2015,NA,Experiment,NA,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,25.44,NA,NA,"Psychosis-like (severity, tot PANSS score)",THC.PLE,NA,Continuous,PANSS (total),PANSS,NA,NA,Single dose IV (0mg vs 0.015 mg/kg THC),Single dose IV (0.015 mg/kg THC),NA,0.015 mg/kg THC,average weight = 80.98 => 0.015*80.98 = 1.2147; 1.2147/5 = ,0.24,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_radhakrishnan_singledose_THC,pEstimate_radhakrishnan_singledose_THC,cohen,,No,No
255,Radhakrishnan,DSouza_2,"Radhakrishnan, Rajiv, Patrick D. Skosnik, Jose Cortes-Briones, R. Andrew Sewell, Michelle Carbuto, Ashley Schnakenberg, John Cahill et al. ""GABA deficits enhance the psychotomimetic effects of Δ 9-THC."" Neuropsychopharmacology 40, no. 8 (2015): 2047-2056.",2015,NA,Experiment,NA,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,25.44,NA,NA,"Psychosis-like (severity, tot PANSS score)",THC.PLE,NA,Continuous,PANSS (total),PANSS,NA,NA,GABAergic function,GABAergic function,NA,NA,NA,NA,NA,NA,NA,yes,GABAergic function,Neurotransmission,yes,meanComparison,dependent,extract_radhakrishnan_THC_IOM,pEstimate_radhakrishnan_THC_IOM,cohen,,Yes,Yes
256,Radhakrishnan,DSouza_2,"Radhakrishnan, Rajiv, Patrick D. Skosnik, Jose Cortes-Briones, R. Andrew Sewell, Michelle Carbuto, Ashley Schnakenberg, John Cahill et al. ""GABA deficits enhance the psychotomimetic effects of Δ 9-THC."" Neuropsychopharmacology 40, no. 8 (2015): 2047-2056.",2015,NA,Experiment,NA,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,25.44,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Event-related potentials (P300a amplitude) while under the influence of THC,ERP,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,"res(radhakrishnan_PANSS_pos_THC_P300a_r, n=radhakrishnan_PANSS_pos_THC_P300a_n, dig=20)",pEstimate_radhakrishnan_PANSS_pos_THC_P300a,cohen,,Yes,Yes
257,Radhakrishnan,DSouza_2,"Radhakrishnan, Rajiv, Patrick D. Skosnik, Jose Cortes-Briones, R. Andrew Sewell, Michelle Carbuto, Ashley Schnakenberg, John Cahill et al. ""GABA deficits enhance the psychotomimetic effects of Δ 9-THC."" Neuropsychopharmacology 40, no. 8 (2015): 2047-2056.",2015,NA,Experiment,NA,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,25.44,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Event-related potentials (P300b amplitude) while under the influence of THC,ERP,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,"res(radhakrishnan_PANSS_pos_THC_P300b_r, n=radhakrishnan_PANSS_pos_THC_P300b_n, dig=20)",pEstimate_radhakrishnan_PANSS_pos_THC_P300b,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
259,Morrison,Morrison_2.25mg,"Morrison, P. D., V. Zois, D. A. McKeown, T. D. Lee, D. W. Holt, J. F. Powell, S. Kapur, and R. M. Murray. ""The acute effects of synthetic intravenous Δ 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning."" Psychological medicine 39, no. 10 (2009): 1607-1616.",2009,NA,Experiment,NA,"within-subject, double-blind, placebo-controlled ",UK,Previous cannabis use,28,21,50,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive symptoms),PANSS,NA,NA,Single dose IV (0mg vs. 2.5 mg THC),Single dose IV (2.5 mg THC),NA,2.5mg,NA,0.5,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_morrison_placebo_PANSS_pos,pEstimate_morrison_placebo_PANSS_pos,cohen,,Yes,Yes
260,Morrison,Morrison_2.25mg,"Morrison, P. D., V. Zois, D. A. McKeown, T. D. Lee, D. W. Holt, J. F. Powell, S. Kapur, and R. M. Murray. ""The acute effects of synthetic intravenous Δ 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning."" Psychological medicine 39, no. 10 (2009): 1607-1616.",2009,NA,Experiment,NA,"within-subject, double-blind, placebo-controlled ",UK,Previous cannabis use,28,21,50,Psychosis-like,THC.PLE,NA,Continuous,CAPE (positive symptoms),,NA,NA,Single dose IV (0mg vs. 2.5 mg THC),Single dose IV (2.5 mg THC),NA,2.5mg,NA,0.5,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_morrison_placebo_CAPE_pos,pEstimate_morrison_placebo_CAPE_pos,cohen,,Yes,Yes
261,Morrison,Morrison_2.25mg,"Morrison, P. D., V. Zois, D. A. McKeown, T. D. Lee, D. W. Holt, J. F. Powell, S. Kapur, and R. M. Murray. ""The acute effects of synthetic intravenous Δ 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning."" Psychological medicine 39, no. 10 (2009): 1607-1616.",2009,NA,Experiment,NA,"within-subject, double-blind, placebo-controlled ",UK,Previous cannabis use,28,21,50,Psychosis-like,High.PLE,NA,Continuous,PANSS (positive symptoms),PANSS,NA,NA,FrequencyCannabisUse,Cannabis in system (high),NA,NA,NA,NA,intravenous,NA,NA,no,Tolerance,Excluded,yes,correlation,independent,"res(morrison_placebo_PANSS_pos_THC_frequency_r, n=n_morrison_2.5mgTHC_PANSS_pos, dig=20) ",pEstimate_morrison_placebo_PANSS_pos_THC_frequency,cohen,,no,no
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
263,Liem-Moolenaar,Liem-Moolenaar,"Liem-Moolenaar, Marieke, Erik T. te Beek, Marieke L. de Kam, Kari L. Franson, René S. Kahn, Ron Hijman, Daan Touw, and J. MA van Gerven. ""Central nervous system effects of haloperidol on THC in healthy male volunteers."" Journal of psychopharmacology 24, no. 11 (2010): 1697-1708.",2010,2007-2008,Experiment,NA,"within-subject, double-blind, placebo-controlled ",Netherlands,Previous cannabis use,NA,18,38,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose intrapulmonary (0mg vs. 2 mg THC),Single dose IP (2 mg THC),NA,2mg,,0.4,intrapulmonary,1,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_liem_2mgTHC_PANSS_pos,pEstimate_liem_2mgTHC_PANSS_pos,cohen,,Yes,Yes
264,Liem-Moolenaar,Liem-Moolenaar,"Liem-Moolenaar, Marieke, Erik T. te Beek, Marieke L. de Kam, Kari L. Franson, René S. Kahn, Ron Hijman, Daan Touw, and J. MA van Gerven. ""Central nervous system effects of haloperidol on THC in healthy male volunteers."" Journal of psychopharmacology 24, no. 11 (2010): 1697-1708.",2010,2007-2008,Experiment,NA,"within-subject, double-blind, placebo-controlled ",Netherlands,Previous cannabis use,NA,18,38,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose intrapulmonary (0mg vs. 4 mg THC),Single dose IP (4 mg THC),NA,4mg,,0.8,intrapulmonary,2,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_liem_4mgTHC_PANSS_pos,pEstimate_liem_4mgTHC_PANSS_pos,cohen,,Yes,Yes
265,Liem-Moolenaar,Liem-Moolenaar,"Liem-Moolenaar, Marieke, Erik T. te Beek, Marieke L. de Kam, Kari L. Franson, René S. Kahn, Ron Hijman, Daan Touw, and J. MA van Gerven. ""Central nervous system effects of haloperidol on THC in healthy male volunteers."" Journal of psychopharmacology 24, no. 11 (2010): 1697-1708.",2010,2007-2008,Experiment,NA,"within-subject, double-blind, placebo-controlled ",Netherlands,Previous cannabis use,NA,18,38,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose intrapulmonary (0mg vs. 6 mg THC),Single dose IP (6 mg THC),NA,6mg,,1.2,intrapulmonary,3,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_liem_6mgTHC_PANSS_pos,pEstimate_liem_6mgTHC_PANSS_pos,cohen,,Yes,Yes
266,Liem-Moolenaar,Liem-Moolenaar,"Liem-Moolenaar, Marieke, Erik T. te Beek, Marieke L. de Kam, Kari L. Franson, René S. Kahn, Ron Hijman, Daan Touw, and J. MA van Gerven. ""Central nervous system effects of haloperidol on THC in healthy male volunteers."" Journal of psychopharmacology 24, no. 11 (2010): 1697-1708.",2010,2007-2008,Experiment,NA,"within-subject, double-blind, placebo-controlled ",Netherlands,Previous cannabis use,NA,18,38,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,"D2 blocker (pretreatment with dopaminergic antagonist, haloperidol)",Dopaminergic function,NA,NA,,NA,NA,NA,NA,no,Dopaminergic function,Neurotransmission,yesyes,p value,dependent,"pes(p=liem_PANSS_pos_THC_vs_haloperidol_p, n.1=n_effective_liem_PANSS_pos/2, n.2=n_effective_liem_PANSS_pos/2, dig=20)",pEstimate_liem_PANSS_pos_THC_vs_haloperidol,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
268,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,NA,"within-subject, placebo-controlled ",UK, cannabis at least 20 times,33,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Single dose oral (0mg vs. 10 mg THC),Single dose oral (10 mg THC),NA,10mg,NA,2,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_stoke_10mgTHC_PSI_tot,pEstimate_stoke_10mgTHC_PSI_tot,cohen,,Yes,Yes
269,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,NA,"within-subject, placebo-controlled ",UK, cannabis at least 20 times,33,NA,NA,Delusions,THC.DEL,NA,Continuous,PSI (delusion subscale),,NA,NA,Single dose oral (0mg vs. 10 mg THC),Single dose oral (10 mg THC),NA,10mg,NA,2,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_stoke_10mgTHC_PSI_delusion,pEstimate_stoke_10mgTHC_PSI_delusion,cohen,,Yes,Yes
270,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,NA,"within-subject, placebo-controlled ",UK, cannabis at least 20 times,33,NA,NA,Paranoia,THC.PAR,NA,Continuous,PSI (paranoia subscale),,NA,NA,Single dose oral (0mg vs. 10 mg THC),Single dose oral (10 mg THC),NA,10mg,NA,2,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_stoke_10mgTHC_PSI_paranoia,pEstimate_stoke_10mgTHC_PSI_paranoia,cohen,,Yes,Yes
271,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,NA,"within-subject, placebo-controlled ",UK, cannabis at least 20 times,33,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,THC plasma levels (10 mg oral THC),THC plasma levels (10 mg oral THC),NA,10mg,NA,2,oral,NA,NA,no,THCplasmaLevel,CannabisDynamics,yes,meanComparison,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_stoke_10mgTHC/2, n.2=n_effective_stoke_10mgTHC/2, dig=20)",pEstimate_stoke_10mgTHC_plasma,cohen,,Yes,Yes
272,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,NA,"within-subject, placebo-controlled ",UK, cannabis at least 20 times,33,NA,NA,Delusions,THC.DEL,NA,Continuous,PSI (delusion subscale),,NA,NA,THC plasma levels (10 mg oral THC),THC plasma levels (10 mg oral THC),NA,10mg,NA,2,oral,NA,NA,no,THCplasmaLevel,CannabisDynamics,yes,meanComparison,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_stoke_10mgTHC/2, n.2=n_effective_stoke_10mgTHC/2, dig=20)",pEstimate_stoke_10mgTHC_plasma,cohen,,Yes,Yes
273,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,NA,"within-subject, placebo-controlled ",UK, cannabis at least 20 times,33,NA,NA,Paranoia,THC.PAR,NA,Continuous,PSI (paranoia subscale),,NA,NA,THC plasma levels (10 mg oral THC),THC plasma levels (10 mg oral THC),NA,10mg,NA,2,oral,NA,NA,no,THCplasmaLevel,CannabisDynamics,yes,meanComparison,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_stoke_10mgTHC/2, n.2=n_effective_stoke_10mgTHC/2, dig=20)",pEstimate_stoke_10mgTHC_plasma,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
275,D'Souza,DSouza,"D’Souza, Deepak Cyril, Gabriel Braley, Rebecca Blaise, Michael Vendetti, Stephen Oliver, Brian Pittman, Mohini Ranganathan et al. ""Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans."" Psychopharmacology 198, no. 4 (2008): 587-603.",2008,NA,Experiment,NA,"within-subject, placebo-controlled ",US,Non-frequenct cannabis users and users with cannabis abuse disorder,24.89,18,55,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose IV THC (2mg) [in individuals with and without CUD],Single dose IV THC (2mg) [in individuals with and without CUD],NA,2mg,NA,0.4,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_dsouza2008_IV_THC_PANSS_pos,pEstimate_dsouza2008_IV_THC_PANSS_pos,cohen,,Yes,Yes
276,D'Souza,DSouza,"D’Souza, Deepak Cyril, Gabriel Braley, Rebecca Blaise, Michael Vendetti, Stephen Oliver, Brian Pittman, Mohini Ranganathan et al. ""Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans."" Psychopharmacology 198, no. 4 (2008): 587-603.",2008,NA,Experiment,NA,"within-subject, placebo-controlled ",US,Non-frequenct cannabis users and users with cannabis abuse disorder,24.89,18,55,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,D2 blocker (haloperidol pretreatment),Dopaminergic function,NA,NA,NA,NA,NA,NA,NA,yes,Dopaminergic function,Neurotransmission,yesyes,meanComparison,dependent,extract_dsouza2008_haloperidol_PANSS_pos,pEstimate_dsouza2008_haloperidol_PANSS_pos,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
278,Freeman,Freeman,"Freeman, D., Dunn, G., Murray, R.M., Evans, N., Lister, R., Antley, A., Slater, M., Godlewska, B., Cornish, R., Williams, J. and Di Simplicio, M., 2015. How cannabis causes paranoia: using the intravenous administration of∆ 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophrenia bulletin, 41(2), pp.391-399.",2015,,Experiment,NA,"between-subject, randomized placebo-controlled, double-blind",UK,Previous cannabis use (at least once),30,21,50,Paranoia,THC.PAR,NA,Continuous,"Paranoid VAS, Hostile VAS, SSPS, PANSS suscpiciousness",,NA,NA,Single dose IV (0mg vs. 1.5mg THC),Single dose IV (1.5mg THC),NA,1.5mg,NA,0.3,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,independent,freeman_paranoia_1.5mgTHCExtracted,pEstimate_freeman_paranoia_1.5mgTHC,cohen,,Yes,Yes
279,Freeman,Freeman,"Freeman, D., Dunn, G., Murray, R.M., Evans, N., Lister, R., Antley, A., Slater, M., Godlewska, B., Cornish, R., Williams, J. and Di Simplicio, M., 2015. How cannabis causes paranoia: using the intravenous administration of∆ 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophrenia bulletin, 41(2), pp.391-399.",2015,,Experiment,NA,"between-subject, randomized placebo-controlled, double-blind",UK,Previous cannabis use (at least once),30,21,50,Paranoia,THC.PAR,NA,Continuous,"Paranoid VAS, Hostile VAS, SSPS, PANSS suscpiciousness",,NA,NA,Awareness training before THC administration,Awareness training,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,freeman_paranoia_cogawareness_1.5mgTHCExtracted,pEstimate_freeman_paranoia_cogawareness_1.5mgTHC,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
281,Tunbridge,Freeman,"Tunbridge, Elizabeth M., Graham Dunn, Robin M. Murray, Nicole Evans, Rachel Lister, Katharina Stumpenhorst, Paul J. Harrison, Paul D. Morrison, and Daniel Freeman. ""Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences."" Journal of psychopharmacology 29, no. 11 (2015): 1146-1151.",2015,,Experiment,NA,"between-subject, randomized placebo-controlled, double-blind",UK,Previous cannabis use (at least once),32,21,50,Paranoia,THC.PLE,NA,Continuous,CAPE (positive dimension),,NA,NA,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",NA,NA,NA,NA,NA,NA,COMT,no,COMT,CandidateGene,yes,meanComparison,independent,extracted_tunbridge2015_COMT_CAPEpos,pEstimate_tunbridge2015_COMT_CAPEpos,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
283,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Hallucinations,Can.HAL,NA,Binary,Single item,,Which did you notice after using cannabis - unusual visual experiences?,8 (in healthy),Caseness (FEP vs healthy),Psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_peters_FEPvsHealthy_visualH,pEstimate_peters_FEPvsHealthy_visualH,cohen,,Yes,Yes
284,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Hallucinations,Can.HAL,NA,Binary,Single item,,Which did you notice after using cannabis - unusual visual experiences?,8 (in healthy),Caseness (UHR vs healthy),UHR,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_peters_UHRvsHealthy_visualH,pEstimate_peters_UHRvsHealthy_visualH,cohen,,Yes,Yes
285,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Hallucinations,Can.HAL,NA,Binary,Single item,,Which did you notice after using cannabis - unusual bodily experiences?,21 (in healthy),Caseness (FEP vs healthy),Psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_peters_FEPvsHealthy_tactileH,pEstimate_peters_FEPvsHealthy_tactileH,cohen,,Yes,Yes
286,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Hallucinations,Can.HAL,NA,Binary,Single item,,Which did you notice after using cannabis - unusual bodily experiences?,21 (in healthy),Caseness (UHR vs healthy),UHR,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_peters_UHRvsHealthy_tactileH,pEstimate_peters_UHRvsHealthy_tactileH,cohen,,Yes,Yes
287,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Hallucinations,Can.HAL,NA,Binary,Single item,,Which did you notice after using cannabis - hearing voices?,2 (in healthy),Caseness (FEP vs healthy),Psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_peters_FEPvsHealthy_auditoryH,pEstimate_peters_FEPvsHealthy_auditoryH,cohen,,Yes,Yes
288,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Hallucinations,Can.HAL,NA,Binary,Single item,,Which did you notice after using cannabis - hearing voices?,2 (in healthy),Caseness (UHR vs healthy),UHR,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_peters_UHRvsHealthy_auditoryH,pEstimate_peters_UHRvsHealthy_auditoryH,cohen,,Yes,Yes
289,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Paranoia,Can.PAR,NA,Binary,Single item,,Which did you notice after using cannabis - suspicion?,6 (in healthy),Caseness (FEP vs healthy),Psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_peters_FEPvsHealthy_paranoia,pEstimate_peters_FEPvsHealthy_paranoia,cohen,,Yes,Yes
290,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Paranoia,Can.PAR,NA,Binary,Single item,,Which did you notice after using cannabis - suspicion?,6 (in healthy),Caseness (UHR vs healthy),UHR,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_peters_UHRvsHealthy_paranoia,pEstimate_peters_UHRvsHealthy_paranoia,cohen,,Yes,Yes
291,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Hallucinations,Can.HAL,psych_like,Binary,Single item,,Which did you notice after using cannabis - voices?,2,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,peters2009_canHalDF,NA,rates,,Yes,Yes
292,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,NA,Survey,Netherlands,Previous cannabis use,22.8,18,28,Paranoia,Can.PAR,psych_like,Binary,Single item,,Which did you notice after using cannabis - suspicion?,6,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,peters2009_canParDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
294,D'Souza,DSouza,"D'souza, Deepak Cyril, Mohini Ranganathan, Gabriel Braley, Ralitza Gueorguieva, Zoran Zimolo, Thomas Cooper, Edward Perry, and John Krystal. ""Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis."" Neuropsychopharmacology 33, no. 10 (2008): 2505-2516.",2008,,Experiment,NA,"within-subject, placebo-controlled ",US,Users with cannabis abuse disorder,24.8,18,55,"Psychosis-like (severity, tot PANSS score)",THC.PLE,NA,Continuous,PANSS (total),PANSS,NA,NA,Single dose IV (0mg vs. 2.5mg THC) [in individuals with CUD],Single dose IV (2.5mg THC) [in individuals with CUD],NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,dependent,extract_dsouza_IV_2.5mgTHC_frequ_user_PANSS_tot,pEstimate_dsouza_IV_2.5mgTHC_frequ_user_PANSS_tot,cohen,,Yes,Yes
295,D'Souza,DSouza,"D'souza, Deepak Cyril, Mohini Ranganathan, Gabriel Braley, Ralitza Gueorguieva, Zoran Zimolo, Thomas Cooper, Edward Perry, and John Krystal. ""Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis."" Neuropsychopharmacology 33, no. 10 (2008): 2505-2516.",2008,,Experiment,NA,"within-subject, placebo-controlled ",US,Non-frequenct cannabis users ,29,18,55,"Psychosis-like (severity, tot PANSS score)",THC.PLE,NA,Continuous,PANSS (total),PANSS,NA,NA,Single dose IV (0mg vs. 2.5mg THC) [in individuals without CUD],Single dose IV (2.5mg THC),NA,2.5mg,NA,0.5,intravenous,1,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_dsouza_IV_2.5mgTHC_control_PANSS_tot,pEstimate_dsouza_IV_2.5mgTHC_control_PANSS_tot,cohen,,Yes,Yes
296,D'Souza,DSouza,"D'souza, Deepak Cyril, Mohini Ranganathan, Gabriel Braley, Ralitza Gueorguieva, Zoran Zimolo, Thomas Cooper, Edward Perry, and John Krystal. ""Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis."" Neuropsychopharmacology 33, no. 10 (2008): 2505-2516.",2008,,Experiment,NA,"within-subject, placebo-controlled ",US,Users with cannabis abuse disorder,24.8,18,55,"Psychosis-like (severity, tot PANSS score)",THC.PLE,NA,Continuous,PANSS (total),PANSS,NA,NA,Single dose IV (0mg vs. 5mg THC) [in individuals with CUD],Single dose IV (5mg THC) [in individuals with CUD],NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,dependent,extract_dsouza_IV_5mgTHC_frequ_user_PANSS_tot,pEstimate_dsouza_IV_5mgTHC_frequ_user_PANSS_tot,cohen,,Yes,Yes
297,D'Souza,DSouza,"D'souza, Deepak Cyril, Mohini Ranganathan, Gabriel Braley, Ralitza Gueorguieva, Zoran Zimolo, Thomas Cooper, Edward Perry, and John Krystal. ""Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis."" Neuropsychopharmacology 33, no. 10 (2008): 2505-2516.",2008,,Experiment,NA,"within-subject, placebo-controlled ",US,Non-frequenct cannabis users ,29,18,55,"Psychosis-like (severity, tot PANSS score)",THC.PLE,NA,Continuous,PANSS (total),PANSS,NA,NA,Single dose IV (0mg vs. 5mg THC) [in individuals without CUD],Single dose IV (5mg THC),NA,5mg,NA,1,intravenous,2,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_dsouza_IV_5mgTHC_control_PANSS_tot,pEstimate_dsouza_IV_5mgTHC_control_PANSS_tot,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
299,Green,Green,"Green, Bob, David Kavanagh, and Ross MCD Young. ""Reasons for cannabis use in men with and without psychosis."" Drug and alcohol review 23, no. 4 (2004): 445-453.",2004,NA,Observational,NA,Observational study,Australia,Weekly cannabis use in the past 3 months,30,18,55,"Psychosis-like (severity, tot PANSS score)",Can.PLE,NA,Binary,Single item,,"The last time you smoked cannabis, did you experience psychotic symptoms?",NA,Caseness (Psychosis vs.healthy),Psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,p-value,independent,"pes(p=0.05, n.1=green_cases_n, n.2=green_healthy_n) ",pEstimate_green_cases_vs_healthy_symptoms_baseline,cohen,,Yes,Yes
300,Green,Green,"Green, Bob, David Kavanagh, and Ross MCD Young. ""Reasons for cannabis use in men with and without psychosis."" Drug and alcohol review 23, no. 4 (2004): 445-453.",2004,NA,Observational,NA,Observational study,Australia,Weekly cannabis use in the past 3 months,30,18,55,Paranoia,Can.PAR,NA,Binary,Single item,,"The last time you smoked cannabis, did you experience paranoia?",8.5,Caseness (Psychosis vs.healthy),Psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_green_cases_vs_healthy_paranoia_baseline,pEstimate_green_cases_vs_healthy_paranoia_baseline,cohen,,Yes,Yes
301,Green,Green,"Green, Bob, David Kavanagh, and Ross MCD Young. ""Reasons for cannabis use in men with and without psychosis."" Drug and alcohol review 23, no. 4 (2004): 445-453.",2004,NA,Observational,NA,Observational study,Australia,Weekly cannabis use in the past 3 months,30,18,55,Paranoia,Can.PAR,psych_like,Binary,Single item,,"The last time you smoked cannabis, did you experience paranoia?",8.5,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,green2004_canParDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
303,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,NA,"randomised, within-subjects design, placebo-controlled",UK,Previous cannabis use,26,21,50,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,42 (in those not pre-treated with CBD),Single dose IV (0mg vs. 1.5mg THC),Single dose IV (1.5mg THC),NA,1.5mg,NA,0.3,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_englund2013_1.5THC_placebo_panss_pos,pEstimate_englund2013_1.5THC_placebo_panss_pos,cohen,,Yes,Yes
304,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,NA,"randomised, between-subjects design",UK,Previous cannabis use,26,21,50,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,42,CBD pre-treatment,CBD pre-treatment,NA,NA,NA,NA,NA,NA,NA,no,CBD (administration),CannabisDynamics,yes,meanComparison,independent,"mes(englund2013_THC_CBD_panss_pos_increase_mean, englund2013_THC_placebo_panss_pos_increase_mean, englund2013_THC_CBD_panss_pos_increase_sd, englund2013_THC_placebo_panss_pos_increase_sd, englund2013_CBD_n, englund2013_THC_n, dig=20)",pEstimate_englund2013_THC_CBD_panss_pos_increase,cohen,,Yes,Yes
305,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,NA,"randomised, between-subjects design",UK,Previous cannabis use,26,21,50,Psychosis-like,THC.PLE,NA,Binary,"PANSS (positive, Acute psychotic reaction)",PANSS,NA,42,CBD pre-treatment,CBD pre-treatment,NA,NA,NA,NA,NA,NA,NA,yes,CBD (administration),CannabisDynamics,yes,meanComparison,independent,"chies(englund2013_THC_CBD_actue_psychotic_chisqu, englund2013_CBD_n+englund2013_THC_n, dig=50)",pEstimate_englund2013_THC_CBD_actue_psychotic,cohen,,Yes,Yes
306,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,NA,"randomised, between-subjects design",UK,Previous cannabis use,26,21,50,Paranoia,THC.PAR,NA,Continuous,SSPS,,NA,NA,CBD pre-treatment,CBD pre-treatment,NA,NA,NA,NA,NA,NA,NA,yes,CBD (administration),CannabisDynamics,yes,meanComparison,independent,englund2013_THC_CBD_actue_paranoiaExtract,pEstimate_englund2013_THC_CBD_paranoia,cohen,,Yes,Yes
307,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,NA,"randomised, between-subjects design",UK,Previous cannabis use,26,21,50,Paranoia,THC.PLE,psych_like,Binary,PANSS positive scores of ≥3 points ,PANSS,NA,42,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,englund2013_THC_CBD_panssposDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
309,Morgan,Morgan_Curran_MRC,"Morgan, Celia JA, Grainne Schafer, Tom P. Freeman, and H. Valerie Curran. ""Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study."" The British Journal of Psychiatry 197, no. 4 (2010): 285-290.",2010,NA,QuasiExperimental,NA,QuasiExperimental (repeated-measure design),UK,Cannabis user,21.47,16,23,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,"Intoxication vs non-intoxication (within-subjcet comparison, low CBD group)",Intoxication vs non-intoxication (within-subject),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,dependent,extract_morgan2010_lowCBD_PSI,pEstimate_morgan2010_lowCBD_PSI,cohen,,No,No
310,Morgan,Morgan_Curran_MRC,"Morgan, Celia JA, Grainne Schafer, Tom P. Freeman, and H. Valerie Curran. ""Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study."" The British Journal of Psychiatry 197, no. 4 (2010): 285-290.",2010,NA,QuasiExperimental,NA,QuasiExperimental (repeated-measure design),UK,Cannabis user,21.47,16,23,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,"Intoxication vs non-intoxication (within-subjcet comparison, high CBD group)",Intoxication vs non-intoxication (within-subject),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,dependent,extract_morgan2010_highCBD_PSI,pEstimate_morgan2010_highCBD_PSI,cohen,,No,No
311,Morgan,Morgan_Curran_MRC,"Morgan, Celia JA, Grainne Schafer, Tom P. Freeman, and H. Valerie Curran. ""Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study."" The British Journal of Psychiatry 197, no. 4 (2010): 285-290.",2010,NA,QuasiExperimental,NA,QuasiExperimental (repeated-measure design),UK,Cannabis user,21.47,16,23,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,CBD content,CBD content,NA,NA,NA,NA,NA,NA,NA,no,CBDcontent,CannabisStrain,yes,meanComparison,independent,extract_morgan2010_highCBD_vs_lowCBD_PSI,pEstimate_morgan2010_highCBD_vs_lowCBD_PSI,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
313,Kleinloog,Kleinloog,"Kleinloog, Daniël, Marieke Liem-Moolenaar, Gabriël Jacobs, Erica Klaassen, Marieke de Kam, Ron Hijman, and Joop van Gerven. ""Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol?."" Journal of Psychopharmacology 26, no. 10 (2012): 1307-1316.",2012,NA,Experiment,NA,"Randomized, double-blind, placebo-controlled, five- way cross-over interaction trial",Netherlands,Last year use,NA,18,45,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,"Increased dopamine (pretreatment with dopaminergic antagonist, olanzapine)",Dopaminergic function,NA,NA,NA,NA,NA,NA,NA,no,Dopaminergic function,Neurotransmission,yesyes,p-value,dependent,"pes(p=kleinloog2010_PANSS_pos_4mgTHC_olanzapine_p, n.1=kleinloog2010_n_effective/2, n.2=kleinloog2010_n_effective/2, dig=20)",pEstimate_kleinloog2010_PANSS_pos_4mgTHC_olanzapine,cohen,,Yes,Yes
314,Kleinloog,Kleinloog,"Kleinloog, Daniël, Marieke Liem-Moolenaar, Gabriël Jacobs, Erica Klaassen, Marieke de Kam, Ron Hijman, and Joop van Gerven. ""Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol?."" Journal of Psychopharmacology 26, no. 10 (2012): 1307-1316.",2012,NA,Experiment,NA,"Randomized, double-blind, placebo-controlled, five- way cross-over interaction trial",Netherlands,Last year use,NA,18,45,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose intrapulmonary (0mg vs. 4 mg THC),Single dose IP (4 mg THC),NA,4mg,NA,0.8,intrapulmonary,NA,NA,no,SingleDose,CannabisDynamics,yes,p-value,dependent,"pes(p=kleinloog2010_PANSS_pos_4mgTHC_p, n.1=kleinloog2010_n_effective/2, n.2=kleinloog2010_n_effective/2, dig=20)",pEstimate_kleinloog2010_PANSS_pos_4mgTHC,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
316,Nottage,Morrison_1.25mg,"Nottage, Judith F., James Stone, Robin M. Murray, Alex Sumich, Elvira Bramon-Bosch, and Paul D. Morrison. ""Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis."" Psychopharmacology 232, no. 3 (2015): 519-528.",2014,NA,Experiment,NA,"randomised, double-blind, within-participant, exper- imental design",UK,Used at least twice,26,NA,NA,Psychosis-like,High.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Ratio of overall 27–45-Hz magnitude to 20–27-Hz magnitude in the resting state on PANSS positive symptoms during intoxication,EEG frequency,NA,NA,NA,NA,NA,NA,NA,no,Excluded,Excluded,yes,correlation,independent,"res(nottage2015_neur_oscill_ratio1_panss_pos_r, n=nottage2015_n, dig=20)",pEstimate_nottage2015_neur_oscill_ratio1_panss_pos,cohen,,no,no
317,Nottage,Morrison_1.25mg,"Nottage, Judith F., James Stone, Robin M. Murray, Alex Sumich, Elvira Bramon-Bosch, and Paul D. Morrison. ""Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis."" Psychopharmacology 232, no. 3 (2015): 519-528.",2014,NA,Experiment,NA,"randomised, double-blind, within-participant, experimental design",UK,Used at least twice,26,NA,NA,Psychosis-like,High.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Ratio of posterior 27–45-Hz magnitude to anterior 20–27-Hz magnitude in the resting state on PANSS positive symptoms during intoxication,EEG frequency,NA,NA,NA,NA,NA,NA,NA,no,Excluded,Excluded,yes,correlation,independent,"res(nottage2015_neur_oscill_ratio2_panss_pos_r, n=nottage2015_n, dig=20)",pEstimate_nottage2015_neur_oscill_ratio2_panss_pos,cohen,,no,no
318,Nottage,Morrison_1.25mg,"Nottage, Judith F., James Stone, Robin M. Murray, Alex Sumich, Elvira Bramon-Bosch, and Paul D. Morrison. ""Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis."" Psychopharmacology 232, no. 3 (2015): 519-528.",2014,NA,Experiment,NA,"randomised, double-blind, within-participant, exper- imental design",UK,Used at least twice,26,NA,NA,Paranoia,High.PAR,NA,Continuous,PANSS (paranoia subscale),PANSS,NA,NA,Ratio of posterior 27–45-Hz magnitude to anterior 20–27-Hz magnitude in the resting state on PANSS positive symptoms during intoxication,EEG frequency,NA,NA,NA,NA,NA,NA,NA,no,Excluded,Excluded,yes,correlation,independent,"res(nottage2015_neur_oscill_ratio2_panss_paranoia_r, n=nottage2015_n, dig=20)",pEstimate_nottage2015_neur_oscill_ratio2_panss_paranoia,cohen,,no,no
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
320,Collin,Collin,"Collin, C., E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, K. Powell, W. Notcutt et al. ""A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis."" Neurological research 32, no. 5 (2010): 451-459.",2010,NA,MedicalTrial,MS,"Medical trial (RCT) - double-blind, randomized, placebo-controlled, parallel-group study",UK,24% of samples reported previous cannabis use,48,NA,NA,Hallucinations,Med.HAL,NA,Binary,Single item,,Reported adverse drug effect: Hallucinations,1,"Medical cannabis (Sativex spray, individual dosage)",MS sample,MS,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_collin2010_sativex_hallucinations,pEstimate_collin2010_sativex_hallucinations,cohen,,Yes,Yes
321,Collin,Collin,"Collin, C., E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, K. Powell, W. Notcutt et al. ""A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis."" Neurological research 32, no. 5 (2010): 451-459.",2010,NA,MedicalTrial,MS,"Medical trial (RCT) - double-blind, randomized, placebo-controlled, parallel-group study",UK,24% of samples reported previous cannabis use,48,NA,NA,Paranoia,Med.PAR,NA,Binary,Single item,,Reported adverse drug effect: Paranoia,1,"Medical cannabis (Sativex spray, individual dosage)",MS sample,MS,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_collin2010_sativex_paranoia,pEstimate_collin2010_sativex_paranoia,cohen,,Yes,Yes
322,Collin,Collin,"Collin, C., E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, K. Powell, W. Notcutt et al. ""A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis."" Neurological research 32, no. 5 (2010): 451-459.",2010,NA,MedicalTrial,MS,"Medical trial (RCT) - double-blind, randomized, placebo-controlled, parallel-group study",UK,24% of samples reported previous cannabis use,48,NA,NA,Hallucinations,Med.HAL,AE,Binary,Single item,,Reported adverse drug effect: Hallucinations,1,"Medical cannabis (Sativex spray, individual dosage)",MS sample,MS,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,collin2010_sativex_HallucinationsDF,NA,rates,collin2010_sativex_HallucinationsControl,Yes,Yes
323,Collin,Collin,"Collin, C., E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, K. Powell, W. Notcutt et al. ""A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis."" Neurological research 32, no. 5 (2010): 451-459.",2010,NA,MedicalTrial,MS,"Medical trial (RCT) - double-blind, randomized, placebo-controlled, parallel-group study",UK,24% of samples reported previous cannabis use,48,NA,NA,Paranoia,Med.PAR,AE,Binary,Single item,,Reported adverse drug effect: Paranoia,1,"Medical cannabis (Sativex spray, individual dosage)",MS sample,MS,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,collin2010_sativex_ParanoiaDF,NA,rates,collin2010_sativex_ParanoiaControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
325,Aragona,Aragona,"Aragona, Massimiliano, Emanuela Onesti, Valentina Tomassini, Antonella Conte, Shiva Gupta, Francesca Gilio, Patrizia Pantano, Carlo Pozzilli, and Maurizio Inghilleri. ""Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study."" Clinical neuropharmacology 32, no. 1 (2009): 41-47.",2009,NA,MedicalTrial,MS,"double-Blind, Placebo Controlled, Crossover Study",Italy,Cannabis-naïve (MS sample),49.8,18,60,Paranoia,Med.PAR,AE,Continuous, Symptom Checklist-90 Revised (paranoia),,NA,NA,"Medical cannabis (Sativex spray, individual dosage)",MS sample,MS,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,meanComparison,dependent,extract_aragona2009_sativex_paranoia,pEstimate_aragona2009_sativex_paranoia,cohen,,Yes,Yes
326,Aragona,Aragona,"Aragona, Massimiliano, Emanuela Onesti, Valentina Tomassini, Antonella Conte, Shiva Gupta, Francesca Gilio, Patrizia Pantano, Carlo Pozzilli, and Maurizio Inghilleri. ""Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study."" Clinical neuropharmacology 32, no. 1 (2009): 41-47.",2009,NA,MedicalTrial,MS,"double-Blind, Placebo Controlled, Crossover Study",Italy,Cannabis-naïve (MS sample),49.8,18,60,Psychosis-like,Med.PLE,AE,Continuous, Symptom Checklist-90 Revised (psychosis),,NA,NA,"Medical cannabis (Sativex spray, individual dosage)",MS sample,MS,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,meanComparison,dependent,extract_aragona2009_sativex_psychosis,pEstimate_aragona2009_sativex_psychosis,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
328,Duran,Duran,"Duran, Marta, Eulàlia Pérez, Sergio Abanades, Xavier Vidal, Cristina Saura, Margarita Majem, Edurne Arriola et al. ""Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy‐induced nausea and vomiting."" British journal of clinical pharmacology 70, no. 5 (2010): 656-663.",2010,2006-2007,MedicalTrial,CINV,"randomized, double-blind, parallel-group, placebo-controlled",Spain,No cannabinoid use in the last month,50,34,76,Hallucinations,Med.HAL,NA,Binary,Single item,,Reported adverse drug effect: Psychosis,NA,"Medical cannabis (Sativex spray, individual dosage)",CINV sample,CINV,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_duran2010_sativex_psychosis,pEstimate_duran2010_sativex_psychosis,cohen,,Yes,Yes
329,Duran,Duran,"Duran, Marta, Eulàlia Pérez, Sergio Abanades, Xavier Vidal, Cristina Saura, Margarita Majem, Edurne Arriola et al. ""Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy‐induced nausea and vomiting."" British journal of clinical pharmacology 70, no. 5 (2010): 656-663.",2010,2006-2007,MedicalTrial,CINV,"randomized, double-blind, parallel-group, placebo-controlled",Spain,No cannabinoid use in the last month,50,34,76,Hallucinations,Med.HAL,AE,Binary,Single item,,Reported adverse drug effect: Psychosis,NA,"Medical cannabis (Sativex spray, individual dosage)",CINV sample,CINV,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),rates,yes,rate,NA,duran2010_sativex_HallucinationsDF,NA,rates,duran2010_sativex_HallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
331,Ranganathan,DSouza_3,"Ranganathan, Mohini, Joao P. De Aquino, Jose A. Cortes-Briones, Rajiv Radhakrishnan, Brian Pittman, Savita Bhakta, and Deepak C. D’Souza. ""Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans."" Psychopharmacology 236, no. 11 (2019): 3209-3219.",2019,NA,Experiment,NA,"double-blind, randomized, placebo-controlled study",US,Previous cannabis exposure,25,18,55,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose IV THC  (0mg vs. 0.05 mg/kg THC),Single dose IV (0.05 mg/kg THC),NA,0.05 mg/kg,0.05*80 =4mg /// 4mg/5mg=0.8 THC unit,0.8,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,p-estimate,dependent,"pes(p=ranganathan2019_PANSS_pos_p, n.1=n_effective_ranganathan2019/2, n.2=n_effective_ranganathan2019/2, dig=20)",pEstimate_ranganathan2019_PANSS_pos,cohen,,Yes,Yes
332,Ranganathan,DSouza_3,"Ranganathan, Mohini, Joao P. De Aquino, Jose A. Cortes-Briones, Rajiv Radhakrishnan, Brian Pittman, Savita Bhakta, and Deepak C. D’Souza. ""Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans."" Psychopharmacology 236, no. 11 (2019): 3209-3219.",2019,NA,Experiment,NA,"double-blind, randomized, placebo-controlled study",US,Previous cannabis exposure,25,18,55,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",NA,NA,NA,NA,NA,NA,COMT,no,COMT,CandidateGene,yes,Two-way interaction,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_ranganathan2019/2, n.2=n_effective_ranganathan2019/2, dig=20)",pEstimate_ranganathan2019_PANSS_pos_comt,cohen,,Yes,Yes
333,Ranganathan,DSouza_3,"Ranganathan, Mohini, Joao P. De Aquino, Jose A. Cortes-Briones, Rajiv Radhakrishnan, Brian Pittman, Savita Bhakta, and Deepak C. D’Souza. ""Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans."" Psychopharmacology 236, no. 11 (2019): 3209-3219.",2019,NA,Experiment,NA,"double-blind, randomized, placebo-controlled study",US,Previous cannabis exposure,25,18,55,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Inhibition of COMT (pretreatment with tolcapone),Inhibition of COMT,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,p-estimate,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_ranganathan2019_tolcapone/2, n.2=n_effective_ranganathan2019_tolcapone/2, dig=20)",pEstimate_ranganathan2019_PANSS_pos_tolcapone,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
335,Thaler,Thaler,"Thaler, Avner, Shira Arad, Lihi Bar-Lev Schleider, Judith Knaani, Tali Taichman, Nir Giladi, and Tanya Gurevich. ""Single center experience with medical cannabis in Gilles de la Tourette syndrome."" Parkinsonism & related disorders 61 (2019): 211-213.",2019,2018-2018,MedicalTrial,Tourette,Medical trial (non-placebo controlled),Israel,NA,34.5,NA,NA,Hallucination,Med.HAL,AE,Binary,Single item,,Have any of the following ever occur when treated with cannabis: Hallucinations,10,"Medical cannabis (THC/CBD mix, individual dosage)",Tourette sample,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (uncontrolled),rates,yes,rate,NA,thaler2019_MedCan_hallucinationsDF,NA,rates,,Yes,Yes
336,Thaler,Thaler,"Thaler, Avner, Shira Arad, Lihi Bar-Lev Schleider, Judith Knaani, Tali Taichman, Nir Giladi, and Tanya Gurevich. ""Single center experience with medical cannabis in Gilles de la Tourette syndrome."" Parkinsonism & related disorders 61 (2019): 211-213.",2019,2018-2018,MedicalTrial,Tourette,Medical trial (non-placebo controlled),Israel,NA,34.5,NA,NA,Acute psychotic episode,Med.PLE,full_episode,Binary,Dropout due to psychotic episode,,Dropout due to psychotic episode,2,"Medical cannabis (THC/CBD mix, individual dosage)",Tourette sample,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (uncontrolled),rates,yes,rate,NA,thaler2019_MedCan_psychosisDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
338,Balash,Balash,"Balash, Yacov, Lihi Bar-Lev Schleider, Amos D. Korczyn, Herzel Shabtai, Judith Knaani, Alina Rosenberg, Yehuda Baruch, Ruth Djaldetti, Nir Giladi, and Tanya Gurevich. ""Medical cannabis in Parkinson disease: Real-life patients' experience."" Clinical neuropharmacology 40, no. 6 (2017): 268-272.",2017,2013-2015,MedicalTrial,Parkinson,Medical trial (non-placebo controlled),Israel,NA,64.2,NA,NA,Hallucinatios,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis - hallucinations,17,"Medical cannabis (THC/CBD mix, individual dosage)",Parkinson sample,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (uncontrolled),rates,yes,rate,NA,balash2019_MedCan_hallucinationsDF,NA,rates,,Yes,Yes
339,Balash,Balash,"Balash, Yacov, Lihi Bar-Lev Schleider, Amos D. Korczyn, Herzel Shabtai, Judith Knaani, Alina Rosenberg, Yehuda Baruch, Ruth Djaldetti, Nir Giladi, and Tanya Gurevich. ""Medical cannabis in Parkinson disease: Real-life patients' experience."" Clinical neuropharmacology 40, no. 6 (2017): 268-272.",2017,2013-2015,MedicalTrial,Parkinson,Medical trial (non-placebo controlled),Israel,NA,64.2,NA,NA,Psychosis,Med.PLE,full_episode,Binary,Single item,,Reported adverse effects of medical cannabis - developed psychosis,17,"Medical cannabis (THC/CBD mix, individual dosage)",Parkinson sample,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (uncontrolled),rates,yes,rate,NA,balash2019_MedCan_psychosisDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
341,Serpell,Serpell,"Serpell, Michael G., William Notcutt, and Christine Collin. ""Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis."" Journal of neurology 260, no. 1 (2013): 285-295.",2013,NA,MedicalTrial,MS,"Medical trial (RCT, non-placebo controlled)",UK,NA,50,18,NA,Hallucination,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,<1,Medical cannabis (Sativex),MS sample,334 days (average),NA,NA,NA,NA,NA,NA,no,Medical cannabis (uncontrolled),rates,yes,rate,NA,serpell2013_Sativex_hallucinationsDF,NA,rates,,Yes,Yes
342,Serpell,Serpell,"Serpell, Michael G., William Notcutt, and Christine Collin. ""Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis."" Journal of neurology 260, no. 1 (2013): 285-295.",2013,NA,MedicalTrial,MS,"Medical trial (RCT, non-placebo controlled)",UK,NA,50,18,NA,Paranoia,Med.PAR,AE,Binary,Single item,,Reported adverse effects of medical cannabis,<1,Medical cannabis (Sativex),MS sample,334 days (average),NA,NA,NA,NA,NA,NA,no,Medical cannabis (uncontrolled),rates,yes,rate,NA,serpell2013_Sativex_paranoiaDF,NA,rates,,Yes,Yes
343,Serpell,Serpell,"Serpell, Michael G., William Notcutt, and Christine Collin. ""Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis."" Journal of neurology 260, no. 1 (2013): 285-295.",2013,NA,MedicalTrial,MS,"Medical trial (RCT, non-placebo controlled)",UK,NA,50,18,NA,Delusions,Med.DEL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,<1,Medical cannabis (Sativex),MS sample,334 days (average),NA,NA,NA,NA,NA,NA,no,Medical cannabis (uncontrolled),rates,yes,rate,NA,serpell2013_Sativex_delusionsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
345,Lichtman,Lichtman,"Lichtman, Aron H., Eberhard Albert Lux, Robert McQuade, Sandro Rossetti, Raymond Sanchez, Wei Sun, Stephen Wright, Elena Kornyeyeva, and Marie T. Fallon. ""Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain."" Journal of pain and symptom management 55, no. 2 (2018): 179-188.",2018,NA,MedicalTrial,Cancer,"Medical trial (RCT, placebo controlled)",Worldwide,NA,60,NA,NA,Hallucination,Med.HAL,NA,Binary,Single item,,Study withdrawal due to hallucinations,<1,Medical cannabis (Sativex),Cancer sample,621 days (average),NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),rates,yes,chi-square,independent,extract_lichtman2018_sativex_hallucinations,pEstimate_lichtman2018_sativex_hallucinations,cohen,,Yes,Yes
346,Lichtman,Lichtman,"Lichtman, Aron H., Eberhard Albert Lux, Robert McQuade, Sandro Rossetti, Raymond Sanchez, Wei Sun, Stephen Wright, Elena Kornyeyeva, and Marie T. Fallon. ""Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain."" Journal of pain and symptom management 55, no. 2 (2018): 179-188.",2018,NA,MedicalTrial,Cancer,"Medical trial (RCT, placebo controlled)",Worldwide,NA,60,NA,NA,Hallucination,Med.HAL,AE,Binary,Single item,,Study withdrawal due to hallucinations,<1,Medical cannabis (Sativex),Cancer sample,621 days (average),NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),rates,yes,chi-square,NA,lichtman2018_sativex_HallucinationsDF,NA,rates,lichtman2018_sativex_HallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
348,Abuhasira,Abuhasira,"Abuhasira, R., Schleider, L. B.-L., Mechoulam, R. and Novack, V. (2018), ‘Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly’, European Journal of Internal Medicine 49, pp. 44-50.",2018,NA,MedicalTrial,Cancer,"Medical trial (RCT, non-placebo controlled)",Israel,NA,74.5,NA,NA,Hallucination,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,<1,Medical cannabis (mixed),Pain-Cancer,183 (6 month follow up),NA,NA,NA,NA,NA,NA,no,Medical cannabis (uncontrolled),rates,,rate,NA,abuhasira2018_cannabisDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
350,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,NA,Observational,US,Exposed to cannabis,22.9,NA,NA,Hallucination,Can.HAL,NA,Binary,Single item,,Questionnaire asking about experiences while under the influence of cannabis ( yes/no answers),7,Family history schizophrenia,Schizophrenia (fam. Hx),NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,"chies(chiSquEstimate_camera2012_hallucinations_famhxSchz, camera2012_n, dig=50)",pEstimate_camera2012_hallucinations_famhxSchz,cohen,,Yes,Yes
351,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,NA,Observational,US,Exposed to cannabis,22.9,NA,NA,Factor component (psychotic-like experiences),Can.PLE,NA,Continuous,Multiple items,,Self-reported hallucinations/paranoia when under the influence of cannabis,NA,Age of onset of cannabis sue,Age onset cannabis use (young),NA,NA,NA,NA,NA,NA,NA,no,Age onset,CannabisHistory,yes,correlation,independent,"res(corEstimate_camera2012_psychFac_ageOnsetCan, n=camera2012_n, dig=50)",pEstimate_camera2012_psychFac_ageOnsetCan,cohen,,Yes,Yes
352,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,NA,Observational,US,Exposed to cannabis,22.9,NA,NA,Factor component (psychotic-like experiences),Can.PLE,NA,Continuous,Multiple items,,Self-reported hallucinations/paranoia when under the influence of cannabis,NA,Family history of alcoholism,Alcoholism (fam. Hx),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,"tes(tEstimate_camera2012_psych_alcFamHx , 68, 32, dig=20)",pEstimate_camera2012_psych_alcFamHx,cohen,,Yes,Yes
353,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,NA,Observational,US,Exposed to cannabis,22.9,NA,NA,Hallucinations,Can.HAL,NA,Binary,Single item,,Questionnaire asking about experiences while under the influence of cannabis ( yes/no answers),7,Alcohol use,Alcohol use,NA,NA,NA,NA,NA,NA,NA,no,Alcohol,OtherDrugs,yes,chi-square,independent,"chies(chiSquEstimate_camera2012_hallucinations_alcUse, camera2012_n, dig=50)",pEstimate_camera2012_psych_alcFamHx,cohen,,Yes,Yes
354,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,NA,Observational,US,Exposed to cannabis,22.9,NA,NA,Hallucinations,Can.HAL,psych_like,Binary,Single item,,Questionnaire asking about experiences while under the influence of cannabis ( yes/no answers),7,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,camera2012_hallucinationsDF,NA,rates,,Yes,Yes
355,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,NA,Observational,US,Exposed to cannabis,22.9,NA,NA,Paranoia,Can.PAR,psych_like,Binary,Single item,,Questionnaire asking about experiences while under the influence of cannabis ( yes/no answers),40,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,camera2012_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
357,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,GeneralPopulation,Observational and quasi-experimental,UK,Cannabis use at least once,23.5,18,65,Factor component (psychotic-like experiences),Can.PLE,NA,Continuous,CEQ,,NA,NA,"FAAH (rs324420, risk allele: A)","FAAH (rs324420, risk allele: A)",NA,NA,NA,NA,NA,NA,FAAH,no,FAAH,CandidateGene,yes,meanComparison,independent,extract_hindocha2020_faah_psych,pEstimate_hindocha2020_faah_psych,cohen,,Yes,Yes
358,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,GeneralPopulation,Observational and quasi-experimental,UK,Cannabis use at least once,23.5,18,65,Factor component (psychotic-like experiences),Can.PLE,NA,Continuous,CEQ,,NA,NA,FAAH genotype (rs324420) x caseness (healhy vs psychosis),FAAH genotype (rs324420) x caseness (healhy vs psychosis),NA,NA,NA,NA,NA,NA,FAAH,no,Other,Other,yes,meanComparison,independent,extract_hindocha2020_faah_x_case_psych,pEstimate_hindocha2020_faah_x_case_psych,cohen,,Yes,Yes
359,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,GeneralPopulation,Observational and quasi-experimental,UK,Cannabis use at least once,23.5,18,65,Factor component (psychotic-like experiences),Can.PLE,NA,Continuous,CEQ,,NA,NA,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",NA,NA,NA,NA,NA,NA,COMT,no,COMT,CandidateGene,yes,meanComparison,independent,extract_hindocha2020_comt_psych,pEstimate_hindocha2020_comt_psych,cohen,,Yes,Yes
360,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,GeneralPopulation,Observational and quasi-experimental,UK,Cannabis use at least once,23.5,18,65,Factor component (psychotic-like experiences),Can.PLE,NA,Continuous,CEQ,,NA,NA,COMT genotype (rs4680) x caseness (healhy vs psychosis),COMT genotype (rs4680) x caseness (healhy vs psychosis),NA,NA,NA,NA,NA,NA,COMT,no,Other,Other,yes,meanComparison,independent,extract_hindocha2020_comt_x_case_psych,pEstimate_hindocha2020_comt_x_case_psych,cohen,,Yes,Yes
361,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,GeneralPopulation,Observational and quasi-experimental,UK,Cannabis use at least once,23.5,18,65,Factor component (psychotic-like experiences),Can.PLE,NA,Continuous,CEQ,,NA,NA,"AKT1 (rs2494732, risk allele: C)","AKT (rs2494732, risk allele: C)",NA,NA,NA,NA,NA,NA,AKT1,no,AKT1,CandidateGene,yes,meanComparison,independent,extract_hindocha2020_akt1_psych,pEstimate_hindocha2020_akt1_x_case_psych,cohen,,Yes,Yes
362,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,GeneralPopulation,Observational and quasi-experimental,UK,Cannabis use at least once,23.5,18,65,Factor component (psychotic-like experiences),Can.PLE,NA,Continuous,CEQ,,NA,NA,AKT1 genotype (rs2494732) x caseness (healhy vs psychosis),AKT genotype (rs2494732) x caseness (healhy vs psychosis),NA,NA,NA,NA,NA,NA,AKT1,no,Other,Other,yes,meanComparison,independent,extract_hindocha2020_akt1_x_case_psych,pEstimate_hindocha2020_akt1_x_case_psych,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
364,Kaufmann,Kaufmann,"Kaufmann RM, Kraft B, Frey R, et al. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry. 2010;43(1):24‐32. doi:10.1055/s-0029-1237397",2010,NA,Experiment,GeneralPopulation,"randomized, double-blind, placebo controlled, single-dose, balanced 2-way cross-over study",Austria,Cannabis naïve,23.6,19,29,Psychosis-like,THC.PLE,NA,Continuous,BPRS,BPRS,NA,NA,"Single dose oral THC  (0mg vs. 20 mg THC, CBD:THC = 1:2)",Single dose oral THC  (20 mg THC),NA,20mg,NA,4,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_kaufmann2010_20mg_bprs_tot,pEstimate_kaufmann2010_20mg_bprs_tot,cohen,,Yes,Yes
365,Kaufmann,Kaufmann,"Kaufmann RM, Kraft B, Frey R, et al. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry. 2010;43(1):24‐32. doi:10.1055/s-0029-1237397",2010,NA,Experiment,GeneralPopulation,"randomized, double-blind, placebo controlled, single-dose, balanced 2-way cross-over study",Austria,Cannabis naïve,23.6,19,29,Paranoia,THC.PAR,NA,Continuous,BPRS (paranoia factor),BPRS,NA,NA,"Single dose oral THC  (0mg vs. 20 mg THC, CBD:THC = 1:2)",Single dose oral THC  (20 mg THC),NA,20mg,NA,4,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_kaufmann2010_20mg_bprs_par,pEstimate_kaufmann2010_20mg_bprs_par,cohen,,Yes,Yes
366,Kaufmann,Kaufmann,"Kaufmann RM, Kraft B, Frey R, et al. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry. 2010;43(1):24‐32. doi:10.1055/s-0029-1237397",2010,NA,Experiment,GeneralPopulation,"randomized, double-blind, placebo controlled, single-dose, balanced 2-way cross-over study",Austria,Cannabis naïve,23.6,19,29,Paranoia,THC.PLE,psych_like,Binary,BPRS (>84 cut-off),BPRS,NA,6,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,kaufmann2010_psychosisDF,NA,rates,kaufmann2010_psychosisControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
368,Hindocha,Curran_Hindocha,"Hindocha, Chandni, T. P. Freeman, J. X. Xia, Natacha DC Shaban, and Helen V. Curran. ""Acute memory and psychotomimetic effects of cannabis and tobacco both ‘joint’and individually: a placebo-controlled trial."" Psychological medicine 47, no. 15 (2017): 2708-2719.",2017,NA,Experiment,GeneralPopulation,"placebo-controlled, four- way, crossover trial ",UK,Regular cannabis user (at least monthly),24.5,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI,,NA,NA,Single dose smoked (0mg vs. 10mg THC),Single dose smoked THC  (10 mg THC),NA,10mg,THC condition: 66.67 mg Bedrobinol (16.1% THC and <1% CBD); THCmg=(66.67/100)*16.1 => 10mg,2,smoked,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_hindocha2017_10mg_PSI,pEstimate_hindocha2017_10mg_PSI,cohen,,No,No
369,Hindocha,Curran_Hindocha,"Hindocha, Chandni, T. P. Freeman, J. X. Xia, Natacha DC Shaban, and Helen V. Curran. ""Acute memory and psychotomimetic effects of cannabis and tobacco both ‘joint’and individually: a placebo-controlled trial."" Psychological medicine 47, no. 15 (2017): 2708-2719.",2017,NA,Experiment,GeneralPopulation,"placebo-controlled, four- way, crossover trial ",UK,Regular cannabis user (at least monthly),24.5,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI,,NA,NA,THC x nicotine interaction,THC x nicotine interaction,NA,NA,NA,NA,NA,NA,NA,no,Nicotine,OtherDrugs,yes,meanComparison,dependent,"pes(pValueNS_allStudies, n.1=n_effective_hindocha2017/2, n.2=n_effective_hindocha2017/2)",pEstimate_hindocha2017_nicotine_x_THC,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
371,Mokrysz,Curran_Mokrysz,"Mokrysz, Claire, Tom P. Freeman, Saana Korkki, Kirsty Griffiths, and H. Valerie Curran. ""Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males."" Translational psychiatry 6, no. 11 (2016): e961-e961.",2016,NA,Experiment,GeneralPopulation,"placebo-controlled, crossover trial ",UK,Regular cannabis user (at least weekly),21.3,16,28,Paranoia,THC.PAR,NA,Continuous,PSI subscale,,NA,NA,Single dose smoked (0mg vs. 8mg THC),Single dose smoked THC  (8 mg THC),NA,8mg,"THC condition: Medicinal-grade active (Bedrobinol; THC 12.0%, ~ 8.0 mg THC per individual) ",1.6,smoked,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_mokrysz2016_8mg_paranoia_tot_sample,pEstimate_mokrysz2016_8mg_paranoia_tot_sample,cohen,,Yes,Yes
372,Mokrysz,Curran_Mokrysz,"Mokrysz, Claire, Tom P. Freeman, Saana Korkki, Kirsty Griffiths, and H. Valerie Curran. ""Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males."" Translational psychiatry 6, no. 11 (2016): e961-e961.",2016,NA,Experiment,GeneralPopulation,"placebo-controlled, crossover trial ",UK,Regular cannabis user (at least weekly),21.3,16,28,Paranoia,THC.PAR,NA,Continuous,PSI subscale,,NA,NA,Age (younger),Age (young),NA,NA,NA,NA,NA,NA,NA,no,Age,Demographic,yes,meanComparison,independent,extract_mokrysz2016_paranoia_ado_vs_adult,pEstimate_mokrysz2016_paranoia_ado_vs_adult,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
374,Dalzell,Dalzell,"Dalzell, A. M., H. Bartlett, and J. S. Lilleyman. ""Nabilone: an alternative antiemetic for cancer chemotherapy."" Archives of disease in childhood 61, no. 5 (1986): 502-505.",1986,NA,MedicalTrial,Cancer,"Medical trial (randomised, double blind, crossover trial)",UK,NA,8,10,17,Hallucinations,Med.HAL,NA,Binary,Single item,,Reported adverse effects of medical cannabis,5,Medical cannabis (Nabilone),Chemotherapy sample (children),NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,dependent,extract_dalzell1986_nabilone_hallucinations,pEstimate_dalzell1986_nabilone_hallucinations,cohen,,Yes,Yes
375,Dalzell,Dalzell,"Dalzell, A. M., H. Bartlett, and J. S. Lilleyman. ""Nabilone: an alternative antiemetic for cancer chemotherapy."" Archives of disease in childhood 61, no. 5 (1986): 502-505.",1986,NA,MedicalTrial,Cancer,"Medical trial (randomised, double blind, crossover trial)",UK,NA,8,10,17,Hallucinations,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,5,Medical cannabis (Nabilone),Chemotherapy sample (children),NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,dalzell1986_nabilone_hallucinationsDF,NA,rates,dalzell1986_nabilone_hallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
378,Laszilo,Laszilo,"LASZLO, JOHN, VIRGIL S. LUCAS JR, DEAN C. HANSON, CAROL M. CRONIN, and STEPHEN E. SALLAN. ""Levonantradol for Chemotherapy‐Induced Emesis: Phase I—II Oral Administration."" The Journal of Clinical Pharmacology 21, no. S1 (1981): 51S-56S.",1981,1980-1980,MedicalTrial,Cancer,Medical trial (not randomized/no placebo condition),US,NA,40,17,66,Hallucinations,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,6,Medical cannabis (Drabinol),Cancer,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,laszilo1981_dronabinol_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
380,Jain,Jain,"JAIN, A.K., RYAN, J.R., McMAHON, F.G. and SMITH, G., 1981. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. The Journal of Clinical Pharmacology, 21(S1), pp.320S-326S.",1981,NA,MedicalTrial,Pain,"Medical trial (placebo controlled, between subjects)",US,NA,28,NA,NA,Hallucinations,Med.HAL,NA,Binary,Single item,,Reported adverse effects of medical cannabis,7.5,Medical cannabis (Drabinol),Pain,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_jain1981_drabinol_hallucinations,pEstimate_jain1981_drabinol_hallucinations,cohen,,Yes,Yes
381,Jain,Jain,"JAIN, A.K., RYAN, J.R., McMAHON, F.G. and SMITH, G., 1981. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. The Journal of Clinical Pharmacology, 21(S1), pp.320S-326S.",1981,NA,MedicalTrial,Pain,"Medical trial (placebo controlled, between subjects)",US,NA,28,NA,NA,Hallucinations,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,7.5,Medical cannabis (Drabinol),Pain,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,jain1981_drabinol_hallucinationsDF,NA,rates,jain1981_drabinol_hallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
383,Herman,Herman,"Herman, Terence S., Lawrence H. Einhorn, Stephen E. Jones, Catherine Nagy, Aurelia B. Chester, Judith C. Dean, Becky Furnas et al. ""Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy."" New England Journal of Medicine 300, no. 23 (1979): 1295-1297.",1979,NA,MedicalTrial,Cancer,"Medical trial (randomised, double blind, crossover trial)",US,NA,33,15,73,Hallucinations,Med.HAL,NA,Binary,Single item,,Reported adverse effects of medical cannabis,3,Medical cannabis (Nabilone),Cancer,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,dependent,"chies(chiSquEstimate_herman1979_nabilone_hallucinations, Ntot_herman1979_nabilone_hallucinations, dig=50)",pEstimate_herman1979_nabilone_hallucinations,cohen,,Yes,Yes
384,Herman,Herman,"Herman, Terence S., Lawrence H. Einhorn, Stephen E. Jones, Catherine Nagy, Aurelia B. Chester, Judith C. Dean, Becky Furnas et al. ""Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy."" New England Journal of Medicine 300, no. 23 (1979): 1295-1297.",1979,NA,MedicalTrial,Cancer,"Medical trial (randomised, double blind, crossover trial)",US,NA,33,15,73,Hallucinations,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,3,Medical cannabis (Nabilone),Cancer,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,herman1979medCan_hallucinationsDF,NA,rates,herman1979medCan_hallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
386,Dittrich,Dittrich,"Dittrich A, Bickel P, Schöpf J, Zimmer D. Vergleich veränderter Bewusstseinszustände unter den Halluzinogenen (--)-delta9-trans-Tetrahydrocannabinol (delta9-THC) und N,N-Dimethyltryptamin (DMT) [Comparison of altered states of consciousness induced by the hallucinogens (--)-delta9-trans-tetrahydrocannabinol (delta9-THC) and N,N-dimethyltryptamine (DMT) (author's transl)]. Arch Psychiatr Nervenkr (1970). 1976;223(1):77-87. doi:10.1007/BF00367455",1976,NA,Experiment,GeneralPopulation,"placebo-controlled, between-subject, double-blind",Germany,Majority (bit not all) have previously used cannabis,27,NA,NA,Visual hallucination,THC.HAL,NA,Cotinuous,ASC subscale,,NA,NA,Single dose oral (0mg vs.0.25mg THC/kg),Single dose oral (0.25mg THC/kg),250 microgram = 0.25 mg; 0.25mg * 80 = 20mg,20,NA,4,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,independent,"mes(dittrich1976_THC_hallucinations_visual_m, dittrich1976_placebo_hallucinations_visual_m, dittrich1976_THC_hallucinations_visual_sd, dittrich1976_placebo_hallucinations_visual_sd, dittrich1976_THC_n, dittrich1976_placebo_n, dig=20)",pEstimate_dittrich1976_THC_hallucinations_visual,cohen,,Yes,Yes
387,Dittrich,Dittrich,"Dittrich A, Bickel P, Schöpf J, Zimmer D. Vergleich veränderter Bewusstseinszustände unter den Halluzinogenen (--)-delta9-trans-Tetrahydrocannabinol (delta9-THC) und N,N-Dimethyltryptamin (DMT) [Comparison of altered states of consciousness induced by the hallucinogens (--)-delta9-trans-tetrahydrocannabinol (delta9-THC) and N,N-dimethyltryptamine (DMT) (author's transl)]. Arch Psychiatr Nervenkr (1970). 1976;223(1):77-87. doi:10.1007/BF00367455",1976,NA,Experiment,GeneralPopulation,"placebo-controlled, between-subject, double-blind",Germany,Majority (bit not all) have previously used cannabis,27,NA,NA,Auditory hallucination,THC.HAL,NA,Cotinuous,ASC subscale,,NA,NA,Single dose oral (0mg vs.0.25mg THC/kg),Single dose oral (0.25mg THC/kg),250 microgram = 0.25 mg; 0.25mg * 80 = 20mg,20,NA,4,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,independent,"mes(dittrich1976_THC_hallucinations_auditory_m, dittrich1976_placebo_hallucinations_auditory_m, dittrich1976_THC_hallucinations_auditory_sd, dittrich1976_placebo_hallucinations_auditory_sd, dittrich1976_THC_n, dittrich1976_placebo_n, dig=20)",pEstimate_dittrich1976_THC_hallucinations_auditory,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
389,Crescioli,Crescioli,"Crescioli, Giada, Niccolò Lombardi, Alessandra Bettiol, Francesca Menniti‐Ippolito, Roberto Da Cas, Maria Parrilli, Martina Del Lungo et al. ""Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database."" British Journal of Clinical Pharmacology 86, no. 1 (2020): 106-120.",2019,2006-2018,MedicalTrial,Mixed,Medical trial (non-placebo controlled),Italy,NA,61.9,NA,NA,Hallucinations,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,NA,Medical cannabis (mixed),Mixed,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,crescioli_medTrial_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
391,Milosev,Milosev,"Milosev, Leonie M., Nikolas Psathakis, Natalia Szejko, Ewgeni Jakubovski, and Kirsten R. Müller-Vahl. ""Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey."" Cannabis and Cannabinoid Research 4, no. 4 (2019): 265-274.",2019,2002-2017,MedicalTrial,Tourette syndrome,"Medical trial (non-placebo controlled,  retrospective report)",Germany,NA,35.8,18,79,Hallucinations,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,3,Medical cannabis (mixed),Tourette syndrome,1891 days (average),NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,milosev_medTrial_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
393,Zuurman,Kleinloog,"Zuurman, L., C. Roy, R. C. Schoemaker, A. Hazekamp, J. Den Hartigh, J. C. M. E. Bender, R. Verpoorte, J. L. Pinquier, A. F. Cohen, and J. M. A. Van Gerven. ""Effect of intrapulmonary tetrahydrocannabinol administration in humans."" Journal of psychopharmacology 22, no. 7 (2008): 707-716.",2008,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use (not more than 1 >/wk in the previous year),23,21,27,Hallucinations,THC.HAL,NA,Binary,VAS (single item),,"THC vs placebo comparison in ""I heard voices and sounds that were not real’""",NA,Single dose inhaled in vaporizer (0mg vs 8mg THC),Single dose vaped THC  (8 mg THC),NA,8mg,NA,1.6,intrapulmonary,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_zuurman2008_8mgTHCvaped_hallucinations,pEstimate_zuurman2008_8mgTHCvaped_hallucinations,cohen,,Yes,Yes
394,Zuurman,Kleinloog,"Zuurman, L., C. Roy, R. C. Schoemaker, A. Hazekamp, J. Den Hartigh, J. C. M. E. Bender, R. Verpoorte, J. L. Pinquier, A. F. Cohen, and J. M. A. Van Gerven. ""Effect of intrapulmonary tetrahydrocannabinol administration in humans."" Journal of psychopharmacology 22, no. 7 (2008): 707-716.",2008,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use (not more than 1 >/wk in the previous year),23,21,27,Paranoia,THC.PAR,NA,Binary,VAS (single item),,"THC vs placebo comparison in ""I had suspicious ideas or the belief that others were against me""",NA,Single dose inhaled in vaporizer (0mg vs 8mg THC),Single dose vaped THC  (8 mg THC),NA,8mg,NA,1.6,intrapulmonary,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_zuurman2008_8mgTHCvaped_paranoia,pEstimate_zuurman2008_8mgTHCvaped_paranoia,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
396,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use,NA,NA,NA,Hallucinations,THC.HAL,NA,Binary,VAS (single item),,"THC vs placebo comparison in ""I heard voices and sounds that were not real’""",16,Single dose inhaled in vaporizer (0mg vs 2mg THC),Single dose vaped THC  (2 mg THC),NA,2mg,NA,0.4,intrapulmonary,1,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_2mgTHC_hallucinations, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_2mgTHC_hallucinations,cohen,,Yes,Yes
397,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use,NA,NA,NA,Hallucinations,THC.HAL,NA,Binary,VAS (single item),,"THC vs placebo comparison in ""I heard voices and sounds that were not real’""",16,Single dose inhaled in vaporizer (0mg vs 4mg THC),Single dose vaped THC  (4 mg THC),NA,4mg,NA,0.8,intrapulmonary,2,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_4mgTHC_hallucinations, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_4mgTHC_hallucinations,cohen,,Yes,Yes
398,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use,NA,NA,NA,Hallucinations,THC.HAL,NA,Binary,VAS (single item),,"THC vs placebo comparison in ""I heard voices and sounds that were not real’""",16,Single dose inhaled in vaporizer (0mg vs 6mg THC),Single dose vaped THC  (6 mg THC),NA,6mg,NA,1.2,intrapulmonary,3,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_6mgTHC_hallucinations, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_6mgTHC_hallucinations,cohen,,Yes,Yes
399,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use,NA,NA,NA,Paranoia,THC.PAR,NA,Binary,VAS (single item),,"THC vs placebo comparison in ""I had suspicious ideas or the belief that others were against me""",19,Single dose inhaled in vaporizer (0mg vs 2mg THC),Single dose vaped THC  (6 mg THC),NA,2mg,NA,0.4,intrapulmonary,1,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_2mgTHC_paranoia, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_2mgTHC_paranoia,cohen,,Yes,Yes
400,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use,NA,NA,NA,Paranoia,THC.PAR,NA,Binary,VAS (single item),,"THC vs placebo comparison in ""I had suspicious ideas or the belief that others were against me""",19,Single dose inhaled in vaporizer (0mg vs 4mg THC),Single dose vaped THC  (4 mg THC),NA,4mg,NA,0.8,intrapulmonary,2,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_4mgTHC_paranoia, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_4mgTHC_paranoia,cohen,,Yes,Yes
401,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use,NA,NA,NA,Paranoia,THC.PAR,NA,Binary,VAS (single item),,"THC vs placebo comparison in ""I had suspicious ideas or the belief that others were against me""",19,Single dose inhaled in vaporizer (0mg vs 6mg THC),Single dose vaped THC  (6 mg THC),NA,6mg,NA,1.2,intrapulmonary,3,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_6mgTHC_paranoia, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_6mgTHC_paranoia,cohen,,Yes,Yes
402,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use,NA,NA,NA,Paranoia,THC.PAR,NA,Binary,VAS (single item),,"THC vs placebo comparison in ""I had suspicious ideas or the belief that others were against me""",19,DoseResponse,"DoseResponse (2mg, 4mg, 6mg)",NA,NA,NA,NA,NA,NA,NA,no,DoseResponseTHC,CannabisDynamics,yes,p-value,dependent,extract_kleinloogMega_analysis2014_doseResp_paranoia,pEstimate_kleinloogMega_analysis2014_doseResp_paranoia,cohen,,Yes,Yes
403,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use,NA,NA,NA,Paranoia,THC.PAR,psych_like,Binary,VAS (single item),,"THC vs placebo comparison in ""I had suspicious ideas or the belief that others were against me""",19,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,kleinloogMega_analysis2014_paranoiaDF,NA,rates,kleinloogMega_analysis2014_paranoiaControl,Yes,Yes
404,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,GeneralPopulation,"double-blind, randomized, two-way balanced placebo-controlled, cross-over study",Netherlands,Mild cannabis use,NA,NA,NA,Hallucinations,THC.HAL,psych_like,Binary,VAS (single item),,"THC vs placebo comparison in ""I heard voices and sounds that were not real’""",16,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,kleinloogMega_analysis2014_hallucinationsDF,NA,rates,kleinloogMega_analysis2014_hallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
406,Ware,Ware,"Ware, Mark A., Tongtong Wang, Stan Shapiro, Jean-Paul Collet, Aline Boulanger, John M. Esdaile, Allan Gordon, Mary Lynch, Dwight E. Moulin, and Colleen O'Connell. ""Cannabis for the management of pain: assessment of safety study (COMPASS)."" The Journal of Pain 16, no. 12 (2015): 1233-1242.",2015,2004-2008,MedicalTrial,Pain,"placebo-controlled, between-subject, double-blind",Canada,NA,49,19,83,Paranoia,Med.PAR,AE,Binary,Single item,,Reported adverse effects of medical cannabis,<1,Medical cannabis (13% THC),Chronic pain,365 days,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,ware2015medCan_paranoiaDF,NA,rates,,Yes,Yes
407,Ware,Ware,"Ware, Mark A., Tongtong Wang, Stan Shapiro, Jean-Paul Collet, Aline Boulanger, John M. Esdaile, Allan Gordon, Mary Lynch, Dwight E. Moulin, and Colleen O'Connell. ""Cannabis for the management of pain: assessment of safety study (COMPASS)."" The Journal of Pain 16, no. 12 (2015): 1233-1242.",2015,2004-2008,MedicalTrial,Pain,"placebo-controlled, between-subject, double-blind",Canada,NA,49,19,83,Hallucinations,Med.HAL,AE,Binary,Single item,,Reported adverse effects of medical cannabis,<1,Medical cannabis (13% THC),Chronic pain,365 days,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,ware2015medCan_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
409,Cooper,Cooper,"Cooper, Ruth E., Emma Williams, Seth Seegobin, Charlotte Tye, Jonna Kuntsi, and Philip Asherson. ""Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial."" European Neuropsychopharmacology 27, no. 8 (2017): 795-808.",2017,2014-2015,MedicalTrial,ADHD,"placebo-controlled, between-subject, double-blind, randomized",UK,NA,37.9,NA,NA,Paranoia,Med.PAR,NA,Cotinuous,Single item,,Adverse Events Scale,0,Medical cannabis (Sativex),ADHD,42 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),excluded,,meanComparison,independent,"pes(1, cooperADHD_sativex_n, cooperADHD_placebo_n)",pEstimate_cooperADHD_sativex,cohen,,No,No
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
411,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover ",US,Previous exposure,25.3,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,DoseResponseTHC,Dose response IV (varying doses),NA,NA,NA,NA,NA,NA,NA,no,DoseResponseTHC,CannabisDynamics,yes,chi-square,dependent,"chies(19.88, n_effective_ganesh2020_megaTHCdose, dig=50)",pEstimate_ganesh2020_megaTHCdose,cohen,,Yes,Yes
412,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover ",US,Previous exposure,25.3,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Frequency of cannabis use,Cannabis frequency,NA,NA,NA,NA,NA,NA,NA,yes,Tolerance,CannabisDynamics,yes,chi-square,independent,"chies( 18.13, ganesh2020_megaTHC_canFrq_n, dig=50) ",pEstimate_ganesh2020_megaTHCcanFrq,cohen,,Yes,Yes
413,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover ",US,Previous exposure,25.3,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Age (younger age),Age (young),NA,NA,NA,NA,NA,NA,NA,yes,Age,Demographic,yes,chi-square,independent,"chies( 5.05, ganesh2020_megaTHC_age_n, dig=50)",pEstimate_ganesh2020_megaTHCage,cohen,,Yes,Yes
414,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover ",US,Previous exposure,25.3,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Gender (male vs. female),Gender (male),NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,meanComparison,independent,"pes(p=pValueNS_allStudies, n.1=ganesh2020_megaTHC_gender_n/2, n.2=ganesh2020_megaTHC_gender_n/2)",pEstimate_ganesh2020_megaTHCgender,cohen,,Yes,Yes
415,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover ",US,Previous exposure,25.3,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Smoking statut (current smoked),Smoking statut (current smoked),NA,NA,NA,NA,NA,NA,NA,no,Nicotine,OtherDrugs,yes,meanComparison,independent,"mes(3, 4.32,  3.46, 3.46, ganesh2020_megaTHC_tobacooSmoker_n, ganesh2020_megaTHC_tobacooNonSmoker_n, dig = 20)",pEstimate_ganesh2020_megaTHC_tobacoo,cohen,,Yes,Yes
416,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover ",US,Previous exposure,25.3,NA,NA,Delusions,THC.DEL,psych_like,Continuous,PANSS (delusions),PANSS,NA,0.75,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,ganesh2020_mega_delusionsDF,NA,rates,,Yes,Yes
417,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover ",US,Previous exposure,25.3,NA,NA,Hallucinations,THC.HAL,psych_like,Continuous,PANSS (hallucinations),PANSS,NA,4.75,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,ganesh2020_mega_hallucinationDF,NA,rates,,Yes,Yes
418,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover ",US,Previous exposure,25.3,NA,NA,Paranoia,THC.PAR,psych_like,Continuous,PANSS (paranoia),PANSS,NA,1,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,ganesh2020_mega_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
420,Ranganathan,Ranganathan,"Ranganathan, Mohini, Michelle Carbuto, Gabriel Braley, Jaqueline Elander, Edward Perry, Brian Pittman, Rajiv Radhakrishnan, Richard A. Sewell, and Deepak C. D'Souza. ""Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans."" International Journal of Neuropsychopharmacology 15, no. 9 (2012): 1251-1264.",2012,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled ",US,Previous exposure,27.14,18,55,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Administration Naltrexone (25mg),Opioid receptor function (Naltrexone),NA,NA,NA,NA,NA,NA,NA,no,Opioidergic function,Neurotransmission,yes,meanComparison,dependent,extract_Ranganathan_PANSSpos_naltrexone,pEstimate_Ranganathan_PANSSpos_naltrexone,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
422,van Amerongen,van_Amerongen,"van Amerongen, G., P. Siebenga, M. L. de Kam, J. L. Hay, and G. J. Groeneveld. ""Effect profile of paracetamol, Δ9‐THC and promethazine using an evoked pain test battery in healthy subjects."" European Journal of Pain 22, no. 7 (2018): 1331-1342.",2018,NA,Experiment,GeneralPopulation,placebo-controlled crossover study ,Netherlands,NA,24,18,45,Hallucinations,THC.HAL,NA,Binary,TEAEs (Hallucinations),,Adverse effects (hallucinations) as reported during intoxication,9,Single dose oral (0mg vs.0.10mg THC),Single dose oral THC  (10 mg),NA,10mg,NA,2,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,"chies(chiSquEstimate_amerongen_oralTHC10mg_hallucinations, Ntot_amerongen_oralTHC10mg_hallucinations, dig=50)",pEstimate_amerongen_oralTHC10mg_hallucinations,cohen,,Yes,Yes
423,van Amerongen,van_Amerongen,"van Amerongen, G., P. Siebenga, M. L. de Kam, J. L. Hay, and G. J. Groeneveld. ""Effect profile of paracetamol, Δ9‐THC and promethazine using an evoked pain test battery in healthy subjects."" European Journal of Pain 22, no. 7 (2018): 1331-1342.",2018,NA,Experiment,GeneralPopulation,placebo-controlled crossover study ,Netherlands,NA,24,18,45,Hallucinations,THC.HAL,AE,Binary,TEAEs (Hallucinations),,Adverse effects (hallucinations) as reported during intoxication,9,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,amerongen_oralTHC10mg_hallucinationsDF,NA,rates,amerongen_oralTHC10mg_hallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
425,Patti,Patti,"Patti, Francesco, Silvia Messina, Claudio Solaro, Maria Pia Amato, Roberto Bergamaschi, Simona Bonavita, R. Bruno Bossio et al. ""Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity."" Journal of Neurology, Neurosurgery & Psychiatry 87, no. 9 (2016): 944-951.",2016,2014-2015,MedicalTrial,MS,Medical trial (non-placebo controlled),Italy,NA,51,NA,NA,Hallucinations,Med.HAL,AE,Binary,Single item,,Dropout due to adverse event,<1,Medical cannabis (Sativex),MS,30 days,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,patti2016Sativex_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
427,Freeman,Morgan_Curran_Experiment,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,PastMonthCannabisUser,21.8,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),NA,8mg,inhale from balloon until empty,1.6,inhaled,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,"des(0.147, n.1=FreemanMega_Hindocha2015_effective/2, n.2=FreemanMega_Hindocha2015_effective/2)",pEstimate_FreemanMega_Hindocha2015_PSI,cohen,,Yes,Yes
428,Freeman,Curran_Hindocha,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,GeneralPopulation,"placebo-controlled, four- way, crossover trial ",UK,Regular cannabis user (at least monthly),24.5,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Single dose smoked (0mg vs. 10mg THC),Single dose smoked THC  (10 mg THC),NA,10mg,THC condition: 66.67 mg Bedrobinol (16.1% THC and <1% CBD); THCmg=(66.67/100)*16.1 => 10mg,2,smoked,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,"des(0.520, n.1=FreemanMega_Hindocha2017_effective/2, n.2=FreemanMega_Hindocha2017_effective/2)",pEstimate_FreemanMega_Hindocha2017_PSI,cohen,,Yes,Yes
429,Freeman,Lawn_experiment,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,GeneralPopulation,"placebo-controlled, crossover trial ",UK,"InfrequentCannabisUser ((⩾4 times in the last year, ⩽3 times/week)",26.9,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Single dose vaped (0.05mg vs. 8mg THC),Single dose vaped THC  (8 mg THC),NA,8mg,cannabis (8 mg THC) and placebo cannabis (0.05 mg THC) delivered by vaporiser,1.6,inhaled,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,"des(0.313, n.1=FreemanMega_Lawn2016_effective/2, n.2=FreemanMega_Lawn2016_effective/2)",pEstimate_FreemanMega_Lawn2016_PSI,cohen,,Yes,Yes
430,Freeman,Curran_Mokrysz,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,GeneralPopulation,"placebo-controlled, crossover trial ",UK,Regular cannabis user (at least weekly),21.3,16,28,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Single dose vaped (0mg vs. 8mg THC),Single dose vaped THC  (8 mg THC),NA,8mg,"THC condition: Medicinal-grade active (Bedrobinol; THC 12.0%, ~ 8.0 mg THC per individual) ",1.6,inhaled,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,"des(0.658, n.1=FreemanMega_Mokrysz_effective/2, n.2=FreemanMega_Mokrysz_effective/2)",pEstimate_FreemanMega_Mokrysz_PSI,cohen,,Yes,Yes
431,Freeman,Morgan_Curran_Experiment__Curran_Hindocha__Lawn_experiment__Curran_Mokrysz,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,GeneralPopulation,"placebo-controlled, crossover trial ",UK,Previous exposure,22.7,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Frequency of cannabis use,Cannabis frequency,NA,NA,NA,NA,NA,NA,NA,yes,Tolerance,CannabisDynamics,yes,meanComparison,dependent,"pes(0.522, n.1=FreemanMega_PSI_freq_all_effective/2, n.2=FreemanMega_PSI_freq_all_effective/2)",pEstimate_FreemanMega_PSI_freq,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
433,Bonn-Miller,Bonn_Miller,"Bonn-Miller, Marcel O., Sue Sisley, Paula Riggs, Berra Yazar-Klosinski, Julie B. Wang, Mallory JE Loflin, Benjamin Shechet et al. ""The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial."" Plos one 16, no. 3 (2021): e0246990.",2021,NA,MedicalTrial,PTSD,"placebo-controlled, crossover trial ",US,NA,44.9,24.3,77.3,Paranoia,Med.PAR,NA,Binary,Single item,,Adverse Events Scale,13%,"Medical cannabis (smoked cannabis, 1) high THC = 12% THC; <0.05% CBD; 2) THC+-CBD =  7.9% THC, 8.1% CBD,)",PTSD,21 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_EstBonn_PAR,pvalEstBonn_PAR,cohen,,Yes,Yes
434,Bonn-Miller,Bonn_Miller,"Bonn-Miller, Marcel O., Sue Sisley, Paula Riggs, Berra Yazar-Klosinski, Julie B. Wang, Mallory JE Loflin, Benjamin Shechet et al. ""The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial."" Plos one 16, no. 3 (2021): e0246990.",2021,NA,MedicalTrial,PTSD,"placebo-controlled, crossover trial ",US,NA,44.9,24.3,77.3,Hallucinations,Med.HAL,NA,Binary,Single item,,Adverse Events Scale,3%,"Medical cannabis (smoked cannabis, 1) high THC = 12% THC; <0.05% CBD; 2) THC+-CBD =  7.9% THC, 8.1% CBD,)",PTSD,21 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_EstBonn_HAL,pvalEstBonn_HAL,cohen,,Yes,Yes
435,Bonn-Miller,Bonn_Miller,"Bonn-Miller, Marcel O., Sue Sisley, Paula Riggs, Berra Yazar-Klosinski, Julie B. Wang, Mallory JE Loflin, Benjamin Shechet et al. ""The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial."" Plos one 16, no. 3 (2021): e0246990.",2021,NA,MedicalTrial,PTSD,"placebo-controlled, crossover trial ",US,NA,44.9,24.3,77.3,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events Scale,13%,"Medical cannabis (smoked cannabis, 1) high THC = 12% THC; <0.05% CBD; 2) THC+-CBD =  7.9% THC, 8.1% CBD,)",PTSD,21 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis,rates,yes,rate,NA,bonn2021HighTC_paranoiaDF,NA,rates,bonn2021HighTC_paranoiaControl,Yes,Yes
436,Bonn-Miller,Bonn_Miller,"Bonn-Miller, Marcel O., Sue Sisley, Paula Riggs, Berra Yazar-Klosinski, Julie B. Wang, Mallory JE Loflin, Benjamin Shechet et al. ""The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial."" Plos one 16, no. 3 (2021): e0246990.",2021,NA,MedicalTrial,PTSD,"placebo-controlled, crossover trial ",US,NA,44.9,24.3,77.3,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events Scale,3%,"Medical cannabis (smoked cannabis, 1) high THC = 12% THC; <0.05% CBD; 2) THC+-CBD =  7.9% THC, 8.1% CBD,)",PTSD,21 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis,rates,yes,rate,NA,bonn2021HighTC_hallucinationsDF,NA,rates,bonn2021HighTC_hallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
438,Aviram,Aviram,"Aviram, Joshua, Dorit Pud, Tamar Gershoni, Bareket Schiff‐Keren, Miriam Ogintz, Simon Vulfsons, Tamar Yashar et al. ""Medical cannabis treatment for chronic pain: Outcomes and prediction of response."" European Journal of Pain 25, no. 2 (2021): 359-374.",2021,2015-2019,MedicalTrial,Pain,uncontrolled,Israel,NA,47,37,60,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events Scale,2%,Medical cannabis,Chronic pain,30 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis,rates,yes,rate,NA,aviramMedCanT1_ParanoiaDF,NA,rates,,Yes,Yes
439,Aviram,Aviram,"Aviram, Joshua, Dorit Pud, Tamar Gershoni, Bareket Schiff‐Keren, Miriam Ogintz, Simon Vulfsons, Tamar Yashar et al. ""Medical cannabis treatment for chronic pain: Outcomes and prediction of response."" European Journal of Pain 25, no. 2 (2021): 359-374.",2021,2015-2019,MedicalTrial,Pain,uncontrolled,Israel,NA,47,37,60,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events Scale,2%,Medical cannabis,Chronic pain,30 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis,rates,yes,rate,NA,aviramMedCanT1_HallucinationsDF,NA,rates,,Yes,Yes
440,Aviram,Aviram,"Aviram, Joshua, Dorit Pud, Tamar Gershoni, Bareket Schiff‐Keren, Miriam Ogintz, Simon Vulfsons, Tamar Yashar et al. ""Medical cannabis treatment for chronic pain: Outcomes and prediction of response."" European Journal of Pain 25, no. 2 (2021): 359-374.",2021,2015-2019,MedicalTrial,Pain,uncontrolled,Israel,NA,47,37,60,Psychosis,Med.PLE,full_episode,Binary,Single item,,Adverse Events Scale,1%,Medical cannabis,Chronic pain,30 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis,rates,yes,rate,NA,aviramMedCanT1_PsychosisDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
442,Gustavsen,Gustavsen,"Gustavsen, S., H. B. Søndergaard, K. Linnet, R. Thomsen, B. S. Rasmussen, P. S. Sorensen, F. Sellebjerg, and A. B. Oturai. ""Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis."" Multiple sclerosis and related disorders 48 (2021): 102708.",2021,2019-2020,MedicalTrial,MS,uncontrolled,Denmark,NA,50,27,74,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events,0%,Medical cannabis,MS,30 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis,rates,yes,rate,NA,gustavsen2021MedCanMS_ParanoiaDF,NA,rates,,Yes,Yes
443,Gustavsen,Gustavsen,"Gustavsen, S., H. B. Søndergaard, K. Linnet, R. Thomsen, B. S. Rasmussen, P. S. Sorensen, F. Sellebjerg, and A. B. Oturai. ""Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis."" Multiple sclerosis and related disorders 48 (2021): 102708.",2021,2019-2020,MedicalTrial,MS,uncontrolled,Denmark,NA,50,27,74,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events,0%,Medical cannabis,MS,30 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis,rates,yes,rate,NA,gustavsen2021MedCanMS_HallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
445,Theunissen,Theunissen,"Theunissen, Eef L., Johannes T. Reckweg, Nadia RPW Hutten, Kim PC Kuypers, Stefan W. Toennes, Merja A. Neukamm, Sebastian Halter, and Johannes G. Ramaekers. ""Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis."" Psychopharmacology (2021): 1-11.",2021,NA,Experiment,GeneralPopulation,"placebo-controlled, double blind, within-subjects trial",Netherlands,"occasional users  (participants had minimum 1 year experience with cannabis, with a minimum and maximum use of 12 and 120 times/year)",22.8,19,34,Paranoia,THC.PAR,NA,Binary,Single item,,Adverse Events,4%,Single dose inhaled (0mg vs 5.52mg THC),Single dose inhaled (5.52mg THC),NA,5.52mg,"inhaled, The average dose of JWH-018 administered was 5.52 mg.",1,inhaled,NA,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,"chies(chiSquEstimate_theunissen2021_JWH_018_paranoia, Ntot_theunissen2021_JWH_018_paranoia, dig=50)",pEstimate_theunissen2021_JWH_018_paranoia,cohen,,Yes,Yes
446,Theunissen,Theunissen,"Theunissen, Eef L., Johannes T. Reckweg, Nadia RPW Hutten, Kim PC Kuypers, Stefan W. Toennes, Merja A. Neukamm, Sebastian Halter, and Johannes G. Ramaekers. ""Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis."" Psychopharmacology (2021): 1-11.",2021,NA,Experiment,GeneralPopulation,"placebo-controlled, double blind, within-subjects trial",Netherlands,"occasional users  (participants had minimum 1 year experience with cannabis, with a minimum and maximum use of 12 and 120 times/year)",22.8,19,34,Paranoia,THC.PAR,AE,Binary,Single item,,Adverse Events,4%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis,rates,yes,rate,NA,theunissen2021_JWH_018_paranoiaDF,NA,rates,theunissen2021_JWH_018_paranoiaDF,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
448,Aran,Aran,"Aran, Adi, Moria Harel, Hanoch Cassuto, Lola Polyansky, Aviad Schnapp, Nadia Wattad, Dorit Shmueli, Daphna Golan, and F. Xavier Castellanos. ""Cannabinoid treatment for autism: a proof-of-concept randomized trial."" Molecular autism 12, no. 1 (2021): 1-11.",2021,2017-2018,MedicalTrial,Autism,"randomized, double-blind, placebo-controlled trial ",Israel,NA,11.8,5,21,Hallucinations,Med.HAL,NA,Binary,Single item,,Adverse Events,6%,Medical cannabis,Autism,84 days,NA,NA,NA,NA,NA,NA,yes,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,dependent,extractedAran2021_medCan_autism_hallucination,pEstimate_aran2021_medCan_autism_hallucination,cohen,,Yes,Yes
449,Aran,Aran,"Aran, Adi, Moria Harel, Hanoch Cassuto, Lola Polyansky, Aviad Schnapp, Nadia Wattad, Dorit Shmueli, Daphna Golan, and F. Xavier Castellanos. ""Cannabinoid treatment for autism: a proof-of-concept randomized trial."" Molecular autism 12, no. 1 (2021): 1-11.",2021,2017-2018,MedicalTrial,Autism,"randomized, double-blind, placebo-controlled trial ",Israel,NA,11.8,5,21,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events,6%,Medical cannabis,Autism,84 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (rate),rates,yes,rate,NA,aran2021_medCan_autism_hallucination_HallucinationsDF,NA,rates,aran2021_medCan_autism_HallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
451,Schmidt,Schmidt,"Schmidt-Wolf, Gabriele, and Peter Cremer-Schaeffer. ""3 Jahre Cannabis als Medizin–Zwischenergebnisse der Cannabisbegleiterhebung."" Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 64, no. 3 (2021): 368-377.",2021,2017-2020,MedicalTrial,Spasticity,uncontrolled,Germnany,NA,54,NA,NA,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events,0.8%%,Medical cannabis (Dronabinol/Sativex),Pain/spasticity,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (rate),rates,yes,rate,NA,schmidtMedCanGermany202_ParanoiaDF,NA,rates,,Yes,Yes
452,Schmidt,Schmidt,"Schmidt-Wolf, Gabriele, and Peter Cremer-Schaeffer. ""3 Jahre Cannabis als Medizin–Zwischenergebnisse der Cannabisbegleiterhebung."" Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 64, no. 3 (2021): 368-377.",2021,2017-2020,MedicalTrial,Spasticity,uncontrolled,Germnany,NA,54,NA,NA,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events,0.8%%,Medical cannabis (Dronabinol/Sativex),Pain/spasticity,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (rate),rates,yes,rate,NA,schmidtMedCanGermany202_HallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
454,Fairhurst,Fairhurst,"Fairhurst, Charlie, Ram Kumar, Daniel Checketts, Bola Tayo, and Susie Turner. ""Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial."" Developmental Medicine & Child Neurology 62, no. 9 (2020): 1031-1039.",2020,2013-2017,MedicalTrial,Spasticity,RCT,"UK,Israel,Czech Republic",NA,12,8,18,Hallucinations,Med.HAL,NA,Binary,Single item,,Adverse Events,6%,Medical cannabis (Nabiximols),Spacsticity,48 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_EstfairhurstNabiximols_HAL,pvalEstfairhurstNabiximols_HAL,cohen,,Yes,Yes
455,Fairhurst,Fairhurst,"Fairhurst, Charlie, Ram Kumar, Daniel Checketts, Bola Tayo, and Susie Turner. ""Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial."" Developmental Medicine & Child Neurology 62, no. 9 (2020): 1031-1039.",2020,2013-2017,MedicalTrial,Spasticity,RCT,"UK,Israel,Czech Republic",NA,12,8,18,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events,6%,Medical cannabis (Nabiximols),Spacsticity,48 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (rate),rates,yes,rate,NA,fairhurstNabiximols_HALDF,NA,rates,fairhurstNabiximols_HALControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
457,Habib,Habib,"Habib, G., & Levinger, U. (2020). CHARACTERISTICS OF MEDICAL CANNABIS USAGE AMONG PATIENTS WITH FIBROMYALGIA. Harefuah, 159(5), 343-348.",2020,NA,MedicalTrial,Fibromyalgia,uncontrolled,Israel,NA,45,NA,NA,Psychosis,Med.PLE,full_episode,Binary,Single item,,Adverse Events ,1%,Medical cannabis,Fibromyalgia,474 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (rate),rates,yes,rate,NA,Habib_medCan_psychDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
459,Okey,Okey,"Okey, Sarah A., and Madeline H. Meier. ""A within-person comparison of the subjective effects of higher vs. lower-potency cannabis."" Drug and alcohol dependence 216 (2020): 108225.",2020,NA,Observational,GeneralPopulation,Observational,US,cannabis use of 5 to 6 times per week,32.2,18,NA,Psychosis-like,Can.PLE,NA,Continuous,CEQ-PLE (total score),,NA,NA,CannabisType (high vs. low potency),CannabisType (concentrates vs. dried buds),NA,NA,NA,NA,NA,NA,NA,no,THCcontent,CannabisStrain,yes,meanComparison,dependent,extract_okey2020_within_CEQ,pEstimate_okey2020_within_CEQ,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
461,Safakish,Safakish,"Safakish, Ramin, Gordon Ko, Vahid Salimpour, Bryan Hendin, Imrat Sohanpal, Gena Loheswaran, and Sun Young Rosalia Yoon. ""Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study."" Pain Medicine 21, no. 11 (2020): 3073-3086.",2020,2015-2019,MedicalTrial,Mixed,uncontrolled,Canada,NA,49.6,25,88,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events,0.8,Medical cannabis,Mixed conditions,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (rate),rates,yes,rate,NA,safakish_medCan_hallucinationsDF,NA,rates,,Yes,Yes
462,Safakish,Safakish,"Safakish, Ramin, Gordon Ko, Vahid Salimpour, Bryan Hendin, Imrat Sohanpal, Gena Loheswaran, and Sun Young Rosalia Yoon. ""Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study."" Pain Medicine 21, no. 11 (2020): 3073-3086.",2020,2015-2019,MedicalTrial,Mixed,uncontrolled,Canada,NA,49.6,25,88,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events,3.5,Medical cannabis,Mixed conditions,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (rate),rates,yes,rate,NA,safakish_medCan_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
464,Abrams,Abrams1,"Abrams, Donald I., Paul Couey, Niharika Dixit, Varun Sagi, Ward Hagar, Elliott Vichinsky, Mary Ellen Kelly, John E. Connett, and Kalpna Gupta. ""Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial."" JAMA network open 3, no. 7 (2020): e2010874-e2010874.",2020,2014-2019,MedicalTrial,Chronic pain,"randomized, placebo-controlled trial ",US,NA,37.6,NA,NA,Paranoia,Med.PAR,NA,Continuous,Score ,,Adverse Events,NA,"Medical cannabis (4.4% THC, 4.9% CBD)",Sickle cell disease,5 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,meanComparison,dependent,extract_abramsMedCan_paranoia,pEstimate_abramsMedCan_paranoia,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
466,Grimison,Grimison,"Grimison, P., A. Mersiades, A. Kirby, N. Lintzeris, R. Morton, P. Haber, I. Olver et al. ""Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial."" Annals of Oncology 31, no. 11 (2020): 1553-1560.# 19 patients received either nabilone (median dose = 0.75 mg) or pla- cebo",2020,2016-2019,MedicalTrial,Cancer," crossover, double-blind, placebo-controlled trial",Australia,NA,55,29,80,Hallucinations,Med.HAL,NA,Binary,Single item,,Adverse Events,0,"Medical cannabis (2.5mg THC, 2.5mg CBD)",Cancer,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),Excluded,yes,chi-square,dependent,extract_grimison2020Cancer_hallucinations,pEstimate_grimison2020Cancer_hallucinations,cohen,,Yes,Yes
467,Grimison,Grimison,"Grimison, P., A. Mersiades, A. Kirby, N. Lintzeris, R. Morton, P. Haber, I. Olver et al. ""Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial."" Annals of Oncology 31, no. 11 (2020): 1553-1560.# 19 patients received either nabilone (median dose = 0.75 mg) or pla- cebo",2020,2016-2019,MedicalTrial,Cancer," crossover, double-blind, placebo-controlled trial",Australia,NA,55,29,80,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events,0,"Medical cannabis (2.5mg THC, 2.5mg CBD)",Cancer,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (rate),rates,yes,rate,NA,grimison2020Cancer_hallucinationsDF,NA,rates,grimison2020Cancer_hallucinationsControls,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
469,Martin-Santos,Martin-Santos,"Martin-Santos, R., J. a Crippa, A. Batalla, S. Bhattacharyya, Z. Atakan, S. Borgwardt, P. Allen et al. ""Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers."" Current pharmaceutical design 18, no. 32 (2012): 4966-4979.",2012,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use,26.4,20,42,Psychosis-like,THC.PLE,psych_like,Continuous,PANSS (positive),PANSS,NA,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,marSan2012acute_paranoiaDF,NA,rates,,Yes,Yes
470,Martin-Santos,Martin-Santos,"Martin-Santos, R., J. a Crippa, A. Batalla, S. Bhattacharyya, Z. Atakan, S. Borgwardt, P. Allen et al. ""Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers."" Current pharmaceutical design 18, no. 32 (2012): 4966-4979.",2012,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use,26.4,20,42,Psychosis-like,High.PLE,psych_like,Continuous,PANSS (total),PANSS,NA,NA,THC in blood [(THC-COOH) whole blood concentration],Cannabis in system (high),NA,NA,NA,NA,NA,NA,NA,no,THC-COOH levels,CannabisDynamics,Excluded,correlation,independent,cohen_marSan2012THC_COOH_panssTS,pEstimate_marSan2012THC_COOH_panssTS,cohen,,no,no
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
472,Favrat,GiroudDronabinol,"Favrat, Bernard, Annick Ménétrey, Marc Augsburger, Laura E. Rothuizen, Monique Appenzeller, Thierry Buclin, Marie Pin, Patrice Mangin, and Christian Giroud. ""Two cases of"" cannabis acute psychosis"" following the administration of oral cannabis."" BMC psychiatry 5, no. 1 (2005): 1-6.",2005,NA,Experiment,GeneralPopulation,double-blind crossover design,Switzerland,Regular cannabis use,26.4,22,30,Psychosis-like,THC.PLE,full_episode,Binary,Adverse reaction (psychosis),,NA,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,favrat2005oralTHC_psychosisDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
474,Cavazos-Rehg,Cavazos-Rehg,"Cavazos-Rehg, Patricia A., Melissa J. Krauss, Shaina J. Sowles, Glennon M. Floyd, Elizabeth S. Cahn, Veronica L. Chaitan, and Marisel Ponton. ""Leveraging user perspectives for insight into cannabis concentrates."" The American journal of drug and alcohol abuse 44, no. 6 (2018): 628-641.",2018,2015,Observational,GeneralPopulation,Survey,US,Users of cannabis concentrates,25,18,35,Paranoia,Can.PAR,psych_like,Binary,Severe paranoia (yes/no) when using cannabis,,NA,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,cavazos_rehgCanConcentrates_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
476,Morvan,Morvan,"Morvan, Y., J. Rouvier, J-P. Olié, H. Lôo, and M-O. Krebs. ""Consommations de substances illicites chez les étudiants: une enquête en service de médecine préventive."" L'Encéphale 35 (2009): S202-S208.",2009,NA,Observational,GeneralPopulation,Survey,France,Users of cannabis concentrates,20,NA,NA,Paranoia,Can.PLE,psych_like,Binary,Psychosis-like experiences at first use,,NA,26%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,morvan2009_PLEDF,NA,rates,,Yes,Yes
477,Morvan,Morvan,"Morvan, Y., J. Rouvier, J-P. Olié, H. Lôo, and M-O. Krebs. ""Consommations de substances illicites chez les étudiants: une enquête en service de médecine préventive."" L'Encéphale 35 (2009): S202-S208.",2009,NA,Observational,GeneralPopulation,Survey,France,Users of cannabis concentrates,20,NA,NA,Paranoia,Can.HAL,psych_like,Binary,visual /  auditory hallucinationsat first use,,NA,8%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,morvan2009_hallucinationDF,NA,rates,,Yes,Yes
478,Morvan,Morvan,"Morvan, Y., J. Rouvier, J-P. Olié, H. Lôo, and M-O. Krebs. ""Consommations de substances illicites chez les étudiants: une enquête en service de médecine préventive."" L'Encéphale 35 (2009): S202-S208.",2009,NA,Observational,GeneralPopulation,Survey,France,Users of cannabis concentrates,20,NA,NA,Paranoia,Can.PAR,psych_like,Binary,Paranoia (feelings of mistrust and persecution) at first use,,NA,11%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,morvan2009_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
480,Costiniuk,Costiniuk,"Costiniuk, Cecilia T., Zahra Saneei, Syim Salahuddin, Joseph Cox, Jean-Pierre Routy, Sergio Rueda, Sara J. Abdallah et al. ""Cannabis consumption in people living with HIV: Reasons for use, secondary effects, and opportunities for health education."" Cannabis and cannabinoid research 4, no. 3 (2019): 204-213.",2019,2018,Observational,Cannabis users with HIV,Survey,Canada,At least several times/year,54,NA,NA,Paranoia,Can.PAR,psych_like,Binary,Psychological effects when using cannabis (paranoia),,Adverse secondary effects of cannabis,22%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,costiniuk2019_HIVparanoiaDF,NA,rates,,No,No
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
482,Barratt,Barratt,"Barratt, Monica J., Vince Cakic, and Simon Lenton. ""Patterns of synthetic cannabinoid use in A ustralia."" Drug and alcohol review 32, no. 2 (2013): 141-146.",2013,2011-2012,Observational,GeneralPopulation,Survey,Australia,Users of synthetic cannabis,27,NA,NA,Paranoia,Can.PAR,psych_like,Binary,Side effects of synthetic cannabis (paranoia),,Side effects of synthetic cannabis,18%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,barratt2016_synthetic_paranoiaDF,NA,rates,,Yes,Yes
483,Barratt,Barratt,"Barratt, Monica J., Vince Cakic, and Simon Lenton. ""Patterns of synthetic cannabinoid use in A ustralia."" Drug and alcohol review 32, no. 2 (2013): 141-146.",2013,2011-2012,Observational,GeneralPopulation,Survey,Australia,Users of synthetic cannabis,27,NA,NA,Psychosis,Can.PLE,psych_like,Binary,Side effects of synthetic cannabis (psychosis),,Side effects of synthetic cannabis,4%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,barratt2016_synthetic_psychosisDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
485,Contreras,Contreras,"Contreras, Alexandra Elyse, Katelyn E. Hall, Daniel I. Vigil, Allison Rosenthal, Alejandro Azofeifa, and Michael Van Dyke. ""Results from the Colorado Cannabis Users Survey on Health (CUSH), 2016."" International Journal of Mental Health and Addiction 18, no. 1 (2020): 1-13.",2020,2016,Observational,GeneralPopulation,Survey,US,Used at least once in the previous month,NA,21,NA,Paranoia,Can.PAR,psych_like,Binary,"
Adverse effects experienced after use",,NA,21%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,contreras2020Colorado_paranoiaDF,NA,rates,,Yes,Yes
486,Contreras,Contreras,"Contreras, Alexandra Elyse, Katelyn E. Hall, Daniel I. Vigil, Allison Rosenthal, Alejandro Azofeifa, and Michael Van Dyke. ""Results from the Colorado Cannabis Users Survey on Health (CUSH), 2016."" International Journal of Mental Health and Addiction 18, no. 1 (2020): 1-13.",2020,2016,Observational,GeneralPopulation,Survey,US,Used at least once in the previous month,NA,21,NA,Hallucinations,Can.HAL,psych_like,Binary,"
Adverse effects experienced after use",,NA,3.40%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,contreras2020Colorado_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
488,LaFrance,LaFrance,"LaFrance, Emily M., Amanda Stueber, Nicholas C. Glodosky, Dakota Mauzay, and Carrie Cuttler. ""Overbaked: assessing and predicting acute adverse reactions to Cannabis."" Journal of Cannabis Research 2, no. 1 (2020): 1-10.",2020,NA,Observational,GeneralPopulation,Survey,US,Cannabis use at least once,20.9,18,61,Paranoia,Can.PAR,psych_like,Binary,ARS,,Adverse experiences while high,50.30%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,laFrance2020arc_paranoiaDF,NA,rates,,Yes,Yes
489,LaFrance,LaFrance,"LaFrance, Emily M., Amanda Stueber, Nicholas C. Glodosky, Dakota Mauzay, and Carrie Cuttler. ""Overbaked: assessing and predicting acute adverse reactions to Cannabis."" Journal of Cannabis Research 2, no. 1 (2020): 1-10.",2020,NA,Observational,GeneralPopulation,Survey,US,Cannabis use at least once,20.9,18,61,Hallucinations (experiences yes/no),Can.HAL,psych_like,Binary,ARS,,Adverse experiences while high,17.00%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,laFrance2020arc_hallucinationDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
491,Naef,Naef,"Naef, Myrtha, Michele Curatolo, Steen Petersen-Felix, Lars Arendt-Nielsen, Alex Zbinden, and Rudolf Brenneisen. ""The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions."" Pain 105, no. 1-2 (2003): 79-88.",2003,NA,Experiment,GeneralPopulation,"randomized, placebo-controlled, double-blinded, crossover study",Switzerland,Cannabis naïve,26,NA,NA,"Hallucinations (yes/no, based on VAS item)",THC.HAL,psych_like,Binary,VAS,,,50%,Single dose oral (0mg vs 20mg THC),Single dose oral (20mg THC),NA,20mg,20 mg THC dronabinol soft gelatine capsules,4,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,extract_naef2003analgesic_THC_hallucinations,pEstimate_naef2003analgesic_THC_hallucinations,cohen,,Yes,Yes
492,Naef,Naef,"Naef, Myrtha, Michele Curatolo, Steen Petersen-Felix, Lars Arendt-Nielsen, Alex Zbinden, and Rudolf Brenneisen. ""The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions."" Pain 105, no. 1-2 (2003): 79-88.",2003,,Experiment,GeneralPopulation,"randomized, placebo-controlled, double-blinded, crossover study",Switzerland,Cannabis naïve,26,NA,NA,"Hallucinations (yes/no, based on VAS item)",THC.HAL,psych_like,Binary,VAS,,,50%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,naef2003analgesic_THC_hallucinationsDF,NA,rates,naef2003analgesic_THC_hallucinationsControl,Yes,Yes
493,Naef,Naef,"Naef, Myrtha, Michele Curatolo, Steen Petersen-Felix, Lars Arendt-Nielsen, Alex Zbinden, and Rudolf Brenneisen. ""The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions."" Pain 105, no. 1-2 (2003): 79-88.",2003,NA,Experiment,GeneralPopulation,"randomized, placebo-controlled, double-blinded, crossover study",Switzerland,Cannabis naïve,26,NA,NA,"Hallucinations (yes/no, based on VAS item)",THC.HAL,psych_like,Continous,VAS score (Hallucinations),,,NA,THC combined with morphine vs THC alone,Opioidergic function,NA,20mg,20 mg THC dronabinol soft gelatine capsules,4,oral,NA,NA,no,Opioidergic function,Neurotransmission,yes,mean,dependent,extract_naef2003analgesic_THC_morphine_hallucinations,pEstimate_naef2003analgesic_THC_morphine_hallucinations,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
495,Zeiger,Zeiger,"Zeiger, Joanna S., William S. Silvers, Tonya A. Winders, Mary K. Hart, and Robert S. Zeiger. ""Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network."" Annals of Allergy, Asthma & Immunology 126, no. 4 (2021): 401-410.",2021,2020,Observational,GeneralPopulation,Survey,US,Ever cannabis use,NA,NA,NA,Paranoia,Can.PAR,AE,Binary (Paranoia yes/no),Questionnaire assessing adverse and Beneficial Effects of Cannabis,,NA,26.50%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,zeiger2021_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
497,Sholler,MEGA_Vandrey_Schlienz_Spindle,"Sholler, D.J., Strickland, J.C., Spindle, T.R., Weerts, E.M. and Vandrey, R., 2020. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addiction biology, p.e12968.",2020,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled ",US,used cannabis infrequently (no use ≥30 days prior to randomization),27,18,45,Paranoia,THC.PAR,psych_like,Continous,DEQ,,NA,NA,Dose response oral (0mg/10mg/25mf/ 50mg THC),Dose response oral (0mg/10mg/25mf/ 50mg THC),NA,NA,NA,NA,NA,NA,NA,no,DoseResponseTHC,CannabisDynamics,yes,meanComparison(change),dependent,extract_shollerMEGA_THC_doseresponse,pEstimate_shollerMEGA_THC_doseresponse,cohen,,Yes,Yes
498,Sholler,MEGA_Vandrey_Schlienz_Spindle,"Sholler, D.J., Strickland, J.C., Spindle, T.R., Weerts, E.M. and Vandrey, R., 2020. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addiction biology, p.e12968.",2020,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled ",US,used cannabis infrequently (no use ≥30 days prior to randomization),27,18,45,Paranoia,THC.PAR,psych_like,Continous,DEQ,,NA,NA,Route (0:oral; 1:vaporized),Route (vaporized),NA,NA,NA,NA,NA,NA,NA,no,Route (vaporized),CannabisDynamics,yes,meanComparison(change),dependent,extract_shollerMEGA_THC_route,pEstimate_shollerMEGA_THC_route,cohen,,Yes,Yes
499,Sholler,MEGA_Vandrey_Schlienz_Spindle,"Sholler, D.J., Strickland, J.C., Spindle, T.R., Weerts, E.M. and Vandrey, R., 2020. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addiction biology, p.e12968.",2020,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled ",US,used cannabis infrequently (no use ≥30 days prior to randomization),27,18,45,Paranoia,THC.PAR,psych_like,Continous,DEQ,,NA,NA,Gender,Gender,NA,NA,NA,NA,NA,NA,NA,yes,Gender,Demographic,yes,meanComparison(change),dependent,extract_shollerMEGA_THC_sex,pEstimate_shollerMEGA_THC_sex,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
501,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, David J. Lythgoe, Steve CR Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol."" Psychological Medicine 52, no. 11 (2022): 2024-2031.",2019,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover design",UK,Previous cannabis use but no use in the last 6 months,24.44,NA,NA,Psychosis-like,THC.PLE,psych_like,Continuous,PANSS (positive),,NA,69,THC-induced change in myo-inositol levels,THC-induced change in myo-inositol levels,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison(change),independent,extract_colizzi2020_THCmyoinositol,pEstimate_colizzi2020_THCmyoinositol,cohen,,Yes,Yes
502,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, David J. Lythgoe, Steve CR Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol."" Psychological Medicine 52, no. 11 (2022): 2024-2031.",2019,NA,Experiment,GeneralPopulation,"double-blind, randomized, placebo-controlled, crossover design",UK,Previous cannabis use but no use in the last 6 months,24.44,NA,NA,Psychosis-like,THC.PLE,psych_like,Continuous,PANSS (positive),,NA,69,THC-induced change in cortisol levels,THC-induced change in cortisol levels,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison(change),independent,extract_colizzi2020_THCcortisol,pEstimate_colizzi2020_THCcortisol,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
504,Mathews,Mathews,"Mathews, Eva M., Emily Jeffries, Chenen Hsieh, Glenn Jones, and Julia D. Buckner. ""Synthetic cannabinoid use among college students."" Addictive behaviors 93 (2019): 219-224.",2019,NA,Observational,GeneralPopulation,Survey,US,Users of synthetic cannabis,20,NA,NA,Paranoia,Can.PAR,AE,Binary,NA,,"Participants were asked about the effects they experienced when using synthetic cannabinoids (e.g., anxiety, time distortion).",63,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,mathews2019synthetic_paranoiaDF,NA,rates,,Yes,Yes
505,Mathews,Mathews,"Mathews, Eva M., Emily Jeffries, Chenen Hsieh, Glenn Jones, and Julia D. Buckner. ""Synthetic cannabinoid use among college students."" Addictive behaviors 93 (2019): 219-224.",2019,NA,Observational,GeneralPopulation,Survey,US,Users of synthetic cannabis,20,NA,NA,Hallucination,Can.HAL,AE,Binary,NA,,"Participants were asked about the effects they experienced when using synthetic cannabinoids (e.g., anxiety, time distortion).",32,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,mathews2019synthetic_hallucinationDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
507,Gilman,Gilman,"Gilman, Jodi M., Meryem A. Yücel, Gladys N. Pachas, Kevin Potter, Nina Levar, Hannah Broos, Eve M. Manghis, Randi M. Schuster, and A. Eden Evins. ""Delta-9-tetrahydrocannabinol intoxication is associated with increased prefrontal activation as assessed with functional near-infrared spectroscopy: A report of a potential biomarker of intoxication."" Neuroimage 197 (2019): 575-585.",2019,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, cross-over study ",US,reported at least weekly cannabis use,26,18,55,Paranoia,THC.PAR,AE,Binary,Adverse effects related to THC administration,,NA,4,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,gilman2019_dronabinol_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
509,Li,ReleafApp,"Li, Xiaoxue, Jacob M. Vigil, Sarah S. Stith, Franco Brockelman, Keenan Keeling, and Branden Hall. ""The effectiveness of self-directed medical cannabis treatment for pain."" Complementary therapies in medicine 46 (2019): 123-130.",2019,2016-2018,MedicalSample,Pain,Survey,US,NA,NA,NA,NA,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events,2,Medical cannabis,Pain,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,li2019_ReleafApp_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
511,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Hippocampal activation,Hippocampal activation,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,bhattacharyya2018_THCsens_hippoActivation,pEstimate_bhattacharyya2018_THCsens_hippoActivation,cohen,,Yes,Yes
512,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Age (younger),Age ,NA,NA,NA,NA,NA,NA,NA,no,Age,Demographic,yes,meanComparison,independent,bhattacharyya2018_THCsens_age,pEstimate_bhattacharyya2018_THCsens_age,cohen,,Yes,Yes
513,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Intellectual functioning (poorer performance),Intellectual functioning,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,meanComparison,independent,bhattacharyya2018_THCsens_IF,pEstimate_bhattacharyya2018_THCsens_IF,cohen,,Yes,Yes
514,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Years in education (more years),Years in education (more years),NA,NA,NA,NA,NA,NA,NA,no,Education,Demographic,yes,meanComparison,independent,bhattacharyya2018_THCsens_education,pEstimate_bhattacharyya2018_THCsens_education,cohen,,Yes,Yes
515,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,CigaretteUse,Cigarette use,NA,NA,NA,NA,NA,NA,NA,no,Nicotine,OtherDrugs,yes,meanComparison,independent,bhattacharyya2018_THCsens_cigarettes,pEstimate_bhattacharyya2018_THCsens_cigarettes,cohen,,Yes,Yes
516,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Previous cannabis use,Previous cannabis use,NA,NA,NA,NA,NA,NA,NA,no,Tolerance,CannabisDynamics,yes,meanComparison,independent,bhattacharyya2018_THCsens_cannabis,pEstimate_bhattacharyya2018_THCsens_cannabis,cohen,,Yes,Yes
517,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Caffeine use,Caffeine use,NA,NA,NA,NA,NA,NA,NA,no,Caffeine,OtherDrugs,yes,meanComparison,independent,bhattacharyya2018_THCsens_caffeine,pEstimate_bhattacharyya2018_THCsens_caffeine,cohen,,Yes,Yes
518,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Alcohol use,Alcohol use,NA,NA,NA,NA,NA,NA,NA,yes,Alcohol,OtherDrugs,yes,chi-square,independent,extract_bhattacharyya2018_THCsens_alc,pEstimate_bhattacharyya2018_THCsens_alc,cohen,,Yes,Yes
519,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Amphetamine use,Amphetamine use,NA,NA,NA,NA,NA,NA,NA,no,Stimulants,OtherDrugs,yes,chi-square,independent,extract_bhattacharyya2018_THCsens_amphetamine,pEstimate_bhattacharyya2018_THCsens_amphetamine,cohen,,Yes,Yes
520,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,LSD use,LSD use,NA,NA,NA,NA,NA,NA,NA,yes,Hallucinogens,OtherDrugs,yes,chi-square,independent,extract_bhattacharyya2018_THCsens_LSD,pEstimate_bhattacharyya2018_THCsens_LSD,cohen,,Yes,Yes
521,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Cocaine use,Cocaine use,NA,NA,NA,NA,NA,NA,NA,yes,Cocaine,OtherDrugs,yes,chi-square,independent,extract_bhattacharyya2018_THCsens_cocaine,pEstimate_bhattacharyya2018_THCsens_cocaine,cohen,,Yes,Yes
522,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,MDMA use,MDMA use,NA,NA,NA,NA,NA,NA,NA,yes,MDMA,OtherDrugs,yes,chi-square,independent,extract_bhattacharyya2018_THCsens_mdma,pEstimate_bhattacharyya2018_THCsens_mdma,cohen,,Yes,Yes
523,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Binary,PANSS (>3 on PANSS-positive),PANSS,NA,40,Opiate use,Opiate use,NA,NA,NA,NA,NA,NA,NA,no,Opioid,OtherDrugs,yes,chi-square,independent,extract_bhattacharyya2018_THCsens_opioid,pEstimate_bhattacharyya2018_THCsens_opioid,cohen,,Yes,Yes
524,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,psych_like,Binart,PANSS (>3 on PANSS-positive),PANSS,NA,40,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,bhattacharyya2018_THCsens_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
526,Abdallah,Abdallah,"Abdallah, Sara J., Benjamin M. Smith, Mark A. Ware, Michelle Moore, Pei Zhi Li, Jean Bourbeau, and Dennis Jensen. ""Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease. A randomized controlled trial."" Annals of the American Thoracic Society 15, no. 10 (2018): 1146-1158.",2018,,MedicalTrial,COPD,randomized controlled trial,Canada,NA,65,47,77,Paranoia,Med.PAR,NA,Continuous,VAS,,NA,NA,Medical cannabis,COPD,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,meanComparison,independent,abdallah2018_COPD_paranoiaChange,pEstimate_abdallah2018_COPD_paranoiaChange,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
528,Bloomfield,Morgan_Curran_MRC,"Bloomfield, M. A. P., E. Mouchlianitis, C. J. A. Morgan, T. P. Freeman, H. V. Curran, J. P. Roiser, and O. D. Howes. ""Salience attribution and its relationship to cannabis-induced psychotic symptoms."" Psychological medicine 46, no. 16 (2016): 3383-3395.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperimental,UK,PastMonthCannabisUser,22.4,18,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Aberrant salience (explicit),Aberrant salience (explicit),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,"res(bloomberg_explicitSalience_psych_r, n=bloomberg_salience_can_user, dig=20)",pEstimate_bloomberg_explicitSalience_psych,cohen,,Yes,Yes
529,Bloomfield,Morgan_Curran_MRC,"Bloomfield, M. A. P., E. Mouchlianitis, C. J. A. Morgan, T. P. Freeman, H. V. Curran, J. P. Roiser, and O. D. Howes. ""Salience attribution and its relationship to cannabis-induced psychotic symptoms."" Psychological medicine 46, no. 16 (2016): 3383-3395.",2016,NA,QuasiExperimental,GeneralPopulation,QuasiExperimental,UK,PastMonthCannabisUser,22.4,18,NA,Psychosis-like,THC.PLE,NA,Continuous,PSI (total),,NA,NA,Aberrant salience (implicit),Aberrant salience (implicit),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,"pes(pValueNS_allStudies, bloomberg_salience_can_user/2, bloomberg_salience_can_user/2, dig=20)",pEstimate_bloomberg_implicitSalience_psych,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
531,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Z. Atakan, R. Martin-Santos, J. A. Crippa, J. Kambeitz, S. Malhi, V. Giampietro et al. ""Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis."" European Neuropsychopharmacology 25, no. 1 (2015): 26-37.",2015,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose oral (0mg vs 10mg THC),Single dose oral (10mg THC),NA,10mg,NA,2,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison(change),dependent,extract_bhattacharyya2015_10mgTHC_PANSS_pos,pEstimate_bhattacharyya2015_10mgTHC_PANSS_pos,cohen,,Yes,Yes
532,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Z. Atakan, R. Martin-Santos, J. A. Crippa, J. Kambeitz, S. Malhi, V. Giampietro et al. ""Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis."" European Neuropsychopharmacology 25, no. 1 (2015): 26-37.",2015,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Inhibitory processing,Inhibitory processing,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,bhattacharyya2015_10mgTHC_inhibit_processing,pEstimate_bhattacharyya2015_10mgTHC_inhibit_processing,cohen,,Yes,Yes
533,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Z. Atakan, R. Martin-Santos, J. A. Crippa, J. Kambeitz, S. Malhi, V. Giampietro et al. ""Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis."" European Neuropsychopharmacology 25, no. 1 (2015): 26-37.",2015,2012,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,25.97,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,THC-induced inhibitory impairment,THC-induced inhibitory impairment,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,bhattacharyya2015_10mgTHC_frontal_activation,pEstimate_bhattacharyya2015_10mgTHC_frontal_activation,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
535,Cortes-Briones,DSouza_2,"Cortes-Briones, Jose A., John D. Cahill, Patrick D. Skosnik, Daniel H. Mathalon, Ashley Williams, R. Andrew Sewell, Brian J. Roach, Judith M. Ford, Mohini Ranganathan, and Deepak Cyril D’Souza. ""The psychosis-like effects of Δ9-tetrahydrocannabinol are associated with increased cortical noise in healthy humans."" Biological psychiatry 78, no. 11 (2015): 805-813.",2015,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,26.21,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose IV (0mg vs 0.015 mg/kg THC),Single dose IV (0.015 mg/kg THC),NA,0.015 mg/kg THC,average weight = 81 => 0.015*81 = 1.2147; 1.2147/5 = ,0.243,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_cortes_singledose_THC15mg,pEstimate_cortes_singledose_THC15mg,cohen,,Yes,Yes
536,Cortes-Briones,DSouza_2,"Cortes-Briones, Jose A., John D. Cahill, Patrick D. Skosnik, Daniel H. Mathalon, Ashley Williams, R. Andrew Sewell, Brian J. Roach, Judith M. Ford, Mohini Ranganathan, and Deepak Cyril D’Souza. ""The psychosis-like effects of Δ9-tetrahydrocannabinol are associated with increased cortical noise in healthy humans."" Biological psychiatry 78, no. 11 (2015): 805-813.",2015,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,26.21,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Single dose IV (0mg vs 0.015 mg/kg THC),Single dose IV (0.015 mg/kg THC),NA,0.03 mg/kg THC,average weight = 81 => (0.03*81)/5 = 0.486,0.486,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,meanComparison,dependent,extract_cortes_singledose_THC30mg,pEstimate_cortes_singledose_THC30mg,cohen,,Yes,Yes
537,Cortes-Briones,DSouza_2,"Cortes-Briones, Jose A., John D. Cahill, Patrick D. Skosnik, Daniel H. Mathalon, Ashley Williams, R. Andrew Sewell, Brian J. Roach, Judith M. Ford, Mohini Ranganathan, and Deepak Cyril D’Souza. ""The psychosis-like effects of Δ9-tetrahydrocannabinol are associated with increased cortical noise in healthy humans."" Biological psychiatry 78, no. 11 (2015): 805-813.",2015,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,26.21,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Neural noise (Lempel-Ziv Complexity),Neural noise,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,,correlation,independent,extract_cortes_neuralNoise,pEstimate_extract_cortes_neuralNoise,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
539,D'Souza,DSouza_2,"D'Souza, Deepak Cyril, Daniel J. Fridberg, Patrick D. Skosnik, Ashley Williams, Brian Roach, Nagendra Singh, Michelle Carbuto et al. ""Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ 9-THC in humans."" Neuropsychopharmacology 37, no. 7 (2012): 1632-1646.",2012,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,25.9,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,P3b amplitude,P3b amplitude,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,extract_dsouza_eeg2012_P3bamplitude,pEstimate_dsouza_eeg2012,cohen,,Yes,Yes
540,D'Souza,DSouza_2,"D'Souza, Deepak Cyril, Daniel J. Fridberg, Patrick D. Skosnik, Ashley Williams, Brian Roach, Nagendra Singh, Michelle Carbuto et al. ""Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ 9-THC in humans."" Neuropsychopharmacology 37, no. 7 (2012): 1632-1646.",2012,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,25.9,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,P3a amplitude,P3b amplitude,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,extract_dsouza_eeg2012_P3aamplitude,pEstimate_dsouza_eeg2012,cohen,,Yes,Yes
541,D'Souza,DSouza_2,"D'Souza, Deepak Cyril, Daniel J. Fridberg, Patrick D. Skosnik, Ashley Williams, Brian Roach, Nagendra Singh, Michelle Carbuto et al. ""Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ 9-THC in humans."" Neuropsychopharmacology 37, no. 7 (2012): 1632-1646.",2012,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,25.9,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,P3b latency,P3b latency,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,extract_dsouza_eeg2012_P3alatency,pEstimate_dsouza_eeg2012,cohen,,Yes,Yes
542,D'Souza,DSouza_2,"D'Souza, Deepak Cyril, Daniel J. Fridberg, Patrick D. Skosnik, Ashley Williams, Brian Roach, Nagendra Singh, Michelle Carbuto et al. ""Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ 9-THC in humans."" Neuropsychopharmacology 37, no. 7 (2012): 1632-1646.",2012,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, rando- mized",US,Previous cannabis use,25.9,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,P3a latency,P3a latency,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,extract_dsouza_eeg2012_P3blatency,pEstimate_dsouza_eeg2012,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
544,Flachenecker,Flachenecker,"Flachenecker, Peter, Thomas Henze, and Uwe K. Zettl. ""Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice."" European neurology 72, no. 1-2 (2014): 95-102.",2014,NA,MedicalSample,MS,Survey,US,NA,NA,NA,NA,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events,1%,Medical cannabis,MS,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,flachenecker2014_medCan_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
546,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, cross-over design",Netherlands,NA,22,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,NA,,NA,NA,Novelty seeking,Novelty seeking,NA,NA,NA,NA,NA,NA,NA,no,Personality,MentalHealthPersonality,yes,p-value,independent,extract_kleinloog2014THC_noveltyseeking,pEstimate_kleinloog2014THC_noveltyseeking,cohen,,Yes,Yes
547,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, cross-over design",Netherlands,NA,22,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,NA,,NA,NA,Harm avoidance,Harm avoidance,NA,NA,NA,NA,NA,NA,NA,no,Personality,MentalHealthPersonality,yes,p-value,independent,extract_kleinloog2014THC_harmavoidance,pEstimate_kleinloog2014THC_harmavoidance,cohen,,Yes,Yes
548,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, cross-over design",Netherlands,NA,22,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,NA,,NA,NA,Reward dependence,Reward dependence,NA,NA,NA,NA,NA,NA,NA,no,Personality,MentalHealthPersonality,yes,p-value,independent,extract_kleinloog2014THC_rewarddependence,pEstimate_kleinloog2014THC_rewarddependence,cohen,,Yes,Yes
549,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, cross-over design",Netherlands,NA,22,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,NA,,NA,NA,Persistence,Persistence,NA,NA,NA,NA,NA,NA,NA,no,Personality,MentalHealthPersonality,yes,p-value,independent,extract_kleinloog2014THC_persistence,pEstimate_kleinloog2014THC_persistence,cohen,,Yes,Yes
550,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, cross-over design",Netherlands,NA,22,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,NA,,NA,NA,Self-directedness,Self-directedness,NA,NA,NA,NA,NA,NA,NA,no,Personality,MentalHealthPersonality,yes,p-value,independent,extract_kleinloog2014THC_selfdirectedness,pEstimate_kleinloog2014THC_selfdirectedness,cohen,,Yes,Yes
551,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, cross-over design",Netherlands,NA,22,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,NA,,NA,NA,Cooperativeness,Cooperativeness,NA,NA,NA,NA,NA,NA,NA,no,Personality,MentalHealthPersonality,yes,p-value,independent,extract_kleinloog2014THC_cooperativeness,pEstimate_kleinloog2014THC_cooperativeness,cohen,,Yes,Yes
552,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, cross-over design",Netherlands,NA,22,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,NA,,NA,NA,Self-transcendence,Self-transcendence,NA,NA,NA,NA,NA,NA,NA,no,Personality,MentalHealthPersonality,yes,p-value,independent,extract_kleinloog2014THC_selftranscendence,pEstimate_kleinloog2014THC_selftranscendence,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
554,Cameron,Cameron,"Cameron, C., Watson, D., & Robinson, J. (2014). Use of a Synthetic Cannabinoid in a Correctional Population for Posttraumatic Stress Disorder–Related Insomnia and Nightmares, Chronic Pain, Harm Reduction, and Other Indications. Journal of Clinical Psychopharmacology, 34(5), 559–564.",2014,NA,MedicalSample,PTSD,Survey,Canada,NA,32.7,19,55,Psychosis,Med.PAR,AE,Binary,NA,,NA,NA,Medical cannabis (Nabilone),PTSD,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,cameron2014_medCanNabilone_psychosisDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
556,Ahmed,Ahmed,"Ahmed, Amir IA, Geke AH van den Elsen, Angela Colbers, Marjolein A. van der Marck, David M. Burger, Ton B. Feuth, Marcel GM Olde Rikkert, and Cornelis Kramers. ""Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial."" European Neuropsychopharmacology 24, no. 9 (2014): 1475-1482.",2014,NA,MedicalTrial,MedicalTrial,"Medical trial (randomized, double-blind, double-dummy, placebo-controlled, cross-over trial)",Netherlands,NA,72,65,NA,Hallucinations,Med.HAL,NA,Binary,Single item,, THC adverse events checklist,9%,Medical cannabis (Namisol),safety test in heathy,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,dependent,extract_ahmed2014namisol_hallucinations,pEstimate_ahmed2014namisol_hallucinations,cohen,,Yes,Yes
557,Ahmed,Ahmed,"Ahmed, Amir IA, Geke AH van den Elsen, Angela Colbers, Marjolein A. van der Marck, David M. Burger, Ton B. Feuth, Marcel GM Olde Rikkert, and Cornelis Kramers. ""Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial."" European Neuropsychopharmacology 24, no. 9 (2014): 1475-1482.",2014,NA,MedicalTrial,MedicalTrial,"Medical trial (randomized, double-blind, double-dummy, placebo-controlled, cross-over trial)",Netherlands,NA,72,65,NA,Hallucinations,Med.HAL,AE,Binary,Single item,, THC adverse events checklist,9%,Medical cannabis (Namisol),safety test in heathy,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,ahmed2014namisol_hallucinationsDF,NA,rates,ahmed2014namisol_hallucinationsControls,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
559,Fernandez,Fernandez,"Fernández, L. Lorente, E. Monte Boquet, F. Perez-Miralles, I. Gil Gomez, M. Escutia Roig, I. Bosca Blasco, JL Poveda Andrés, and B. Casanova-Estruch. ""Clinical experiences with cannabinoids in spasticity management in multiple sclerosis."" Neurología (English Edition) 29, no. 5 (2014): 257-260.",2014,2008-2012,MedicalSample,MS,Survey,Spain,47.8,25.6,76.8,NA,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events,NA,Medical cannabis (Sativex),MS,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,fernandezSativex_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
561,Portenoy,Portenoy,"Portenoy, R.K., Ganae-Motan, E.D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S. and Fallon, M.T., 2012. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. The Journal of Pain, 13(5), pp.438-449.",2012,NA,MedicalTrial,Cancer,"randomized, double- blind, placebo-controlled, parallel group, graded-dose design",US,58,NA,NA,NA,Hallucinations,Med.HAL,NA,Binary,Single item,,Adverse Events,3%,Medical cannabis (Nabiximols),Cancer,28 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_portenoyNabiximols_hallucinations,pvalportenoyNabiximols_HAL,cohen,,Yes,Yes
562,Portenoy,Portenoy,"Portenoy, R.K., Ganae-Motan, E.D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S. and Fallon, M.T., 2012. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. The Journal of Pain, 13(5), pp.438-449.",2012,NA,MedicalTrial,Cancer,"randomized, double- blind, placebo-controlled, parallel group, graded-dose design",US,58,NA,NA,NA,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events,3%,Medical cannabis (Nabiximols),Cancer,28 days,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,portenoyNabiximols_HALDF,NA,rates,portenoyNabiximols_HALControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
564,Morrison,Morrison_1.25mg,"Morrison, Paul D., Judith Nottage, James M. Stone, Sagnik Bhattacharyya, Nigel Tunstall, Rudolf Brenneisen, David Holt et al. ""Disruption of frontal theta coherence by Δ 9-tetrahydrocannabinol is associated with positive psychotic symptoms."" Neuropsychopharmacology 36, no. 4 (2011): 827-836.",2011,NA,Experiment,GeneralPopulation,"randomised, double-blind, within-participant, exper- imental design",UK,Used at least twice,26,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Theta power (EEG),Theta power (EEG),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,extract_morrison_theta_PLE,pEstimate_morrison_theta_PLE,cohen,,Yes,Yes
565,Morrison,Morrison_1.25mg,"Morrison, Paul D., Judith Nottage, James M. Stone, Sagnik Bhattacharyya, Nigel Tunstall, Rudolf Brenneisen, David Holt et al. ""Disruption of frontal theta coherence by Δ 9-tetrahydrocannabinol is associated with positive psychotic symptoms."" Neuropsychopharmacology 36, no. 4 (2011): 827-836.",2011,NA,Experiment,GeneralPopulation,"randomised, double-blind, within-participant, exper- imental design",UK,Used at least twice,26,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,Theta coherence (EEG),Theta coherence (EEG),NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,extract_morrison_theta_coherence_PLE,pEstimate_morrison_theta_coherence_PLE,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
567,Ware,Ware_RCT,"Ware, Mark A., Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, Ann Gamsa, Gary J. Bennett, and Jean-Paul Collet. ""Smoked cannabis for chronic neuropathic pain: a randomized controlled trial."" Cmaj 182, no. 14 (2010): E694-E701.",2010,NA,MedicalTrial,Pain,randomized controlled crossover trial,Canada,NA,45.4,NA,NA,Paranoia,Med.PAR,NA,Binary,Single item,, THC adverse events checklist,5%,Medical cannabis (Namisol),Pain,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,dependent,extract_ware2010RCT_paranoia,pEstimate_ware2010RCT_paranoia,cohen,,Yes,Yes
568,Ware,Ware_RCT,"Ware, Mark A., Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, Ann Gamsa, Gary J. Bennett, and Jean-Paul Collet. ""Smoked cannabis for chronic neuropathic pain: a randomized controlled trial."" Cmaj 182, no. 14 (2010): E694-E701.",2010,NA,MedicalTrial,Pain,randomized controlled crossover trial,Canada,NA,45.4,NA,NA,Paranoia,Med.PAR,AE,Binary,Single item,, THC adverse events checklist,5%,Medical cannabis,Pain,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (rate),rates,yes,rate,NA,ware2010RCT_paranoiaDF,NA,rates,ware2010RCT_paranoiaControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
570,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Paul D. Morrison, Paolo Fusar-Poli, Rocio Martin-Santos, Stefan Borgwardt, Toby Winton-Brown, Chiara Nosarti et al. ""Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology."" Neuropsychopharmacology 35, no. 3 (2010): 764-774.",2010,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,26,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,THC-induced changes in striatum,THC-induced changes in striatum,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,bhattacharyya2010_10mgTHC_striatum,pEstimate_bhattacharyya2010_10mgTHC_striatum,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
572,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Paolo Fusar-Poli, Stefan Borgwardt, Rocio Martin-Santos, Chiara Nosarti, Colin O’Carroll, Paul Allen et al. ""Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis."" Archives of general psychiatry 66, no. 4 (2009): 442-451.",2009,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,26,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,THC-induced changes in ventral stiatum,THC-induced changes in ventral stiatum,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,bhattacharyya2009_10mgTHC_fmri_ventral_striatum,pEstimate_bhattacharyya2009_10mgTHC_fmri_ventral_striatum,cohen,,Yes,Yes
573,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Paolo Fusar-Poli, Stefan Borgwardt, Rocio Martin-Santos, Chiara Nosarti, Colin O’Carroll, Paul Allen et al. ""Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis."" Archives of general psychiatry 66, no. 4 (2009): 442-451.",2009,NA,Experiment,GeneralPopulation,"randomised, double-blind crossover design",UK,Previous cannabis use but not more than 25 times/lifetime,26,NA,NA,Psychosis-like,THC.PLE,NA,Continuous,PANSS (positive),PANSS,NA,NA,THC-induced changes in rostro-anterior cingulate cortex,THC-induced changes in rostro-anterior cingulate cortex,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,correlation,independent,bhattacharyya2009_10mgTHC_fmri_cingulate_cortex,pEstimate_bhattacharyya2009_10mgTHC_fmri_cingulate_cortex,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
575,Cooper,Cooper,"Cooper, Ziva D., and Margaret Haney. ""Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts."" Drug and alcohol dependence 103, no. 3 (2009): 107-113.",2009,NA,Experiment,GeneralPopulation,"randomised, within-participant, experimental design",US,smoke marijuana blunts at least twice a week,25.5,NA,NA,Paranoia,THC.PAR,AE,Binary,NA,, THC adverse event,4%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,cooper2005joints_ParanoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
577,Abrams,Abrams2,"Abrams, Donald I., C. A. Jay, S. B. Shade, H. Vizoso, H. Reda, S. Press, M. E. Kelly, M. C. Rowbotham, and K. L. Petersen. ""Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial."" Neurology 68, no. 7 (2007): 515-521.",2007,NA,MedicalTrial,HIV,randomized placebo-controlled trial ,US,prior experience smoking cannabis (defined as six or more times in their lifetime),49,NA,NA,Paranoia,Med.PAR,NA,Binary,Single item,, THC adverse events checklist,NA,Medical cannabis (Namisol),HIV,5 days,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,meanComparison,independent,extract_abrams_HIVmedcan_paranoia,pEstimate_abrams_HIVmedcan_paranoia,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
579,Haney,Haney,"Haney, Margaret. ""Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers."" Neuropsychopharmacology 32, no. 6 (2007): 1391-1403.",2007,NA,Experiment,GeneralPopulation,randomized placebo-controlled trial ,US,no history of daily marijuana use,29.7,NA,NA,Paranoia,THC.PAR,NA,Binary,NA,, THC adverse event,0%,Administration Naltrexone (12mg),Opioid receptor function (Naltrexone),NA,NA,NA,NA,NA,NA,NA,yes,Opioidergic function,Neurotransmission,yes,chi-square,dependent,extract_haney2007THCopioid_10mgTHC_naltrexone,pEstimate_haney2007THCopioid_paranoia,cohen,,Yes,Yes
580,Haney,Haney,"Haney, Margaret. ""Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers."" Neuropsychopharmacology 32, no. 6 (2007): 1391-1403.",2007,NA,Experiment,GeneralPopulation,randomized placebo-controlled trial ,US,no history of daily marijuana use,29.7,NA,NA,Paranoia,THC.PAR,NA,Binary,NA,, THC adverse event,0%,Single dose inhaled (0mg vs 2.5mg THC),Single dose inhaled (2.5mg THC),NA,2.5mg,capsule,0.5,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,extract_haney2007THCopioid_2.5mgTHC,pEstimate_haney2007THCopioid_paranoia,cohen,,No,No
581,Haney,Haney,"Haney, Margaret. ""Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers."" Neuropsychopharmacology 32, no. 6 (2007): 1391-1403.",2007,NA,Experiment,GeneralPopulation,randomized placebo-controlled trial ,US,no history of daily marijuana use,29.7,NA,NA,Paranoia,THC.PAR,NA,Binary,NA,, THC adverse event,0%,Single dose inhaled (0mg vs 5mg THC),Single dose inhaled (5mg THC),NA,5mg,capsule,1,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,extract_haney2007THCopioid_5mgTHC,pEstimate_haney2007THCopioid_paranoia,cohen,,Yes,Yes
582,Haney,Haney,"Haney, Margaret. ""Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers."" Neuropsychopharmacology 32, no. 6 (2007): 1391-1403.",2007,NA,Experiment,GeneralPopulation,randomized placebo-controlled trial ,US,no history of daily marijuana use,29.7,NA,NA,Paranoia,THC.PAR,NA,Binary,NA,, THC adverse event,0%,Single dose inhaled (0mg vs 10mg THC),Single dose inhaled (10mg THC),NA,10mg,capsule,2,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,chi-square,dependent,extract_haney2007THCopioid_10mgTHC_naltrexone,pEstimate_haney2007THCopioid_paranoia,cohen,,No,No
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
584,Brady,Brady,"Brady, C. M., R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, and C. J. Fowler. ""An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis."" Multiple Sclerosis Journal 10, no. 4 (2004): 425-433.",2004,NA,MedicalTrial,MS,uncontrolled,UK,NA,48,31,64,Hallucinations,Med.HAL,AE,Binary,NA,,Adverse Events,14%,Medical cannabis,MS,300 days,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,brady2004MedCanMS_HallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
586,Menetrey,GiroudDronabinol,"Ménétrey, Annick, Marc Augsburger, Bernard Favrat, Marie A. Pin, Laura E. Rothuizen, Monique Appenzeller, Thierry Buclin, Patrice Mangin, and Christian Giroud. ""Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Δ9-THC."" Journal of analytical toxicology 29, no. 5 (2005): 327-338.",2005,NA,Experiment,GeneralPopulation,double-blind crossover design,Switzerland,Regular cannabis use,26.4,22,30,Paranoia,THC.PAR,AE,Binary,Adverse reaction (paranoia),,NA,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,menetrey2005oralTHC_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
588,Beaulieu,Beaulieu,"Beaulieu, Pierre. ""Effects of nabilone, a synthetic cannabinoid, on postoperative pain."" Canadian Journal of Anesthesia 53, no. 8 (2006): 769-775.",2006,NA,MedicalTrial,Pain,"double-blind, randomized, placebo-controlled, parallel-group pilot trial",Canada,NA,52,NA,NA,Psychosis,Med.PLE,full_episode,Binary,Adverse reaction (psychosis),,NA,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,beaulieu2006medPain_psychosisDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
590,Holdcroft,Holdcroft,"Holdcroft, Anita, Mervyn Maze, Caroline Dore, Susan Tebbs, and Simon Thompson. ""A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management."" The Journal of the American Society of Anesthesiologists 104, no. 5 (2006): 1040-1046.",2006,NA,MedicalTrial,Pain,uncontrolled,UK,NA,53,NA,NA,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse events checklist,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,holdcroft2006medPain_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
592,Buggy,Buggy,"Buggy, Donal J., Lynn Toogood, Shelagh Maric, Paul Sharpe, David G. Lambert, and David J. Rowbotham. ""Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain."" Pain 106, no. 1-2 (2003): 169-172.",2003,NA,MedicalTrial,Pain,"randomized double-blind, placebo-controlled, single-dose trial",UK,NA,45,NA,NA,Hallucination,Med.HAL,AE,Binary,Single item,,Adverse events checklist,0%,Medical cannabis (Namisol),Pain,NA,NA,NA,NA,NA,NA,NA,yes,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_Buggy200_HAL,pvalBuggy200_HAL,cohen,,Yes,Yes
593,Buggy,Buggy,"Buggy, Donal J., Lynn Toogood, Shelagh Maric, Paul Sharpe, David G. Lambert, and David J. Rowbotham. ""Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain."" Pain 106, no. 1-2 (2003): 169-172.",2003,NA,MedicalTrial,Pain,"randomized double-blind, placebo-controlled, single-dose trial",UK,NA,45,NA,NA,Hallucination,Med.HAL,AE,Binary,Single item,,Adverse events checklist,0%,Medical cannabis (Namisol),Pain,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rates,NA,buggy200_HAL_DF,NA,rates,buggy200_HAL_Control,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
595,Niederle,Niederle,"Niederle, N., J. Schütte, and C. G. Schmidt. ""Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy."" Klinische Wochenschrift 64, no. 8 (1986): 362-365.",1986,1982-1984,MedicalTrial,Cancer,uncontrolled,Germany,NA,25,19,45,Hallucination,Med.HAL,AE,Binary,Single item,,Adverse events,5%,Nabilone (4mg daily) ,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,niederleNabilone1986_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
597,Pomeroy,Pomeroy,"Pomeroy, Mauve, James J. Fennelly, and Mark Towers. ""Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis."" Cancer chemotherapy and pharmacology 17, no. 3 (1986): 285-288.",1986,NA,MedicalTrial,Cancer,uncontrolled,Ireland,NA,42,21,66,Hallucination,Med.HAL,AE,Binary,Single item,,Adverse events,0%,Nabilone,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,pomeroyNabilone1986_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
599,Niiranen,Niiranen,"Niiranen, Aila, and Karin Mattson. ""A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy."" American journal of clinical oncology 8, no. 4 (1985): 336-340.",1985,NA,MedicalTrial,Cancer,uncontrolled,Finnland,NA,61,48,78,Hallucination,Med.HAL,AE,Binary,Single item,,Adverse events,11%,Nabilone (2mg daily),rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,niiranenNabilone1985_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
601,Ahmedzai,Ahmedzai,"Ahmedzai, S., D. L. Carlyle, I. T. Calder, and F. Moran. ""Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy."" British Journal of Cancer 48, no. 5 (1983): 657-663.",1983,NA,MedicalTrial,Cancer,uncontrolled,UK,NA,58,NA,NA,Hallucination,Med.HAL,AE,Binary,Single item,,Adverse events,0%,Nabilone,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,ahmedzaiNabilone1983_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
603,Sweet,Sweet,"Sweet, Donald L., Nancy J. Miller, William Wellington, Edward Senay, and Lisa Sushelsky. ""Δ9‐tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study."" The Journal of Clinical Pharmacology 21, no. S1 (1981): 70S-75S.",1981,NA,MedicalTrial,Cancer,uncontrolled,US,NA,51.5,22,67,Hallucination,Med.HAL,AE,Binary,Single item,,Adverse events,4%,THC (oral dose 5mg/m2),rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,sheetTHC1981_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
605,Noyes,Noyes,"Noyes, Russell, S. Fred Brunk, David H. Avery, and Arthur Canter. ""Psychologic effects of oral delta-9-tetrahydrocannabinol in advanced cancer patients."" Comprehensive psychiatry (1976).",1976,NA,MedicalTrial,Cancer,"placebo-controlled, double-blind, cross-over",US,NA,51,NA,NA,Hallucination,Med.HAL,psych_like,Binary,Single item (visual hallucinations),,SDES (Subjective Drug Effects Questionnaire),14%,Medical cannabis (5mg THC),Cancer,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,dependent,extract_noyesCancerTHC_hallucinations,pEstimate_noyesCancerTHC_hallucinations,cohen,,Yes,Yes
606,Noyes,Noyes,"Noyes, Russell, S. Fred Brunk, David H. Avery, and Arthur Canter. ""Psychologic effects of oral delta-9-tetrahydrocannabinol in advanced cancer patients."" Comprehensive psychiatry (1976).",1976,NA,MedicalTrial,Cancer,"placebo-controlled, double-blind, cross-over",US,NA,51,NA,NA,Hallucination,Med.HAL,psych_like,Binary,Single item (visual hallucinations),,SDES (Subjective Drug Effects Questionnaire),14%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,noyesCancerTHC_hallucinationsDF,NA,rates,noyesCancerTHC_hallucinationsControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
608,Marcus,Marcus,"Marcus, Anthony M., Harry Klonoff, and Morton Low. ""Psychiatric status of the marihuana user."" Canadian Psychiatric Association Journal 19, no. 1 (1974): 31-39.",1974,1971-1972,Observational,GeneralPopulation,observational,Canada,Cannabis user,22.5,19,31,Hallucination,Can.HAL,AE,Binary,Single item,,Adverse Effects from marihuana and/or hashish: Hallucinations followed by anxiety,2%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,marcus1974_hallucinationsDF,NA,rates,,Yes,Yes
609,Marcus,Marcus,"Marcus, Anthony M., Harry Klonoff, and Morton Low. ""Psychiatric status of the marihuana user."" Canadian Psychiatric Association Journal 19, no. 1 (1974): 31-39.",1974,1971-1972,Observational,GeneralPopulation,observational,Canada,Cannabis user,22.5,19,31,Paranoia,Can.PAR,AE,Binary,Single item,,Adverse Effects from marihuana and/or hashish: Paranoid features,5%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,marcus1974_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
611,Kassim,Kassim,"Kassim, Faiz M., Sophie Tod, Jennifer Rodger, Sean D. Hood, Joseph WY Lee, Matthew A. Albrecht, and Mathew T. Martin-Iverson. ""Nabilone Impairs Spatial and Verbal Working Memory in Healthy Volunteers."" Cannabis and Cannabinoid Research (2022).",2022,NA,Experiment,GeneralPopulation,"randomized, double-blind, counter-balanced, crossover",Australia,Ever cannabis use,25.9,17,60,Psychosis-like,Can.PLE,psych_like,Continuous,Score,,"Sum of: Brief Psychiatric Rating Scale Scale for the Assessment of Positive Symptoms, Revised Launay-Slade Hallucinations Scale, Magical Ideation Scale, Perceptual Aberrations Scale.",,Single dose oral (0mg vs 1mg THC),Single dose oral (1mg THC),NA,1mg,NA,0.2,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,p-value,dependent,extract_kassimNabilone,pEstimate_kassimNabilone,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
613,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Gender,Gender,NA,NA,NA,NA,NA,NA,NA,yes,Gender,Demographic,yes,chi-square,independent,extract_Schoeler_gender,pEstimate_Schoeler_gender,cohen,,Yes,Yes
614,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Age,Age,NA,NA,NA,NA,NA,NA,NA,yes,Age,Demographic,yes,chi-square,independent,extract_Schoeler_age,pEstimate_Schoeler_age,cohen,,Yes,Yes
615,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Exercise,Exercise,NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,chi-square,independent,extract_Schoeler_exercise,pEstimate_Schoeler_exercise,cohen,,Yes,Yes
616,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Education (more),Education (more),NA,NA,NA,NA,NA,NA,NA,no,Education,Demographic,yes,chi-square,independent,extract_Schoeler_edu,pEstimate_Schoeler_edu,cohen,,Yes,Yes
617,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,BMI (underweight),Underweight,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,chi-square,independent,extract_Schoeler_underW,pEstimate_Schoeler_underW,cohen,,Yes,Yes
618,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,BMI (overweight),Overweight,NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,chi-square,independent,extract_Schoeler_overW,pEstimate_Schoeler_overW,cohen,,Yes,Yes
619,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Recreational use (vs. medical),Recreational use (vs. medical),NA,NA,NA,NA,NA,NA,NA,yes,Reason (medicinal vs. recreational),CannabisHistory,yes,chi-square,independent,extract_Schoeler_reason,pEstimate_Schoeler_reason,cohen,,Yes,Yes
620,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,CannabisType (high vs. low potency),Cannabis type (high potency),NA,NA,NA,NA,NA,NA,NA,yes,THCcontent,CannabisStrain,yes,chi-square,independent,extract_Schoeler_potency,pEstimate_Schoeler_potency,cohen,,Yes,Yes
621,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Frequency (heavy vs. light),Frequency (heavy),NA,NA,NA,NA,NA,NA,NA,yes,CannabisSeverity,CannabisHistory,yes,chi-square,independent,extract_Schoeler_frequency,pEstimate_Schoeler_frequency,cohen,,Yes,Yes
622,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Mix cannabis with tobacco,Mix cannabis with tobacco,NA,NA,NA,NA,NA,NA,NA,no,Nicotine,OtherDrugs,yes,chi-square,independent,extract_Schoeler_tobacco,pEstimate_Schoeler_tobacco,cohen,,Yes,Yes
623,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,ROA (eaten),ROA (eaten),NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,chi-square,independent,extract_Schoeler_eaten,pEstimate_Schoeler_eaten,cohen,,Yes,Yes
624,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,ROA (knife),ROA (knife),NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,chi-square,independent,extract_Schoeler_knife,pEstimate_Schoeler_knife,cohen,,Yes,Yes
625,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,ROA (pipe),ROA (pipe),NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,chi-square,independent,extract_Schoeler_pipe,pEstimate_Schoeler_pipe,cohen,,Yes,Yes
626,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,ROA (vape),ROA (vape),NA,NA,NA,NA,NA,NA,NA,yes,Other,Other,yes,chi-square,independent,extract_Schoeler_vape,pEstimate_Schoeler_vape,cohen,,Yes,Yes
627,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Alcohol use,Alcohol use,NA,NA,NA,NA,NA,NA,NA,yes,Alcohol,OtherDrugs,yes,chi-square,independent,extract_Schoeler_alc,pEstimate_Schoeler_alc,cohen,,Yes,Yes
628,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Cocaine use,Cocaine use,NA,NA,NA,NA,NA,NA,NA,yes,Cocaine,OtherDrugs,yes,chi-square,independent,extract_Schoeler_cocaine,pEstimate_Schoeler_cocaine,cohen,,Yes,Yes
629,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,MDMA use,MDMA use,NA,NA,NA,NA,NA,NA,NA,no,MDMA,OtherDrugs,yes,chi-square,independent,extract_Schoeler_mdma,pEstimate_Schoeler_mdma,cohen,,Yes,Yes
630,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Amphetamine use,Amphetamine use,NA,NA,NA,NA,NA,NA,NA,no,Stimulants,OtherDrugs,yes,chi-square,independent,extract_Schoeler_amphetamine,pEstimate_Schoeler_amphetamine,cohen,,Yes,Yes
631,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Methamphetamine use,Methamphetamine use,NA,NA,NA,NA,NA,NA,NA,no,Stimulants,OtherDrugs,yes,chi-square,independent,extract_Schoeler_methamphetamine,pEstimate_Schoeler_methamphetamine,cohen,,Yes,Yes
632,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Ketamine use,Ketamine use,NA,NA,NA,NA,NA,NA,NA,yes,Ketamine,OtherDrugs,yes,chi-square,independent,extract_Schoeler_ketamine,pEstimate_Schoeler_ketamine,cohen,,Yes,Yes
633,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,LSD use,LSD use,NA,NA,NA,NA,NA,NA,NA,yes,Hallucinogens,OtherDrugs,yes,chi-square,independent,extract_Schoeler_lsd,pEstimate_Schoeler_lsd,cohen,,Yes,Yes
634,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Diagnosis depression,Diagnosis depression,NA,NA,NA,NA,NA,NA,NA,no,Depression,MentalHealthPersonality,yes,chi-square,independent,extract_Schoeler_depression,pEstimate_Schoeler_depression,cohen,,Yes,Yes
635,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Diagnosis anxiety,Diagnosis anxiety,NA,NA,NA,NA,NA,NA,NA,no,Anxiety,MentalHealthPersonality,yes,chi-square,independent,extract_Schoeler_anxiety,pEstimate_Schoeler_anxiety,cohen,,Yes,Yes
636,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Diagnosis bipolar,Diagnosis bipolar,NA,NA,NA,NA,NA,NA,NA,no,Bipolar,MentalHealthPersonality,yes,chi-square,independent,extract_Schoeler_bipolar,pEstimate_Schoeler_bipolar,cohen,,Yes,Yes
637,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Diagnosis psychosis,Diagnosis psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_Schoeler_psychosis,pEstimate_Schoeler_psychosis,cohen,,Yes,Yes
638,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,1%,Diagnosis ADHD,Diagnosis ADHD,NA,NA,NA,NA,NA,NA,NA,no,ADHD,MentalHealthPersonality,yes,chi-square,independent,extract_Schoeler_adhd,pEstimate_Schoeler_adhd,cohen,,Yes,Yes
639,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PLE,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,independent,schoelerRatesEver_psychosisDF,NA,rates,,Yes,Yes
640,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.PAR,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,independent,schoelerRatesEver_paranoiaDF,NA,rates,,No,No
641,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,GeneralPopulation,observational,Wordwide,Cannabis used in the last year,NA,18,NA,Psychosis,Can.HAL,full_episode,Binary,Single item,,“Have you ever sought emergency medical treatment following your use of cannabis?”,NA,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,independent,schoelerRatesEver_hallucinationsDF,NA,rates,,No,No
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
643,Bassir,DSouza_2,"Bassir Nia, Anahita, Maria J. Orejarena, Leigh Flynn, Christina Luddy, Deepak Cyril D’Souza, Patrick D. Skosnik, Brian Pittman, and Mohini Ranganathan. ""Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC)."" Psychopharmacology 239, no. 5 (2022): 1621-1628.",2022,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, randomized",US,Previous cannabis use,26,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,psych_like,Continuous,PSI,,NA,NA,Gender,Gender,NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,F-statistic,independent,sexTHC_bassir2022,pEstimate_sexTHC_bassir2022,cohen,,no,already included in Ganesh mega analysis
644,Bassir,DSouza_2,"Bassir Nia, Anahita, Maria J. Orejarena, Leigh Flynn, Christina Luddy, Deepak Cyril D’Souza, Patrick D. Skosnik, Brian Pittman, and Mohini Ranganathan. ""Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC)."" Psychopharmacology 239, no. 5 (2022): 1621-1628.",2022,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, randomized",US,Previous cannabis use,26,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,psych_like,Continuous,PSI,,NA,NA,Single dose IV (0mg vs 0.015 mg/kg THC),Single dose IV (0.015 mg/kg THC),NA,0.03 mg/kg THC,average weight = 81 => 0.03*81 = 2.43; 2.43/5 = 0.486,0.486,intravenous,NA,NA,no,SingleDose,CannabisDynamics,yes,F-statistic,dependent,mainTHC_bassir2022,pEstimate_mainTHC_bassir2022,cohen,,no,already included in Ganesh mega analysis
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
646,Ganesh,DSouza_2,"Ganesh, Suhas, Jose Cortes-Briones, Ashley M. Schnakenberg Martin, Patrick D. Skosnik, Deepak C. D'Souza, and Mohini Ranganathan. ""Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior."" Cannabis and Cannabinoid Research (2022).",2022,NA,Experiment,GeneralPopulation,"double-blind, placebo-controlled, randomized",US,Previous cannabis use,25,NA,NA,"Psychosis-like (severity, pos PANSS score)",THC.PLE,psych_like,Continuous,PANSS (positive),PANSS,NA,NA,THC vs CBD 7.5 mg,CBD (7.5mg),NA,NA,NA,NA,NA,NA,NA,yes,CBDcontent,CannabisStrain,yes,p-value,dependent,extraxted_cbdTHC_ganesh2022,pEstimate_cbdTHC_ganesh2022,cohen,,no,already included in Ganesh mega analysis
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
648,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,GeneralPopulation,observational,Canada/US,Cannabis use in the past 12 months,21.4,16,65,Hallucinations,Can.HAL,full_episode,Binary,Cannabis leading to seeking medical help for hallucinations,,"In the past 12 months, did you seek medical help for any adverse or negative health effects?",1%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,rupSurvey2022_hallucinationsDF,NA,rates,,Yes,Yes
649,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,GeneralPopulation,observational,Canada/US,Cannabis use in the past 12 months,21.4,16,65,Hallucinations,Can.HAL,full_episode,Binary,Cannabis leading to seeking medical help for hallucinations,,"In the past 12 months, did you seek medical help for any adverse or negative health effects?",1%,Diagnosis anxiety,Diagnosis anxiety,NA,NA,NA,NA,NA,NA,NA,yes,Anxiety,MentalHealthPersonality,yes,chi-square,independent,extract_RupSurvey2022_anxiety,pEstimate_RupSurvey2022_anxiety,cohen,,Yes,Yes
650,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,GeneralPopulation,observational,Canada/US,Cannabis use in the past 12 months,21.4,16,65,Hallucinations,Can.HAL,full_episode,Binary,Cannabis leading to seeking medical help for hallucinations,,"In the past 12 months, did you seek medical help for any adverse or negative health effects?",1%,Diagnosis depression,Diagnosis depression,NA,NA,NA,NA,NA,NA,NA,yes,Depression,MentalHealthPersonality,yes,chi-square,independent,extract_RupSurvey2022_depression,pEstimate_RupSurvey2022_depression,cohen,,Yes,Yes
651,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,GeneralPopulation,observational,Canada/US,Cannabis use in the past 12 months,21.4,16,65,Hallucinations,Can.HAL,full_episode,Binary,Cannabis leading to seeking medical help for hallucinations,,"In the past 12 months, did you seek medical help for any adverse or negative health effects?",1%,Diagnosis ptsd,Diagnosis ptsd,NA,NA,NA,NA,NA,NA,NA,no,Anxiety,MentalHealthPersonality,yes,chi-square,independent,extract_RupSurvey2022_ptsd,pEstimate_RupSurvey2022_ptsd,cohen,,Yes,Yes
652,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,GeneralPopulation,observational,Canada/US,Cannabis use in the past 12 months,21.4,16,65,Hallucinations,Can.HAL,full_episode,Binary,Cannabis leading to seeking medical help for hallucinations,,"In the past 12 months, did you seek medical help for any adverse or negative health effects?",1%,Diagnosis bipolar,Diagnosis bipolar,NA,NA,NA,NA,NA,NA,NA,no,Bipolar,MentalHealthPersonality,yes,chi-square,independent,extract_RupSurvey2022_bipolar,pEstimate_RupSurvey2022_bipolar,cohen,,Yes,Yes
653,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,GeneralPopulation,observational,Canada/US,Cannabis use in the past 12 months,21.4,16,65,Hallucinations,Can.HAL,full_episode,Binary,Cannabis leading to seeking medical help for hallucinations,,"In the past 12 months, did you seek medical help for any adverse or negative health effects?",1%,Diagnosis psychosis,Diagnosis psychosis,NA,NA,NA,NA,NA,NA,NA,no,PsychosisLiability,MentalHealthPersonality,yes,chi-square,independent,extract_RupSurvey2022_psychosis,pEstimate_RupSurvey2022_psychosis,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
655,Ueberall,Ueberall,"Ueberall, Michael A., Johannes Horlemann, Norbert Schuermann, Maja Kalaba, and Mark A. Ware. ""Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry."" Pain Medicine (2022).",2022,2017-2019,MedicalSample,Pain,"exploratory, retrospective analyssi",Germany,NA,57,24,88,Hallucinations (adverse event),Med.HAL,AE,Binary,NA,,NA,1.60%,Medical cannabis (Drabinol),Pain,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,UeberallDrabinol_hallucinationsDF,NA,rates,,Yes,Yes
656,Ueberall,Ueberall,"Ueberall, Michael A., Johannes Horlemann, Norbert Schuermann, Maja Kalaba, and Mark A. Ware. ""Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry."" Pain Medicine (2022).",2022,2017-2019,MedicalSample,Pain,"exploratory, retrospective analyssi",Germany,NA,57,24,88,Paranoia (adverse event),Med.PAR,AE,Binary,NA,,NA,1.60%,Medical cannabis (Drabinol),Pain,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,UeberallDrabinol_paranoiaDF,NA,rates,,Yes,Yes
657,Ueberall,Ueberall,"Ueberall, Michael A., Johannes Horlemann, Norbert Schuermann, Maja Kalaba, and Mark A. Ware. ""Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry."" Pain Medicine (2022).",2022,2017-2019,MedicalSample,Pain,"exploratory, retrospective analyssi",Germany,NA,57,24,88,Delusions (adverse event),Med.DEL,AE,Binary,NA,,NA,1.60%,Medical cannabis (Drabinol),Pain,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,UeberallDrabinol_delusionsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
659,Melen,Melen,"Melén, Christopher M., Magali Merrien, Agata M. Wasik, Georgios Panagiotidis, Olof Beck, Kristina Sonnevi, Henna-Riikka Junlén, Birger Christensson, Birgitta Sander, and Björn Engelbrekt Wahlin. ""Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia."" Leukemia & Lymphoma 63, no. 6 (2022): 1387-1397.",2022,2019-2020,MedicalSample,Cancer,uncontrolled,Sweden,NA,73,64,79,Hallucinations,Med.HAL,AE,Binary,NA,,NA,30.00%,Medical cannabis,Cancer,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,melenMedCan_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
661,Abi-Jaoude,Abi_Jaoude,"Abi-Jaoude, Elia, Tracy Bhikram, Ferdous Parveen, Jody Levenbach, Myriam Lafreniere-Roula, and Paul Sandor. ""A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome."" Cannabis and Cannabinoid Research (2022).",2022,2018-2020,MedicalTrial,Tourette,placebo controlled,Canada,NA,NA,NA,NA,Hallucinations,Med.HAL,AE,Binary,NA,,NA,0%%,Medical cannabis,Tourette,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,Abi_Jaoude_tourette_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
663,Peters,Peters,"Peters, Erica N., Irina Mosesova, Laura MacNair, Ryan Vandrey, M. Hunter Land, Mark A. Ware, Cynthia Turcotte, and Marcel O. Bonn-Miller. ""Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants."" Journal of Analytical Toxicology 46, no. 5 (2022): 528-539.",2022,2019-2020,MedicalTrial,Healthy,"placebo-controlled, crossover trial ",Australia,NA,28.1,18,55,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events Scale,6%,Medical cannabis (Mixed THC condictiions: Treatment A: 5 mg total THC and 0.06 mg CBD daily; B: 10 mg total THC and 0.12 mg total CBD daily; C: 15 mg total THC and 0.18 mg total CBD daily; D: 20 mg total THC and 0.24 mg total CBD daily),Healthy,NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi-square,independent,extract_petersMedTrialHealthy_paranoia,pEstimate_petersMedTrialHealthy_paranoia,cohen,,Yes,Yes
664,Peters,Peters,"Peters, Erica N., Irina Mosesova, Laura MacNair, Ryan Vandrey, M. Hunter Land, Mark A. Ware, Cynthia Turcotte, and Marcel O. Bonn-Miller. ""Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants."" Journal of Analytical Toxicology 46, no. 5 (2022): 528-539.",2022,2019-2020,MedicalTrial,Healthy,"placebo-controlled, crossover trial ",Australia,NA,28.1,18,55,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events Scale,6%,Medical cannabis (Mixed THC condictiions: Treatment A: 5 mg total THC and 0.06 mg CBD daily; B: 10 mg total THC and 0.12 mg total CBD daily; C: 15 mg total THC and 0.18 mg total CBD daily; D: 20 mg total THC and 0.24 mg total CBD daily),Healthy,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,petersMedTrialHealthy_paranoiaDF,NA,rates,petersMedTrialHealthy_paranoiaControl,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
666,Santarossa,Santarossa,"Santarossa, Talia M., Randy So, Penelope Smyth, Stefan Gustavsen, and Ross T. Tsuyuki. ""Medical cannabis use in Canadians with multiple sclerosis."" Multiple Sclerosis and Related Disorders 59 (2022): 103638.",2022,NA,MedicalSample,MS,uncontrolled,Canada,NA,44,NA,NA,Hallucinations,Med.HAL,AE,Categorical (light/moderate/severe symptoms) - binary measure indexing AE was created by including moderate/severe symptoms,NA,,Adverse effects,1%,Medical cannabis (prescribed or unprescribed),MS,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,nMS_Santarossa_hallucinationsDF,NA,rates,,Yes,Yes
667,Santarossa,Santarossa,"Santarossa, Talia M., Randy So, Penelope Smyth, Stefan Gustavsen, and Ross T. Tsuyuki. ""Medical cannabis use in Canadians with multiple sclerosis."" Multiple Sclerosis and Related Disorders 59 (2022): 103638.",2022,NA,MedicalSample,MS,uncontrolled,Canada,NA,44,NA,NA,Paranoia,Med.PAR,AE,Categorical (light/moderate/severe symptoms) - binary measure indexing AE was created by including moderate/severe symptoms,NA,,Adverse effects,5%,Medical cannabis (prescribed or unprescribed),MS,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,nMS_Santarossa_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
669,Tumati,Tumati,"Tumati, Shankar, Krista L. Lanctôt, RuoDing Wang, Abby Li, Andrew Davis, and Nathan Herrmann. ""Medical cannabis use among older adults in Canada: self-reported data on types and amount used, and perceived effects."" Drugs & aging 39, no. 2 (2022): 153-163.",2022,2014-2020,MedicalSample,Pain,uncontrolled,Canada,NA,73.2,NA,NA,Hallucinations,Med.HAL,AE,Binary,Single item,,Adverse Events,1%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,TumatiCanOil_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
671,Ergisi,Ergisi,"Ergisi, Mehmet, Simon Erridge, Michael Harris, Michal Kawka, Devaki Nimalan, Oliver Salazar, Katerina Loupasaki et al. ""UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder."" Expert review of clinical pharmacology (2022): 1-9.",2022,2019-2022,MedicalSample,PTSD,uncontrolled,UK,NA,37.42,NA,NA,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events,2%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,ErgisiCanMedPTSD_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
673,Tofthagen,Tofthagen,"Tofthagen, Cindy, Adam Perlman, Pooja Advani, Brenda Ernst, Judith Kaur, Winston Tan, Katharine Sheffield, John Crump, Joshua Henry, and Jason Starr. ""Medical Marijuana Use for Cancer-Related Symptoms among Floridians: A Descriptive Study."" Journal of Palliative Medicine 25, no. 10 (2022): 1563-1570.",2022,NA,MedicalSample,Cancer,uncontrolled,Canada,NA,57.33,19,82,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events,3%,rates,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,NA,TofthagenMedCanCancer_paranoiaDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
675,Gibson,Gibson,"Gibson, Laurel P., Hollis C. Karoly, Jarrod M. Ellingson, Jost Klawitter, Cristina Sempio, Julia E. Squeri, Angela D. Bryan, L. Cinnamon Bidwell, and Kent E. Hutchison. ""Effects of cannabidiol in cannabis flower: implications for harm reduction."" Addiction Biology 27, no. 1 (2022): e13092.",2021,NA,Experiment,GeneralPopulation,randomized THC/CBD designs,US,Cannabis use at least 4 times in the past month,36,NA,NA,Paranoia,THC.PLE,psych_like,Continuous,POMS (Profile of Mood States questionnaire),,NA,NA,THC vs CBD,THC vs CBD,NA,NA,NA,NA,NA,NA,NA,yes,CBD (administration),CannabisDynamics,yes,p-value,independent,Gibson2022CBD_paranoia,pEstimate_Gibson2022CBD_paranoia,cohen,,Yes,Yes
676,Gibson,Gibson,"Gibson, Laurel P., Hollis C. Karoly, Jarrod M. Ellingson, Jost Klawitter, Cristina Sempio, Julia E. Squeri, Angela D. Bryan, L. Cinnamon Bidwell, and Kent E. Hutchison. ""Effects of cannabidiol in cannabis flower: implications for harm reduction."" Addiction Biology 27, no. 1 (2022): e13092.",2021,NA,Experiment,GeneralPopulation,randomized THC/CBD designs,US,Cannabis use at least 4 times in the past month,36,NA,NA,Paranoia,THC.PLE,psych_like,Continuous,POMS (Profile of Mood States questionnaire),,NA,NA,THCplasmaLevel,THCplasmaLevel,NA,NA,NA,NA,NA,NA,NA,yes,THCplasmaLevel,CannabisDynamics,yes,correlation,independent,Gibson2022plasmaTHC_paranoia,pEstimate_Gibson2022plasmaTHC_paranoia,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
678,Drennan,Drennan,"Drennan, M. L., H. C. Karoly, A. D. Bryan, K. E. Hutchison, and L. C. Bidwell. ""Acute objective and subjective intoxication effects of legal-market high potency THC-dominant versus CBD-dominant cannabis concentrates."" Scientific reports 11, no. 1 (2021): 1-10.",2021,NA,QuasiExperimental,GeneralPopulation,QuasiExperimental,US,cannabis use at least four times in the past month,29.8,21,60,Paranoia,THC.PAR,psych_like,Continuous,POMS,,NA,NA,THC (smoked),THC with and without THC (in a natural setting),NA,NA,NA,NA,NA,NA,NA,yes,CBDcontent,CannabisStrain,yes,p-value,independent,drennanColoradoTHC_CBD,pEstimate_drennanColoradoTHC_CBD,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
680,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,GeneralPopulation,Survey,Australia,Exposed to cannabis,19.24,16,25,Paranoia,Can.PAR,psych_like,Continuous,CEQ (paranoid-dysphoric subscale),,NA,NA,Childhood trauma,Childhood trauma,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,standardized beta,independent,carlyleSurveyCT_trauma,pEstimate_carlyleSurveyCT_trauma,cohen,,Yes,Yes
681,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,GeneralPopulation,Survey,Australia,Exposed to cannabis,19.24,16,25,Paranoia,Can.PAR,psych_like,Continuous,CEQ (paranoid-dysphoric subscale),,NA,NA,Age,Age,NA,NA,NA,NA,NA,NA,NA,no,Age,Demographic,yes,standardized beta,independent,carlyleSurveyCT_age,pEstimate_carlyleSurveyCT_age,cohen,,Yes,Yes
682,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,GeneralPopulation,Survey,Australia,Exposed to cannabis,19.24,16,25,Paranoia,Can.PAR,psych_like,Continuous,CEQ (paranoid-dysphoric subscale),,NA,NA,Indigenous Status ,Indigenous Status ,NA,NA,NA,NA,NA,NA,NA,no,Other,Other,yes,standardized beta,independent,carlyleSurveyCT_indigenous,pEstimate_carlyleSurveyCT_indigenous,cohen,,Yes,Yes
683,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,GeneralPopulation,Survey,Australia,Exposed to cannabis,19.24,16,25,Paranoia,Can.PAR,psych_like,Continuous,CEQ (paranoid-dysphoric subscale),,NA,NA,GAD-7 - Generalised Anxiety Disorder-7,Anxiety,NA,NA,NA,NA,NA,NA,NA,no,Anxiety,MentalHealthPersonality,yes,standardized beta,independent,carlyleSurveyCT_anxiety,pEstimate_carlyleSurveyCT_anxiety,cohen,,Yes,Yes
684,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,GeneralPopulation,Survey,Australia,Exposed to cannabis,19.24,16,25,Paranoia,Can.PAR,psych_like,Continuous,CEQ (paranoid-dysphoric subscale),,NA,NA,PHQ-9 - Patient Health Questionnaire-9 (depression severity),Depression,NA,NA,NA,NA,NA,NA,NA,no,Depression,MentalHealthPersonality,yes,standardized beta,independent,carlyleSurveyCT_depression,pEstimate_carlyleSurveyCT_depression,cohen,,Yes,Yes
685,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,GeneralPopulation,Survey,Australia,Exposed to cannabis,19.24,16,25,Paranoia,Can.PAR,psych_like,Continuous,CEQ (paranoid-dysphoric subscale),,NA,NA,Mental Health Liability (Family History of Mental Illness),Mental Health Liability,NA,NA,NA,NA,NA,NA,NA,no,MentalHealthLiability,MentalHealthPersonality,yes,standardized beta,independent,carlyleSurveyCT_MHliability,pEstimate_carlyleSurveyCT_MHliability,cohen,,Yes,Yes
686,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,GeneralPopulation,Survey,Australia,Exposed to cannabis,19.24,16,25,Paranoia,Can.PAR,psych_like,Continuous,CEQ (paranoid-dysphoric subscale),,NA,NA,AddictionLiability (Family History of Drug Dependence),Addiction Liability,NA,NA,NA,NA,NA,NA,NA,no,AddictionLiability ,MentalHealthPersonality,yes,standardized beta,independent,carlyleSurveyCT_AddictionLiability,pEstimate_carlyleSurveyCT_AddictionLiability,cohen,,Yes,Yes
687,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,GeneralPopulation,Survey,Australia,Exposed to cannabis,19.24,16,25,Paranoia,Can.PAR,psych_like,Continuous,CEQ (paranoid-dysphoric subscale),,NA,NA,Male vs female,Male vs female,NA,NA,NA,NA,NA,NA,NA,no,Gender,Demographic,yes,mean comparison,independent,carlyleSurveyCT_gender,pEstimate_carlyleSurveyCT_gender,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
689,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,GeneralPopulation,"naturalistic, randomized, double-blind, crossover, placebo-controlled study",Spain,Current cannabis user (>3 times/wk),29.94,21,NA,Hallucinations (hearing voices),THC.HAL,psych_like,Continuous,VAS (hearing voices),,,NA,Single dose vaped (0mg vs high potency THC),Single dose vaped (0mg vs high potency THC),NA,NA,Participants inhaled the content of the encoded capsule by inhaling 3 balloons of the Volcano Medic vaporizer.,NA,NA,NA,NA,no,SingleDose,CannabisDynamics,yes,Friedman test,dependent,extract_bousoExpTHC_CBD_VAS_hallucinations,pEstimate_bousoExpTHC_CBD_VAS_hallucinations,cohen,,Yes,Yes
690,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,GeneralPopulation,"naturalistic, randomized, double-blind, crossover, placebo-controlled study",Spain,Current cannabis user (>3 times/wk),29.94,21,NA,Paranoia,THC.PAR,psych_like,Continuous,VAS (suspicious),,,NA,Single dose vaped (0mg vs high potency THC),Single dose vaped (0mg vs high potency THC),NA,NA,Participants inhaled the content of the encoded capsule by inhaling 3 balloons of the Volcano Medic vaporizer.,NA,NA,NA,NA,no,SingleDose,CannabisDynamics,yes,Friedman test,dependent,extract_bousoExpTHC_CBD_VAS_paranoia,pEstimate_bousoExpTHC_CBD_VAS_paranoia,cohen,,Yes,Yes
691,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,GeneralPopulation,"naturalistic, randomized, double-blind, crossover, placebo-controlled study",Spain,Current cannabis user (>3 times/wk),29.94,21,NA,Paranoia,THC.PAR,psych_like,Continuous,PSI (paranoia),,,NA,Single dose vaped (0mg vs high potency THC),Single dose vaped (0mg vs high potency THC),NA,NA,Participants inhaled the content of the encoded capsule by inhaling 3 balloons of the Volcano Medic vaporizer.,NA,NA,NA,NA,no,SingleDose,CannabisDynamics,yes,Friedman test,dependent,extract_bousoExpTHC_CBD_PSI_paranoia,pEstimate_bousoExpTHC_CBD_PSI_paranoia,cohen,,Yes,Yes
692,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,GeneralPopulation,"naturalistic, randomized, double-blind, crossover, placebo-controlled study",Spain,Current cannabis user (>3 times/wk),29.94,21,NA,Delusions,THC.DEL,psych_like,Continuous,PSI (delusions),,,NA,Single dose vaped (0mg vs high potency THC),Single dose vaped (0mg vs high potency THC),NA,NA,Participants inhaled the content of the encoded capsule by inhaling 3 balloons of the Volcano Medic vaporizer.,NA,NA,NA,NA,no,SingleDose,CannabisDynamics,yes,Friedman test,dependent,extract_bousoExpTHC_CBD_PSI_delusions,pEstimate_bousoExpTHC_CBD_PSI_delusions,cohen,,Yes,Yes
693,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,GeneralPopulation,"naturalistic, randomized, double-blind, crossover, placebo-controlled study",Spain,Current cannabis user (>3 times/wk),29.94,21,NA,Hallucinations (hearing voices),THC.HAL,psych_like,Continuous,VAS (hearing voices),,,NA,THC vs CBD,THC vs CBD,NA,NA,Participants inhaled the content of the encoded capsule by inhaling 3 balloons of the Volcano Medic vaporizer.,NA,NA,NA,NA,yes,CBD (administration),CannabisDynamics,yes,Friedman test,dependent,extract_bousoExpTHC_CBD_VAS_hallucinations_cbdAdmin,pEstimate_bousoExpTHC_CBD_VAS_hallucinations_cbdAdmin,cohen,,Yes,Yes
694,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,GeneralPopulation,"naturalistic, randomized, double-blind, crossover, placebo-controlled study",Spain,Current cannabis user (>3 times/wk),29.94,21,NA,Paranoia,THC.PAR,psych_like,Continuous,VAS (suspicious),,,NA,THC vs CBD,THC vs CBD,NA,NA,Participants inhaled the content of the encoded capsule by inhaling 3 balloons of the Volcano Medic vaporizer.,NA,NA,NA,NA,yes,CBD (administration),CannabisDynamics,yes,Friedman test,dependent,extract_bousoExpTHC_CBD_VAS_paranoia_cbdAdmin,pEstimate_bousoExpTHC_CBD_VAS_paranoia_cbdAdmin,cohen,,Yes,Yes
695,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,GeneralPopulation,"naturalistic, randomized, double-blind, crossover, placebo-controlled study",Spain,Current cannabis user (>3 times/wk),29.94,21,NA,Paranoia,THC.PAR,psych_like,Continuous,PSI (paranoia),,,NA,THC vs CBD,THC vs CBD,NA,NA,Participants inhaled the content of the encoded capsule by inhaling 3 balloons of the Volcano Medic vaporizer.,NA,NA,NA,NA,yes,CBD (administration),CannabisDynamics,yes,Friedman test,dependent,extract_bousoExpTHC_CBD_PSI_paranoia_cbdAdmin,pEstimate_bousoExpTHC_CBD_PSI_paranoia_cbdAdmin,cohen,,Yes,Yes
696,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,GeneralPopulation,"naturalistic, randomized, double-blind, crossover, placebo-controlled study",Spain,Current cannabis user (>3 times/wk),29.94,21,NA,Delusions,THC.DEL,psych_like,Continuous,PSI (delusions),,,NA,THC vs CBD,THC vs CBD,NA,NA,Participants inhaled the content of the encoded capsule by inhaling 3 balloons of the Volcano Medic vaporizer.,NA,NA,NA,NA,yes,CBD (administration),CannabisDynamics,yes,Friedman test,dependent,extract_bousoExpTHC_CBD_PSI_delusions_cbdAdmin,pEstimate_bousoExpTHC_CBD_PSI_delusions_cbdAdmin,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
698,Bloomfield,Freeman_Dronabinol_3325/002,"Bloomfield, Michael AP, Katherine Petrilli, Rachel Lees, Chandni Hindocha, Katherine Beck, Ryan J. Turner, Ellis Chika Onwordi et al. ""The effects of acute Δ9-tetrahydrocannabinol on striatal glutamatergic function: A proton magnetic resonance spectroscopy study."" Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 6, no. 6 (2021): 660-667.",2021,NA,Experiment,GeneralPopulation,"within-subjects, randomized, double-blind, crossover design",UK,at least one previous exposure to cannabis,23.5,19,35,"Psychosis-like (severity, pos PANSS score)",THC.PLE,NA,Continuous,PSI,,NA,NA,Single dose oral (0mg vs 15mg THC),Single dose oral (0mg vs 15mg THC),NA,15mg oral,NA,3,oral,NA,NA,no,SingleDose,CannabisDynamics,yes,mean comparison,dependent,bloomfieldGlutamateTHC_dose,pEstimate_bloomfieldGlutamateTHC_dose,cohen,,Yes,Yes
699,Bloomfield,Freeman_Dronabinol_3325/002,"Bloomfield, Michael AP, Katherine Petrilli, Rachel Lees, Chandni Hindocha, Katherine Beck, Ryan J. Turner, Ellis Chika Onwordi et al. ""The effects of acute Δ9-tetrahydrocannabinol on striatal glutamatergic function: A proton magnetic resonance spectroscopy study."" Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 6, no. 6 (2021): 660-667.",2021,NA,Experiment,GeneralPopulation,"within-subjects, randomized, double-blind, crossover design",UK,at least one previous exposure to cannabis,23.5,19,35,"Psychosis-like (severity, pos PANSS score)",HIGH.PLE,NA,Continuous,PSI,,NA,NA,Glutamate (striatal Glx/Cre measures),Glutamate (striatal Glx/Cre measures),NA,NA,NA,NA,NA,NA,NA,no,Glutamate,Neurotransmission,yes,correlation,independent,bloomfieldGlutamateTHC_Gl,pEstimate_bloomfieldGlutamateTHC_Gl,cohen,,no,no
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
670,Walsh,Walsh,"Walsh, Jennifer H., Kathleen J. Maddison, Tim Rankin, Kevin Murray, Nigel McArdle, Melissa J. Ree, David R. Hillman, and Peter R. Eastwood. ""Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo."" Sleep 44, no. 11 (2021): zsab149.",2021,2019-2019,MedicalTrial,Insomnia,"double-blind, randomized, placebo-controlled, crossover design study",Australia,NA,53,25,70,Hallucinations,Med.HAL,AE,Binary,Adverse event,,NA,4%,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,,NA,WalshInsomnia_2021_hallucinationsDF,NA,rates,,Yes,Yes
671,Walsh,Walsh,"Walsh, Jennifer H., Kathleen J. Maddison, Tim Rankin, Kevin Murray, Nigel McArdle, Melissa J. Ree, David R. Hillman, and Peter R. Eastwood. ""Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo."" Sleep 44, no. 11 (2021): zsab149.",2021,2019-2019,MedicalTrial,Insomnia,"double-blind, randomized, placebo-controlled, crossover design study",Australia,NA,53,25,70,Hallucinations,Med.HAL,AE,Binary,Adverse event,,NA,4%,Medical cannabis (placebo controlled),NA,NA,NA,NA,NA,NA,NA,no,Medical cannabis (placebo controlled),CannabisDynamics,yes,chi square,,dependent,extractWalshInsomnia_2021_hallucinations,pEstimate_walshInsomnia_2021_hallucinations,cohen,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
672,Halikas,Halikas,"Halikas, James A., Donald W. Goodwin, and Samuel B. Guze. ""Marihuana effects: a survey of regular users."" Jama 217, no. 5 (1971): 692-694.",1971,NA,Observational,GeneralPopulation,observational,US,regular users (using marihuana on at least 50 occasions over at least a six-month period),22,18,31,Hallucinations,Can.HAL,psych_like,Binary,Acute intoxication effects - checklist,,NA,27%,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,,NA,regularCan_Halikas1971_hallucinationsDF,NA,rates,,Yes,Yes
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
673,Greywoode,Greywoode,"Greywoode, Ruby, Chinazo Cunningham, Maegan Hollins, and Olga Aroniadis. ""Medical Cannabis Use Patterns and Adverse Effects in Inflammatory Bowel Disease."" Journal of Clinical Gastroenterology (2022): 10-1097.",2022,2020-2021,MedicalSample,Inflammatory bowel disease,uncontrolled,US,NA,40,18,NA,Paranoia,Med.PAR,AE,Binary,Single item,,Adverse Events,3%,rates,NA,NA,NA,NA,NA,NA,NA,no,rates,rates,yes,rate,,NA,greywoodeIBD_paranoiaDF,NA,rates,,Yes,Yes